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Abstract 
University of Liverpool, Eilidh Carrington for the Degree of Doctor of Philosophy, 
2016. 
Reconstructing ICAM-1-binding var genes of Plasmodium falciparum 
Malaria is a major cause of morbidity and mortality globally. Severe malaria in 
patients infected with the most deadly species, Plasmodium falciparum, involves 
sequestration of P. falciparum-infected erythrocytes in the microvasculature, a 
process involving the interaction of numerous parasite and host factors. The highly 
variable gene family var encodes PfEMP1 proteins which are thought to be 
responsible for the majority of endothelial cell binding via receptors such as CD36, 
ICAM-1 and EPCR. To date, knowledge of the specific PfEMP1 domains that mediate 
binding to these receptors has emerged from the study of two reference parasite 
strains IT4 and 3D7.  
The aim of this study is to identify and characterise new ICAM-1 binding var genes 
from several culture-adapted ICAM-1-selected patient isolates. Sequencing var 
genes is complicated by their high variability within the 50-60 gene copies per 
genome and the absence of overlap between var repertoires of different isolates. 
We test the predictive powers of a new var gene database of > 62,000 var genes 
generated by the Pf3k genome sequencing project. We find database matches to be 
a useful starting point for primer design in this targeted sequencing approach. 
However, key differences between database genes and those amplified from the 
patient isolates highlights the need for experimental validation. We perform 
sequence analysis of var genes from three patient isolates, BC12, J1 and PCM7, and 
identify their PfEMP1 domain structures. We extensively characterise the DBLβ 
domains, which are responsible for ICAM-1 binding, of these genes by phylogenetic 
and homology block analysis and compare them to known ICAM-1 binding DBLβ 
domains.   
We express two of the newly identified DBLβ domains as recombinant proteins and 
analyse their binding to ICAM-1. Using SPR assays, we show that the recombinant 
DBLβ domains of J1a and BC12a bind ICAM-1D1D5 with nanomolar affinity. We 
compared their binding to the previously characterised IT4var13DBLβ and studied the 
binding of all three DBLβ domains to four ICAM-1 mutant proteins. Residues K29, 
L42 and L44 are essential for ICAM-1 binding of all three DBLβ domains, whereas 
S22 is essential for J1aDBLβ and BC12aDBLβ binding but not IT4var13DBLβ binding. 
These results have important implications for the design of anti-disease therapies 
targeting severe malaria.  
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Chapter 1. Introduction 
1.1 Malaria prevalence and control 
Malaria is a vector borne disease caused by species of the Plasmodium parasite. It 
occurs throughout the tropics and subtropics with distribution depending on 
suitable climatic conditions to support the Anopheles mosquito vectors and parasite 
development. In 2013, an estimated 3.3 billion people worldwide were at risk of 
malaria infection (WHO, 2014), with the percentage of at risk populations varying 
between countries (Figure 1.1). The latest figures place the estimated number of 
global malaria cases at 214 million (range: 149-303 million) and the number of 
estimated malaria deaths at 438,000 (range: 236,000-635,000) (WHO, 2015). This 
represents an 18% reduction in cases and a 48% reduction in deaths since 2000, 
largely due to widespread control programmes (WHO, 2015). Control strategies 
include distribution of insecticide-treated bed nets (ITN) which prevent mosquito 
bites at night, indoor residual spraying (IRS) which targets mosquitoes that land on 
indoor surfaces and treatment of clinical malaria cases using artemisinin based 
combination therapy (ACT) which has an enhanced impact on severe malaria (SM) 
and death compared to quinine-based drugs (Dondorp et al., 2010).  Of these 
control strategies, ITN has been the most successful with 68% of the decline in 
cases from 2000-2015 attributed to this strategy (Bhatt et al., 2015). However, this 
is largely due to the early implementation of ITNs and the scale of distribution that 
has been achieved and does not necessarily identify ITNs as a more effective 
strategy than either IRS or ACT (Bhatt et al., 2015). Implementation of IRS and ACT 
at a larger scale and continued ITN distribution will be required to continue the 
declining trend of malaria prevalence. However, threats to these programmes are 
increasing with the emergence of insecticide resistance (Ranson and Lissenden, 
2016) and widespread artemisinin resistance in South East Asia (Fairhurst, 2015). 
The majority of malaria cases (88%) and deaths (90%) occur in the WHO African 
Region (WHO, 2015). This region has the most unreliable malaria reporting system 
and incidence figures are predicted by mathematical modelling based on  
2  
 
Figure 1.1. Global population at risk of malaria infection, 2013.  
The percentage of the population at risk of malaria infection is shown for each 
country (WHO, 2014). The map was obtained from the WHO Global Malaria 
Mapper available at http://www.worldmalariareport.org/, accessed 14/04/2016. 
 
prevalence data (WHO, 2015). Despite the increasing sophistication of these 
models, which can be calibrated to empirical data (Cameron et al., 2015), they still 
rely on figures based on small areas which are then extrapolated to a country wide 
level and therefore remain unreliable. Despite this, these estimated figures can still 
be useful in planning control programmes and, as these become more widespread, 
reporting systems are also likely to improve. The majority of malaria deaths in sub-
Saharan Africa occur in children under five, accounting for 10% of all child deaths in 
2015 (WHO, 2015).  Therefore, despite the positive effect of control programmes in 
reducing disease, malaria is still a major cause of morbidity and mortality, 
particularly in sub-Saharan Africa. New insecticides and drugs are required to 
counteract resistance but new strategies such as vaccines and improved diagnostics 
will be required to increase the likelihood of successful malaria control and 
elimination (Hemingway et al., 2016).  
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1.2 Clinical symptoms of malaria 
Malaria disease encompasses a range of clinical symptoms that can be divided into 
uncomplicated malaria (UM) and severe malaria (SM). UM, also referred to as mild 
malaria, is characterised initially with headaches, fatigue, muscle aches and 
abdominal pain, followed by fever, nausea, vomiting and postural hypotension 
(White et al., 2014). Of the six Plasmodium species known to infect humans, P. 
falciparum, P. vivax, P. malariae, P. ovale curtisi and P. ovale wallikeri (Sutherland et 
al., 2010) and P. knowlesi (Brock et al., 2016), P. falciparum is responsible for the 
majority of cases of SM. This is related to the unique ability of P. falciparum 
infected erythrocytes (IEs) to sequester in the microcirculatory system of the 
human host causing obstruction of blood flow and interfering with endothelial cell 
function and metabolism (White et al., 2014). IE sequestration results in the ability 
of later stage parasites to avoid the spleen, where they would otherwise be 
destroyed. SM consists of several disease phenotypes that are often grouped into 
severe malarial anaemia (SMA), respiratory distress and cerebral malaria (CM) but 
can overlap. SM symptoms vary between young children and adults with mainly the 
former described here. 
SMA is common in high transmission areas where repeat infection often occurs. 
SMA is characterised by haemoglobin levels < 5 g per decilitre of blood in the 
presence of P. falciparum parasitaemia (Calis et al., 2008). Both erythrocyte 
destruction upon parasite release and an increase in splenic clearance of 
erythrocytes, infected and uninfected, contribute to SMA (White et al., 2014). In 
addition, erythropoiesis is affected resulting in a decrease in erythrocyte production 
(Dormer et al., 1983). Platelet deficiency is also common and coagulation pathways 
are affected (White et al., 2014).  
Respiratory distress often results from metabolic acidosis. This refers to the build 
up of lactic acid, a by-product of anaerobic glycolysis, in the blood which occurs 
when insufficient oxygenated blood is available due to parasite sequestration 
(White et al., 2014). Other causes of respiratory distress are pneumonia, fluid 
overload, acute lung injury and severe anaemia (Taylor et al., 2012). Respiratory 
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distress is a key identifier of P. falciparum infected children at risk of death (Marsh 
et al., 1995).  
CM is classified as an unrousable coma, defined as a score of ≤ 2 on the Blantyre 
Coma Score in children (Molyneux et al., 1989), in the presence of P. falciparum 
parasitaemia and no other apparent cause of coma. However, ruling out other 
causes of coma can be difficult and one study found that in 23% of CM patients the 
cause of death was not CM (Taylor et al., 2004). One method of differentiation is 
detection of retinopathy which is present in CM but not other causes of coma, 
resulting in a more accurate clinical definition of CM (Taylor and Molyneux, 2015). 
Pathogenesis of CM is not entirely clear but is thought to be related to parasite 
sequestration in the brain, disruption of the blood brain barrier (BBB) and 
endothelial cell activation, processes that involve a complex interplay of parasite 
and host components. Brain swelling and the associated increase in intracranial 
pressure are associated with fatal outcomes of CM, with two distinct clinical groups 
identified suggesting that different mechanisms lead to brain swelling (Seydel et al., 
2015).  
Sequestered parasites are found both in the brains of patients who died of CM and 
those who died of other causes but the number of parasitized vessels and number 
of sequestered parasites is higher in CM (MacPherson et al., 1985, Dorovini-Zis et 
al., 2011). However, there is also variation in pathology observed in those with true 
CM, namely brain swelling and parasitized vessels (CM1) and brain swelling, 
parasitized vessels and presence of haemorrhaging and thrombi (CM2) (Taylor et 
al., 2004), suggesting either different mechanisms leading to these pathologies or 
the death of patients at different stages of the same process. BBB breakdown can 
be shown by detecting fibrinogen in the brain, which is excluded if BBB is intact 
(Dorovini-Zis et al., 2011). The mechanisms involved are not fully understood but 
are thought to include parasite sequestration and cytokine release (Dorovini-Zis et 
al., 2011). Endothelial activation is linked to BBB breakdown and is present in CM 
but also UM making it difficult to decipher cause and effect (Storm and Craig, 2014). 
Angiopoietein-1 and -2, which stabilise and antagonise endothelium respectively, 
von Willebrand factor, increase in expression of endothelial cell receptors and 
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soluble endothelial receptors are all associated with endothelial activation (Storm 
and Craig, 2014). The study of host endothelial cell-parasite interactions is a key 
focus of current research in the field and will provide insight into the molecular 
mechanisms leading to CM. Patients that recover from CM often display 
neurological symptoms, such as epilepsy, cerebral palsies, cognitive impairments 
and language deficits, many of which resolve within six months (Idro et al., 2010, 
Birbeck et al., 2010). However, long-lasting effects have been reported (Carter et 
al., 2005), the full impact of which require further study.  
Many clinical symptoms of severe malaria have been linked to IE sequestration in 
the microcirculatory system. We will now look more closely at the P. falciparum 
parasite and the molecular mechanisms surrounding this phenomenon.  
1.3 Plasmodium falciparum life cycle 
P. falciparum is an Apicomplexan parasite which has a complex life cycle requiring 
human and mosquito stages for completion (Figure 1.2). Sporozoites are stored in 
the salivary glands of the female Anopheles mosquito vector and injected into the 
skin of the human host upon blood feeding. Sporozoites then migrate via blood 
vessels to the liver where they first traverse (Tavares et al., 2013) and then invade 
hepatic cells. A single sporozoite then undergoes multiple rounds of asexual 
replication within a vacuole to produce tens of thousands of merozoites. 
Merozoites are released in vesicles called merosomes, after parasite-induced cell 
death of the hepatocyte (Sturm et al., 2006), which protect merozoites until they 
reach the microvasculature of the lung where they are released into the 
bloodstream (Baer et al., 2007). Merozoites invade erythrocytes within seconds of 
release in a complex process involving many parasite-host protein interactions 
which can be divided into four key stages: initial attachment and re-orientation, 
tight junction formation, invasion via an actin-myosin motor and completion by 
membrane sealing and shedding of surface proteins (recently reviewed in (Beeson 
et al., 2016)). The parasite then undergoes an asexual cycle within the resulting 
parasitophorous vacuole (PV) inside the erythrocyte consisting of early ring 
trophozoite, late trophozoite, developing schizont and developed schizont stages 
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culminating in merozoites ready for re-invasion. Release of merozoites and rupture 
of the IE occurs in synchronisation after every ~ 48 hour cycle and contributes to 
inflammatory response and clinical symptoms observed. A small proportion of 
parasites are committed to forming gametocytes which are required for onward 
transmission.  
 
 
Figure 1.2. Life cycle of Plasmodium falciparum.  
Life cycle stages in the human (a) and mosquito (b) hosts. See text for a detailed 
description. Figure is reprinted by permission from Macmillan Publishers Ltd: 
[Nature] (Wirth, 2002), copyright (2002). 
 
Only the presence of mature gametocytes in a blood meal of the mosquito vector 
can facilitate the necessary sexual development which occurs in this host (Figure 
1.2b). Once in the mosquito gut, gametocytes egress from the erythrocyte and form 
gametes, which for males includes an exflagellation process in which DNA is 
replicated and eight microgametes are produced. Fertilisation occurs to produce a 
zygote which undergoes DNA replication before differentiating into an ookinete 
which traverses the midgut epithelium by gliding motility. Once in the extracellular 
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matrix on the haemocoel side of the epithelium, the ookinete differentiates into an 
oocyst which produces thousands of sporozoites by sporogony. These then invade 
the salivary gland via the haemolymph where they reside until the mosquito takes a 
blood meal, completing transmission to the next human host (Smith et al., 2014). 
1.4 Modification of the host erythrocyte 
Erythrocytes are highly specialised for gaseous exchange throughout the tissues 
and are unusual in that they do not contain organelles. As a result, they do not 
synthesise and traffic proteins. Therefore, in order for P. falciparum to survive 
within erythrocytes they extensively modify both the cytoplasm and surface of their 
host cells. These modifications begin during the early ring stage and result in the 
appearance of several structures including Maurer’s clefts (MC) (Mundwiler-
Pachlatko and Beck, 2013), the tubovesicular network (Elmendorf and Haldar, 
1994), J-dots (Kulzer et al., 2010) and knobs (Gruenberg et al., 1983). These 
modifications are thought to collectively facilitate nutrient acquisition and 
localisation of parasite adherence proteins on the IE surface and reduce erythrocyte 
deformability as a consequence. The major adherence protein found on the IE 
surface is P. falciparum erythrocyte membrane protein 1 (PfEMP1) which is a key 
protein involved in IE sequestration in the host tissues. Many of the modifications 
are involved in protein trafficking systems, although specific mechanisms are only 
just beginning to be elucidated. 
Proteins exported into the erythrocyte fall into two categories, those which contain 
the Plasmodium export element/host-targeting (PEXEL/HT) targeting motif (Marti 
et al., 2004, Hiller et al., 2004) and those that do not, termed PEXEL-negative 
exported proteins (PNEPs) (Heiber et al., 2013). PEXEL/HT proteins are processed by 
Plasmepsin V in the endoplasmic reticulum (Russo et al., 2010, Boddey et al., 2013) 
and both protein categories are transported across the PV membrane (PVM) into 
the erythrocyte cytoplasm by the Plasmodium translocon complex (PTEX) (de 
Koning-Ward et al., 2009). From there, the exact mechanism of export to the IE cell 
surface is unclear but MCs are thought to act as intermediate sorting centres due to 
only transient localisation of PfEMP1 here (Mundwiler-Pachlatko and Beck, 2013). 
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MCs are not linked to the PVM or the erythrocyte membrane (McMillan et al., 
2013, Gruring et al., 2011) and so a vesicular system has been proposed to traffic 
proteins to and from the MCs, supported by the identification of trafficking 
compartments (Hanssen et al., 2010) and J-dots, which contain chaperone proteins 
(Kulzer et al., 2012). PfEMP1 proteins are structurally similar to PNEPs but contain a 
modified PEXEL motif (Marti et al., 2004). Two proteins that have been shown to be 
important in PfEMP1 trafficking, P. falciparum skeleton binding protein 1 (PfSBP1) 
(Blisnick et al., 2000, Cooke et al., 2006) and PfEMP1 trafficking protein 1 (PfPTP1) 
(Rug et al., 2014) form a complex and are required for PfEMP1 trafficking to the 
MCs (Rug et al., 2014). Membrane-associated histidine-rich protein 1 (MAHRP1) is 
also important in transfer to MCs with depletion of this protein resulting in PfEMP1 
accumulation at the PVM (Spycher et al., 2003, Spycher et al., 2008). Several other 
proteins are important in PfEMP1 trafficking but have not been characterised in 
detail (Maier et al., 2009). Once at the IE surface, PfEMP1 is found in clusters on 
knobs. 
Knobs are protrusions of the IE membrane which provide contact points for 
adherence to host endothelium. Knob-associated histidine-rich protein (KAHRP) is a 
major knob component and is required for their formation (Crabb et al., 1997). 
KAHRP has a role in anchoring knobs to the erythrocyte cytoskeleton via 
interactions with cytoskeleton components spectrin (Pei et al., 2005) and ankyrin R 
(Weng et al., 2014). PfEMP3 is another component of knobs whose exact role is 
unclear but both PfEMP3 and KAHRP are involved in PfEMP1 trafficking and 
functional display on the IE surface with disruption of either leading to reduction of 
cytoadherence (Waterkeyn et al., 2000, Crabb et al., 1997). KAHRP was originally 
thought to bind the acidic terminal sequence (ATS) of PfEMP1, linking it to the 
cytoskeleton (Kilejian et al., 1991, Oh et al., 2000, Waller et al., 1999). However, 
recent evidence suggests that members of the Plasmodium helical interspersed 
subtelomeric (PHIST) protein family carry out this function (Mayer et al., 2012, 
Oberli et al., 2014, Proellocks et al., 2014), with co-operation between PHIST 
proteins and a level of PfEMP1 type specificity suggested but not yet proven (Oberli 
et al., 2014, Oberli et al., 2016). Disruption of one of these proteins resulted in a 
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decrease in IE adhesion but did not affect knob formation or PfEMP1 trafficking 
(Proellocks et al., 2014). There is still much to elucidate about the mechanisms that 
lead to PfEMP1 display on the IE surface. Once embedded in the membrane, the 
extracellular domains of PfEMP1 are exposed to the bloodstream where they can 
adhere to host receptors leading to sequestration of the parasite. Here, PfEMP1 
also functions as the major parasite protein responsible for antigenic variation. 
1.5 Antigenic variation 
Many human pathogens are recognised and cleared by the immune system, while 
others have developed strategies to avoid recognition and establish long-lasting 
infections. One such strategy is to constantly change the proteins that are 
recognised by the host immune system, mainly surface exposed antigens, a process 
referred to as antigenic variation. Many pathogens achieve antigenic variation 
through sequential expression of multi-copy gene families, including bacteria (e.g. 
Borrelia and Neisseria spp), fungi (e.g. Pneumocystis carinii and Candida spp), and 
protozoan parasites (e.g. Trypanosoma brucei and P. falciparum) (Deitsch et al., 
2009). Antigenic variation in P. falciparum is mediated by surface proteins 
collectively known as variant surface antigen (VSA). PfEMP1 encoded by var genes, 
the most extensively studied VSA of P. falciparum, are the focus of this thesis and 
are introduced below.  Other important VSA are repetitive interspersed family 
(RIFIN) proteins (Cheng et al., 1998, Kyes et al., 1999, Fernandez et al., 1999), sub-
telomeric variable open reading frame (STEVOR) proteins (Kaviratne et al., 2002, 
Blythe et al., 2008, Niang et al., 2009) and possibly surface associated interspersed 
gene family (SURFIN) proteins (Winter et al., 2005) and P. falciparum Maurer’s cleft 
two transmembrane (PfMC-2TM) proteins (Sam-Yellowe et al., 2004, Lavazec et al., 
2006).  
RIFINs and STEVORs are encoded by rif and stevor genes, respectively, which are 
found in subtelomeric regions of all P. falciparum chromosomes (Gardner et al., 
2002). There are around 150-200 rif gene and 30-40 stevor gene copies per parasite 
genome of which there are both strain-specific and strain-transcending genes 
(Claessens et al., 2011, Blythe et al., 2008). RIFINs are small 30-45 kDa proteins that 
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are grouped into A- and B-types (Joannin et al., 2008), both of which are expressed 
simultaneously with only A-types reportedly found at the IE surface (Petter et al., 
2007). They were originally thought to be involved in rosetting, the binding of IEs to 
uninfected erythrocytes (Kyes et al., 1999, Fernandez et al., 1999) but the 
identification of PfEMP1 as a rosette mediator (Rowe et al., 1997) shifted research 
focus away from RIFINs. It is now thought that RIFINs mediate rosetting by binding 
to blood group A antigen on erythrocytes (Goel et al., 2015). RIFINs are also 
expressed in sporozoite, merozoite and gametocyte stages suggesting they may 
play an important role throughout the parasite life cycle (Petter et al., 2007, Wang 
et al., 2010). Antibodies are generated against RIFINs that are associated with 
parasite clearance (Abdel-Latif et al., 2002, Abdel-Latif et al., 2003, Abdel-Latif et 
al., 2004) and have been shown to be acquired rapidly in experimental infections in 
naive individuals (Turner et al., 2011), supporting their role in antigenic variation. 
STEVOR are similarly small, 30-40 kDa, proteins and have also been shown to have a 
role in rosetting (Niang et al., 2014). STEVOR binds to uninfected erythrocytes via 
the glycophorin C receptor to form rosettes, a process that was shown to be 
protective against merozoite invasion blocking antibodies, contributing to parasite 
growth efficiency (Niang et al., 2014). Additionally, STEVOR has a mechanical role at 
the IE membrane contributing to rigidity and enhancing IE sequestration (Sanyal et 
al., 2012), a function which is also important in gametocyte sequestration (Tiburcio 
et al., 2012). The role of anti-STEVOR antibodies in human infection is unclear as 
they were not found to be protective in children and are, therefore, speculated to 
be simply a marker of exposure (Schreiber et al., 2008). More studies will be 
required to corroborate these findings. Overall, STEVORs and RIFINs appear to be 
secondary targets of the immune response against VSA with PfEMP1 remaining the 
predominant target (Chan et al., 2012).  
Little is known about the role of other VSAs. SURFINs are high molecular weight 
(280-300 kDa) proteins encoded by surf genes of which there are 10 gene copies 
(Winter et al., 2005). surf genes are differentially expressed throughout the parasite 
life cycle (Mphande et al., 2008) and SURFINs are reported to localise at the IE 
surface (Winter et al., 2005). It is unknown if these proteins have a role in antigenic 
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variation. PfMC-2TM proteins are encoded by ~13 subtelomeric genes of which 
several are expressed at any one time (Sam-Yellowe et al., 2004). They are 
relatively conserved with the exception of a short loop region which is exposed at 
the IE surface (Bachmann et al., 2015). Whether this loop is the target of host 
antibodies has not been determined. In addition to parasite VSAs, P. falciparum 
infection induces a conformational change in an erythrocyte integral membrane 
protein, band 3 (Winograd and Sherman, 2004). Chemical modification of band 3 is 
reported to result in CD36 binding, thereby contributing to sequestration 
(Winograd et al., 2004). A role in thrombospondin binding has also been reported 
(Eda et al., 1999, Lucas and Sherman, 1998). However, the significance of modified 
band 3 is not understood.  
1.6 var genes 
The variant gene family encoding PfEMP1 proteins comprises 50-60 genes per 
genome (Gardner et al., 2002, Rask et al., 2010), collectively named var genes 
(Baruch et al., 1995, Smith et al., 1995, Su et al., 1995). var genes are highly 
variable, not only within, but between parasite isolates resulting in vast global 
diversity (Rask et al., 2010). They are classified by their 5’ upstream sequence (UPS) 
into groups A, B, C and E with the relative abundance of each type similar between 
parasites (Gardner et al., 2002, Lavstsen et al., 2003, Kraemer and Smith, 2003, 
Rask et al., 2010). Each parasite contains approximately 20% group A, 60% group B 
and 20% group C var genes (Rask et al., 2010). Group E is unique in that it comprises 
only one gene, var2csa, whose protein product binds the chondroitin sulphate A 
(CSA) receptor of placental cells, resulting in pregnancy associated malaria (PAM) 
(Salanti et al., 2003). var2csa is relatively conserved across isolates (Rask et al., 
2010) and appears to play an additional role in var gene regulation (Ukaegbu et al., 
2015). Group A and B genes are found in subtelomeric regions and are transcribed 
in opposite directions, while group C genes occupy a central chromosome position 
and are transcribed towards the telomere (Figure 1.3) (Gardner et al., 2002). Two 
intermediate groups exist: B/A which are chimeric UPS B genes with UPS A gene  
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Figure 1.3. Chromosomal position and structure of P. falciparum var genes. 
A, The chromosomal position and orientation of var gene subgroups. Group A and B 
var genes are subtelomeric and are transcribed in opposite directions as indicated. 
Group C var genes are found in central chromosome regions and are transcribed 
towards the telomere. The transitional group B/C var genes are upstream sequence 
(UPS) type B but are centrally located (not shown). B, The two exon structure of a 
var gene and the modular PfEMP1 protein it encodes. Numbers indicate length in 
kilobase pairs. Exon 1 encodes the extracellular region of PfEMP1 which consists of 
an N-terminal segment (NTS) and a variable number of Duffy binding-like (DBL) and 
cysteine-rich interdomain region (CIDR) domains. Exon 2 encodes the 
transmembrane (TM) and acidic terminal segment (ATS) domains.  
 
properties and B/C which consist of centrally located UPS B genes (Lavstsen et al., 
2003). var genes consist of two exons: exon 1, which encodes the highly variable 
extracellular domains and the transmembrane (TM) domain, and exon 2 which 
encodes the semi-conserved intracellular acidic terminal sequence (ATS) (Figure 
1.3).  
1.7 var gene expression and regulation 
Expression of var genes occurs via allelic exclusion whereby only one gene is 
transcribed and presented on the IE surface and switching of the expressed variant 
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occurs, resulting in clonal antigenic variation, a process regulated by epigenetic 
mechanisms (Scherf et al., 1998). Expression is partly determined by the chromatin 
architecture with the active var gene in a euchromatic state and the remaining 
silenced var genes in areas of heterochromatin. Exact mechanisms of activation and 
switching between var genes are unknown but recent work implicates histone 
modifications, a var expression site (VES) and the var intron.  
Silent var genes are marked by the histone modification H3K9me3 and P. 
falciparum heterochromatin protein 1 (PfHP1) (Flueck et al., 2009, Lopez-Rubio et 
al., 2007, Perez-Toledo et al., 2009). The histone modifying enzymes involved are 
PfSIR2A which acts on UPS A, C and E var genes (Freitas-Junior et al., 2005, 
Duraisingh et al., 2005, Tonkin et al., 2009, Merrick et al., 2010), PfSIR2B which acts 
on UPS B genes (Tonkin et al., 2009), and P. falciparum histone deacetylase 2 
(PfHDA2) which acts on all genes (Coleman et al., 2014). The active var gene is 
characterised by H3K9ac and H3K4me2/3 (Lopez-Rubio et al., 2007) and the variant 
histones H2A.Z and H2B.Z (Petter et al., 2013). The H3K36me3 modification, carried 
out by PfSET2, marks both the active var gene and silenced var genes but is 
depleted at the active gene during transcription, suggesting a role in regulation of 
expression of the active var gene within the 48 hour life cycle, i.e. keeping it in a 
poised state (Jiang et al., 2013, Ukaegbu et al., 2014). The histone 
methyltransferase PfSET10 has also been associated with the poised gene and is 
suggested to play a role in this transient repression (Volz et al., 2012).  
The expression of the active var gene is reported to occur at a specific site (var 
expression site, VES) and it is suggested that switching is mediated by transfer of a 
silent gene to and the active gene away from the VES (Lopez-Rubio et al., 2009, 
Duraisingh et al., 2005, Marty et al., 2006, Ralph et al., 2005, Voss et al., 2006, 
Dzikowski et al., 2007). This repositioning is mediated by actin which binds 
indirectly to the var gene intron (Zhang et al., 2011a). The var intron plays a further 
role by pairing with the 5’ upstream promoter region to carry out essential gene 
regulatory functions (Deitsch et al., 2001, Voss et al., 2006, Frank et al., 2006, 
Swamy et al., 2011). Additionally, the var intron transcribes both sense and 
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antisense non-coding RNA (Epp et al., 2009) which has been shown to mediate UPS 
A gene silencing (Zhang et al., 2014).  
The exact molecular mechanisms involved in var gene switching remain unknown. 
However, switch rates between genes are variable (Fastman et al., 2012, Horrocks 
et al., 2004) with centrally located var genes more highly transcribed in vitro (Frank 
et al., 2007, Peters et al., 2007, Zhang et al., 2011b, Fastman et al., 2012). This is 
thought to be due to high activation bias towards centrally located var genes in 
vitro (Noble et al., 2013). This activation bias supports theories that switching 
follows, to a certain extent, pre-programmed patterns (Recker et al., 2011, Enderes 
et al., 2011, Fastman et al., 2012). A recent study of a newly culture-adapted field 
isolate supported the notion of variable switch rates between genes and showed 
that some switching patterns were maintained between clones but that switching 
from one dominant gene did not always lead to expression of another particular 
gene (Ye et al., 2015). This presents a very complex view of var gene switching. It is 
likely that our study of in vitro cultures will not be sufficient to elucidate switching 
patterns as they may be influenced by a variety of host factors, such as immune 
pressure and receptor availability e.g. presence of CSA in pregnancy.  
1.8 PfEMP1 structure and classification 
PfEMP1 are large (200-450 kDa) modular proteins made up of an N-terminal 
segment (NTS), a variable number of Duffy binding-like (DBL) and cysteine-rich 
interdomain region (CIDR) domains, a TM domain and ATS region. DBL and CIDR 
domains mediate the binding capabilities of PfEMP1 and are classified into types 
DBLα, β, γ, δ, ε, ζ and x and CIDRα, β, γ and δ based on small regions of semi-
conserved sequence (Smith et al., 2000b, Lavstsen et al., 2003, Rask et al., 2010) 
and further into subtypes, e.g. DBLα1, also based on sequence similarity (Rask et 
al., 2010). DBL domains belong to a wider family of Plasmodium adhesive domains 
which are mainly involved in erythrocyte binding and invasion (Adams et al., 1992, 
Chitnis and Miller, 1994). In addition to classification by type, DBL domains can be 
separated into three structural subdomains, S1-S3, which are flanked by regions of 
sequence homology (homology blocks, HBs) (Smith et al., 2000b, Rask et al., 2010).  
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Figure 1.4. PfEMP1 domain architecture. 
A, PfEMP1 proteins consist of a variable number of DBL and CIDR domains. Group B 
and C protein predominantly have a four domain structure made up of the N-
terminal head structure (DBLα-CIDR) and a second DBL-CIDR pair. Group A PfEMP1 
proteins (and some larger group B and C proteins) have addition DBL domains 
downstream of the head structure and/or the second DBL-CIDR pair. B, DBL and 
CIDR domains occur in tandem to form domain cassettes (DCs) which are linked to 
adhesion phenotypes, as indicated. DC8 is a chimeric B/A gene consisting of UPS 
type B with a structure typical of group A PfEMP1 proteins. * not CIDRα1.2 or 1.3. 
Figure modified from (Hviid and Jensen, 2015). 
 
The domain composition varies between PfEMP1 proteins but the majority contain 
an N-terminal head structure, also known as component 1, consisting of DBLα- CIDR 
domains (Rask et al., 2010) (summarised in Figure 1.4A). Most group B, B/C and C 
NTS DBLα0 CIDRα2-6 DBLδ CIDRβ/γ/δ TM ATS... ...Groups B and C
NTS DBLα1 CIDRβ/γ/δ DBLδ CIDRβ/γ/δ TM ATS... ...
NTS DBLα1 CIDRα1 DBLδ CIDRβ/γ/δ TM ATS... ...Group A
DBLβ/γ DBLγ/ε/ζ
UPSA NTS DBLα1.1/1.4 CIDRα1.6 DBLβ3 DC4
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UPSA DBLγ12 DBLδ5 CIDRβ3/4 DBLδ7/9
UPSB NTS DBLα2 CIDRα1.1/1.8 DBLβ12 DBLγ4/6 DC8
UPSA NTS DBLα1.7 CIDRα1.1-1.8* DC13
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proteins contain another DBL-CIDR pair downstream of the head structure, whereas 
most group A and B/A proteins contain this second DBL-CIDR pair plus additional 
DBL domains (Rask et al., 2010). As a result, group A and B/A proteins are much 
longer than group B, B/C and C proteins. In a study of seven distinct genomes, 
combinations of DBL and CIDR domain types that frequently occur together were 
identified and are known as domain cassettes (DCs) (Rask et al., 2010) (Figure 1.4B). 
There are two unique var genes that are semi-conserved across isolates, type 3 and 
VAR2CSA. The role of type 3 is unknown whereas VAR2CSA is important in PAM and 
the var2csa gene is thought to play a role in regulation of var gene expression 
(Salanti et al., 2003, Ukaegbu et al., 2015). 
Crystal structures of several DBL (Higgins, 2008a, Khunrae et al., 2009, Vigan-
Womas et al., 2012) and CIDR (Klein et al., 2008, Lau et al., 2015) domains have 
been solved and reveal them to consist mainly of α-helices joined by variable loops. 
This structure is conducive to sequence variation both in the loops, which lack 
structure, and in the variety of residues which can result in α-helices (Higgins and 
Carrington, 2014). Crystal structures, along with small angle x-ray scattering (SAXS) 
data, have identified two different overall quaternary PfEMP1 structures. VAR2CSA 
has a compact structure where the domains are folded together (Clausen et al., 
2012), whereas IT4var13 has a rigid, elongated structure (Brown et al., 2013). The 
majority of PfEMP1 proteins are predicted to have a structure similar to IT4var13 
based on the unique nature of VAR2CSA as a conserved protein responsible for a 
very particular case of receptor binding to placental syncytiotrophoblasts. However, 
the structures of additional full length PfEMP1 proteins will be required to confirm 
this theory.  
1.9 PfEMP1 receptor binding and host disease 
PfEMP1 proteins bind to a number of host receptors, with domain subtypes 
reported to determine specificity. However, determining the role of each PfEMP1-
receptor interaction in development of severe disease is challenging due to the 
variety of SM phenotypes (see section 1.2) and the inconsistency of clinical 
definitions and control groups between studies. There are also difficulties in 
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relating a single interaction to a role in such a complex multi-faceted disease. 
However, a number of host receptors for PfEMP1 have been identified and their 
associations with malarial disease are discussed here. Specific domain subtypes that 
mediate binding are discussed extensively in Chapter 4 and so are not explicitly 
mentioned here.  
1.9.1 CD36 
CD36 is a glycoprotein expressed on endothelium cells, monocytes, macrophages, 
dendritic cells and platelets (Silverstein and Febbraio, 2009) and it was one of the 
first receptors identified as a mediator of IE binding (Ockenhouse et al., 1989). 
CD36 binding is common in field isolates (Newbold et al., 1997, Rogerson et al., 
1999) and is mediated by subtypes of CIDRα domains (Baruch et al., 1997, Robinson 
et al., 2003). However, the role of CD36 binding in disease is unclear with studies of 
patient isolates variously showing associations with UM (Udomsangpetch et al., 
1996, Ochola et al., 2011), CM (Almelli et al., 2014) or no associations (Newbold et 
al., 1997, Marsh et al., 1988, Rogerson et al., 1999, Heddini et al., 2001b). However, 
the majority of group B and C PfEMP1 contain CD36 binding domains and 
expression of these groups has been associated with UM (Kirchgatter and del 
Portillo, 2002, Kyriacou et al., 2006, Rottmann et al., 2006, Warimwe et al., 2009). 
In addition, deficiency in CD36 does not protect against SM (Fry et al., 2009). 
Overall, evidence supports an association of CD36 with UM (Cabrera et al., 2014). 
However, some PfEMP1 proteins can bind to multiple receptors and a role for CD36 
in co-operative binding has been observed with ICAM-1 (McCormick et al., 1997, 
Yipp et al., 2000, Gray et al., 2003), an observation which alludes to the complexity 
of PfEMP1-host interactions.  
The role of CD36 expressed on immune cells and platelets in IE adhesion is not 
clear. IE adherence to dendritic cells has been shown to inhibit their maturation 
with consequent reduced ability to stimulate T cells (Urban et al., 1999). However, 
dendritic cell dysfunction was shown to be related to a high IE dose and to occur 
independently of PfEMP1 mediated adhesion to CD36 in another study (Elliott et 
al., 2007b). Therefore, the relevance of dendritic cell CD36 binding in infection 
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remains disputed. However, functional dendritic cells have been shown to be 
essential for parasite clearance in animal models (Wykes et al., 2007), highlighting 
their importance. A large scale association study found that monocyte CD36 
expression is significantly higher in UM versus SM, suggesting a protective effect, 
whereas high platelet CD36 expression is associated with CM and lactic acidosis 
(Cserti-Gazdewich et al., 2012). The mechanism by which platelet CD36 leads to 
disease is unknown but may involve IE adherence. 
1.9.2 ICAM-1  
Intercellular adhesion molecule-1 (ICAM-1), an immunoglobulin (Ig)-like molecule 
expressed on endothelium and leukocytes involved in transmigration of leukocytes 
to sites of inflammation (Lawson and Wolf, 2009), is another host receptor of 
PfEMP1 (Berendt et al., 1989). Binding to ICAM-1 is mediated by DBLβ domains 
(Smith et al., 2000a, Chattopadhyay et al., 2004, Springer et al., 2004) which bind at 
sites that are distinct but overlap with native binding of lymphocyte function 
associated molecule 1 (LFA-1) (Berendt et al., 1992, Ockenhouse et al., 1992a), 
suggesting that IE binding may interfere with native function. The link between 
ICAM-1 binding and disease severity has been studied in cultured field isolates with 
varying results. Some studies link ICAM-1 binding with severe malaria (Turner et al., 
2013) and cerebral malaria specifically (Newbold et al., 1997, Ochola et al., 2011), 
whereas others found no association with disease (Rogerson et al., 1999, Heddini et 
al., 2001b, Almelli et al., 2014). However, ICAM-1 has been associated with 
sequestered parasites at autopsy (Turner et al., 1994) and ICAM-1 expression levels 
are up-regulated in malaria infection (Turner et al., 1998, Moxon et al., 2013) as a 
consequence of endothelial activation. A recent study demonstrated that parasites 
from children with intestinal disease bound more strongly to ICAM-1 than those 
without, although sample sizes were small (Church et al., 2016), implicating ICAM-1 
binding in the development of organ-specific disease. Further studies will be 
required to investigate this link. It has also been shown that ICAM-1 binding can act 
in synergy with CD36 to contribute to sequestration (Yipp et al., 2000, McCormick 
et al., 1997, Gray et al., 2003), suggesting that multi-receptor binding of a single 
PfEMP1 may contribute to disease progression.  
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The majority of ICAM-1 binding DBLβ domains occur in group B and C PfEMP1 
which also contain CD36 binding domains (Howell et al., 2008, Janes et al., 2011, 
Rask et al., 2010), a trait generally associated with UM (see section 1.9.1 above). 
One exception is a group A gene containing DC4 which binds ICAM-1 but not CD36 
(Bengtsson et al., 2013b). DC4 was identified when a gene from the 3D7 P. 
falciparum clone (PFD1235w) was specifically recognised by IgG from semi-immune 
African children and orthologues were found in other parasite isolates (Jensen et 
al., 2004, Bengtsson et al., 2013b). Antibodies against PFD123w are acquired in 
early life and are associated with protection against clinical disease (Jensen et al., 
2004, Lusingu et al., 2006).The association of ICAM-1 binding with both UM and SM 
suggests that a single domain-receptor interaction is not informative of disease 
outcome but rather that the combination of domain binding characteristics of each 
PfEMP1 is important. Indeed, it is now thought that DCs are more informative of 
the clinical significance of PfEMP1 variants after DC8 and DC13 were found to be 
preferentially expressed by parasites selected for adhesion to brain endothelial cells 
(Avril et al., 2012, Claessens et al., 2012). However, very recent work on these DCs 
suggests that the situation is complex (see section 1.9.3 below). Interestingly, these 
particular DCs do not bind ICAM-1, suggesting the role of an additional receptor in 
brain endothelial cell binding. 
1.9.3 EPCR 
As mentioned above, panning of IEs on brain endothelial cells selected parasites 
expressing DC8 and DC13 containing PfEMP1 (Avril et al., 2012, Claessens et al., 
2012). The transcription of these DCs in patient isolates is associated with CM 
(Lavstsen et al., 2012, Bertin et al., 2013, Almelli et al., 2014) and SMA (Lavstsen et 
al., 2012), suggesting a link to pathogenesis. The receptor for DC8 and DC13 was 
identified, by screening the full length IT4var20 protein (DC8) against a library of 
2,500 human receptors, as the endothelial protein C receptor (EPCR) (Turner et al., 
2013). EPCR is an endothelial cell receptor which binds protein C and, in 
conjunction with thrombomodulin, produces activated protein C (APC) which 
mediates anticoagulant systems (Aird et al., 2014). Additionally, EPCR is required 
for APC activation of PAR-1 which promotes cytoprotection, including activation of 
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anti-inflammatory responses and protection of the endothelial barrier (Aird et al., 
2014). Therefore, disruption of the native role of EPCR by IE binding suggests an 
important role in pathogenesis by promoting thrombi and by breakdown of the 
endothelial barrier. EPCR and thrombomodulin are expressed at low levels in brain 
endothelium (Laszik et al., 1997) making them vulnerable to disruption. 
Interestingly, the loss of these receptors is observed in CM in association with 
adherent IEs (Moxon et al., 2013). The mechanism by which EPCR is lost in CM is 
unknown and may well be separate from EPCR disruption by IE binding.   
The presence of DC8 and DC13 in all but one of seven parasite genomes studied 
(Rask et al., 2010) led to great optimism that EPCR binding is a common parasite 
feature that can be disrupted as a therapeutic method to prevent SM. The CIDRα 
domain mediates ECPR binding (Turner et al., 2013) and the majority of non-CD36 
binding CIDRα subtypes have been shown to bind EPCR with nanomolar affinity in 
recombinant protein assays (Lau et al., 2015). Co-crystals of CIDRα bound to EPCR 
show an overlapping binding site with APC (Lau et al., 2015), supporting IE blockage 
of native EPCR function. However, two recent papers challenge the relative 
importance of EPCR binding between different PfEMP1 proteins (Sampath et al., 
2015, Gillrie et al., 2015). Several CIDRα domains were shown to bind EPCR with 
variable affinity but all within the nanomolar range (Sampath et al., 2015), in 
keeping with previous results (Lau et al., 2015). However, the ability of CIDRα 
domains to block APC binding varied, as did the effect of anti-EPCR antibodies, 
suggesting overlapping but distinct binding sites between CIDRα domains (Sampath 
et al., 2015). These results are reminiscent of DBLβ∷ICAM-1 interaction studies 
which show variable binding affinity and overlapping but distinct binding sites of 
different DBLβ domains (Brown et al., 2013, Tse et al., 2004, Madkhali et al., 2014). 
Gillrie et al. (2015) assessed binding of parasite lines expressing a DC8 PfEMP1 
(IT4var19) and a DC13 PfEMP1 (IT4var07) to human microvascular endothelial cells 
(HMEC) under flow conditions. The authors found that binding to transformed brain 
HMECs and lung HMECs was partially dependant on EPCR, whereas binding to 
primary brain HMECs and dermal HMECs was not dependant on EPCR, suggesting 
binding is mediated by different receptor(s) (Gillrie et al., 2015). There is still much 
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to learn about EPCR, the most recently identified PfEMP1 receptor, and the 
contribution of this interaction to pathogenesis.  
1.9.4 PECAM-1 
Parasites, both laboratory-adapted (Treutiger et al., 1997) and clinical isolates 
(Heddini et al., 2001a), are known to bind platelet endothelial cell adhesion 
molecule 1 (PECAM-1). However, there appears to be no correlation to disease 
severity (Newbold et al., 1997, Heddini et al., 2001b). PfEMP1 is the parasite ligand 
responsible for binding and was originally mapped to CIDRα and DBLδ domains 
(Chen et al., 2000). However, a recent study has shown PECAM-1 binding by group 
A PfEMP1 containing DC5, which consists of C-terminal domains (DBLγ12-DBLδ5-
CIDRβ3/4-DBLβ7/9) (Berger et al., 2013). The exact binding domain was not 
mapped conclusively (Berger et al., 2013) and, therefore, the involvement of the N-
terminal head structure has not been ruled out. A 3D7 parasite PfEMP1 containing 
DC5 was previously associated with SM (Jensen et al., 2004) and antibodies against 
this PfEMP1 are developed early in infection (Cham et al., 2009, Cham et al., 2010) 
and are associated with protection against malarial disease (Magistrado et al., 
2007). It is therefore possible that PECAM-1 binding is mediated by distinct PfEMP1 
that have differential roles in disease progression, similar to findings with ICAM-1 
(see section 1.9.2).  
1.9.5 Rosetting 
Rosetting is the binding of multiple uninfected erythrocytes to a central IE, a 
process associated with SM (Carlson et al., 1990, Rowe et al., 1995, Kun et al., 
1998). Rosettes mediate pathogenesis by blocking microvessels and obstructing 
blood flow (Kaul et al., 1991). Rosetting parasites have been shown to retain 
endothelial binding ability (Kaul et al., 1991, Adams et al., 2014) which could 
suggest a duel mechanism of disease progression. Several interactions are required 
to form rosettes and are mediated by the PfEMP1 head structure binding to host 
complement receptor 1 (CR1) (Rowe et al., 1997, Rowe et al., 2000), blood group A 
and B antigens (Vigan-Womas et al., 2012, Barragan et al., 2000) and heparin 
sulphate (Carlson and Wahlgren, 1992, Vogt et al., 2003). In addition, certain 
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rosetting PfEMP1 proteins bind IgM via the C-terminal domains (Pleass et al., 2016) 
which is thought to strengthen interactions between infected and uninfected 
erythrocytes (Clough et al., 1998, Somner et al., 2000). Recent studies have shown 
RIFIN and STEVOR proteins to mediate rosetting via blood group A antigen and 
glycophorin C, respectively (Goel et al., 2015, Niang et al., 2009) (discussed in 
section 1.5 above). Whether these VSAs act in tandem with, or independently of, 
PfEMP1 remains to be seen and will likely depend on the specific VSAs expressed on 
the IE surface at any one time.  
1.9.6 Platelet mediated clumping 
Platelet mediated clumping is similar to rosetting but involves binding of IEs to 
other IEs through platelets (Pain et al., 2001). This phenotype is associated with SM 
(Pain et al., 2001, Chotivanich et al., 2004, Wassmer et al., 2008) and has been 
proposed to cause disease by forming a bridge between IE and endothelium, 
allowing binding even in the absence of PfEMP1-specific receptors (Wassmer et al., 
2004), and through activation of platelets resulting in increased immune response 
(Srivastava et al., 2008). The parasite factor that mediates clumping is unknown but 
PfEMP1 has been suggested. The platelet receptors involved are CD36 (Pain et al., 
2001), globular C1q receptor (Biswas et al., 2007) and P-selectin (Wassmer et al., 
2008).   
1.9.7 CSA and malaria in pregnancy 
Pregnancy associated malaria (PAM) is associated with IE binding to CSA in the 
placenta (Fried and Duffy, 1996) and results in vessel blockage and pro-
inflammatory response which leads to reduced placental efficiency, low birth 
weight and increased risk of fetal loss (Fried et al., 1998, Rogerson et al., 2007, 
Umbers et al., 2011). The semi-conserved VAR2CSA PfEMP1 is responsible for 
specific binding to CSA expressed on placental cells (Salanti et al., 2003). The 
second DBL domain has been shown to bind CSA with affinity comparable to the full 
length VAR2CSA (Clausen et al., 2012, Srivastava et al., 2011). However, previous 
studies suggested that the full length protein conferred much higher binding affinity 
(Khunrae et al., 2010, Srivastava et al., 2010) and a recent study conducted in a 
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physiologically relevant context corroborates this (Rieger et al., 2015). PAM mainly 
affects women in their first pregnancy and antibodies against VAR2CSA increase 
with the number of pregnancies and are protective against PAM (Oleinikov et al., 
2007, Tuikue Ndam et al., 2005, Tuikue Ndam et al., 2006, Tutterrow et al., 2012a, 
Tutterrow et al., 2012b). Interestingly, VAR2CSA is rarely recognised (or is 
insignificant) by antibodies from men and children (Beeson et al., 1999, Ricke et al., 
2000, Staalsoe et al., 2001), suggesting VAR2CSA-expressing IEs are rapidly cleared 
in these patients (Oleinikov et al., 2007). This very specific case of PfEMP1-ligand 
binding has led to optimism of an anti-disease vaccine, one of which (PlacMalVac) 
has completed Phase I clinical trials and is in preparation for Phase II clinical trials 
(PlacMalVac).  
1.9.8 Other possible host receptors 
A number of other host receptors have been shown to mediate IE binding with 
PfEMP1 suggested as the ligand but evidence is scarce. These include P-selectin, 
thrombospondin, E-selectin, VCAM-1, fractalkine, integrin ανβ3, fibronectin, NCAM 
and gC1qR-HABP1-p32 [reviewed by Rowe et al. (2009)].  
1.10 Acquired immunity against VSAs 
Immunity to symptomatic malaria is acquired gradually over the course of repeated 
P. falciparum infections (Marsh and Kinyanjui, 2006). In areas of endemic 
transmission, young children are most at risk of developing SM with one study 
reporting acquisition of immunity after just a few infections and the development 
of immune protection from non-cerebral SM by the age of 5 years (Gupta et al., 
1999). However, a recent study suggested a more gradual acquisition of protection 
against SM, based on models of hospital admission data (Griffin et al., 2015). 
Immunity against UM symptoms is not acquired until adolescence or adulthood and 
sterilising immunity is thought to never, or very rarely, be achieved (McGregor, 
1964), resulting in widespread asymptomatic infections. The acquired immunity 
achieved is very complex and consists of responses to a variety of antigens 
expressed at all parasite stages and is effected by both humoral and cell-mediated 
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responses (Beeson et al., 2008). This poses a formidable challenge in the 
development of vaccines against malaria.  
Antibodies are generated against surface exposed antigens, both VSAs on the IE 
surface and merozoite antigens. Important merozoite proteins include merozoite 
surface proteins (MSP) 1-3, erythrocyte binding antigens (EBAs), reticulocyte-
binding protein homologues (RH) and apical membrane antigen 1 (AMA-1), all of 
which have been extensively studied and are considered vaccine candidates 
(Richards and Beeson, 2009). The antibodies acquired against VSAs display a high 
level of strain specificity due to the variable nature of these surface molecules 
(Newbold et al., 1992, Biggs et al., 1991, Marsh and Howard, 1986). Serum from 
adults in convalescence is able to recognise a diverse range of P. falciparum isolates 
(Chattopadhyay et al., 2003), in keeping with exposure dependant development of 
immunity. However, acute infection of naive adults was shown to elicit cross-
reactive antibodies in returned travellers (Elliott et al., 2007a), suggesting the 
presence of shared epitopes between isolates. Anti-VSA antibodies are associated 
with protection against malarial disease in the majority (Marsh et al., 1989, Tebo et 
al., 2002, Dodoo et al., 2001) but not all (Bull et al., 1998) studies. 
The relative contribution of anti-PfEMP1 antibodies to protection against disease is 
difficult to study due to the presence of other VSAs such as RIFINs and STEVORs. 
However, parasites genetically modified to inhibit surface PfEMP1 expression show 
markedly reduced recognition by immune serum compared to wild type parasites , 
suggesting only a minor role of other VSAs (Chan et al., 2012). In addition, PfEMP1 
alone was associated with protective immunity suggesting this protein family is the 
main target of anti-VSA immunity (Chan et al., 2012). However, further study is 
required to establish the role of RIFIN, STEVOR and other VSAs in developing 
immunity. Anti-PfEMP1 response has been demonstrated to be variant-specific in 
children under 3 years but broadly cross-reactive in adults as measured by 
recognition of diverse DBLα domains, following the pattern observed for overall 
immune response to IEs (Barry et al., 2011). The acquisition of antibodies against 
PfEMP1 appears to be structured in relation to the different groups A, B and C. 
Antibodies against PfEMP1 encoded by group A var genes are acquired first (Cham 
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et al., 2009, Cham et al., 2010), supporting the role of particular PfEMP1 in 
development of SM (Rottmann et al., 2006, Jensen et al., 2004). The mechanisms by 
which anti-PfEMP1 antibodies mediate protection against SM include blocking 
adhesion, preventing rosette formation and opsonising IEs for phagocytosis, 
although specific mechanisms are not yet fully understood (Chan et al., 2014).   
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1.11 PhD aims  
 Identify the dominantly expressed var genes of several recently 
characterised ICAM-1-selected culture-adapted patient isolates. 
 Perform targeted sequencing of these var genes by testing the predictive 
power of a new database of ~ 62,000 var genes. 
 Obtain the full length sequence of two var genes identified specifically in the 
brains of children who died of cerebral malaria. 
 Perform extensive sequence analysis of the var genes identified to elucidate 
their predicted binding phenotypes.  
 Recombinantly express the DBLβ domains of the ICAM-1-selected culture-
adapted patient isolates and characterise their ability to bind wild type 
ICAM-1 and four mutant ICAM-1 proteins.  
 Relate the recombinant protein findings to the known IE binding profiles of 
these isolates and assess the implications for anti-adhesion therapies.  
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Chapter 2.  General Methods 
2.1 Parasite techniques 
2.1.1 Parasite culture 
Parasites were cultured according to standard techniques (Trager and Jensen, 1976) 
using RPMI-1640 medium (Sigma) supplemented with 37.5 mM HEPES, 7 mM D-
glucose, 25 ng/ml gentamicin sulphate, 2 mM L-glutamine and 10% human serum 
(Haematology Department, Royal Liverpool University Hospital) at pH 7.2, 
hereafter, referred to as complete medium or serum-free medium when 10% 
human serum is omitted. O+ human erythrocytes were obtained from the National 
Blood and Transfusion Service and added at 2% haematocrit. Cultures were kept at 
a gas mixture of 96% nitrogen, 3% carbon dioxide and 1% oxygen (supplied by BOC). 
Parasitaemia was calculated by examination of 500 red blood cells on Giemsa 
stained (Giemsa’s azur eosin methylene blue solution, Merck Millipore) thin blood 
films. Blood films were made by smearing a drop of parasite culture across a glass 
slide, which was left to air-dry. The smear was then fixed with absolute methanol 
for 10 seconds before staining with Giemsa (Giemsa’s azur eosin methylene blue 
solution, Merck Millipore) diluted 1 in 10 with 10% phosphate-buffered water (20 
mM Na2HPO4, 4 mM KH2PO4, pH 7.2) for at least 5 minutes. Slides were then 
washed with tap water and air-dried before for examination. 
2.1.2 Reconstitution of frozen parasites 
Parasites were removed from liquid nitrogen and placed at 37 °C to thaw quickly 
before being transferred to a 50 ml falcon tube. One fifth volume of pre-warmed 
12% NaCl solution was added dropwise with continual mixing and allowed to stand 
for 5 minutes at room temperature. 5 ml of 1.8% NaCl solution was added dropwise 
over 5 minutes then allowed to stand for 5 minutes at room temperature. 5 ml of 
0.9% NaCl solution was added dropwise over 5 minutes then allowed to stand for 5 
minutes at room temperature. The solution was centrifuged at 600 x g for 5 
minutes to pellet the cells. The supernatant was removed and the cells 
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resuspended in 25 ml pre-warmed serum-free medium (see 2.1.1). Cells were 
pelleted by centrifugation at 600 x g for 5 minutes. The supernatant was removed 
and the cells were resuspended in complete medium, transferred to a sterile tissue 
culture flask and cultured by standard techniques (see 2.1.1). 
2.1.3 Cryopreservation of parasites 
Parasite cultures at 3-5% ring stage parasitaemia were centrifuged at 600 x g for 5 
minutes and the supernatant removed. Glycerolyte freezing solution (6.2 M 
glycerol, 140 mM sodium lactate, 130 mM sodium dihydrogen orthophosphate, 1.6 
mM potassium chloride, pH 6.8) was added in a ratio of 5 volumes to 3 volumes of 
cell pellet with the first volume added dropwise over 5 minutes and left to stand for 
5 minutes. The remaining 4 volumes were then added slowly with constant mixing. 
The resulting solution was transferred to sterile freezing vials and placed at - 80 °C 
for 24 hours before being transferred to liquid nitrogen. 
2.1.4 Trophozoite enrichment by Plasmagel flotation 
Plasmagel solution (Plasmion, Fresenius Kabi France) and serum-free medium was 
pre-warmed to 37 °C. Parasite cultures were centrifuged at 600 x g for 5 minutes 
and the supernatant removed. The cell pellet was resuspended such that the pellet 
made up 20%, serum-free medium 30% and Plasmagel 50% of the total volume. The 
solution was transferred to a 15 ml falcon tube and incubated for 20 minutes at 37 
°C. The supernatant was removed and transferred to a new 15 ml falcon tube, 
centrifuged at 600 x g for 5 minutes and the pellet washed in 10 ml serum free 
medium. After centrifugation, the cell pellet was resuspended in either complete 
medium to continue the culture (see 2.1.1) or 1% Bovine Serum Albumin (BSA) in 
phosphate buffered saline (PBS; hereafter referred to as 1%BSA/PBS) for ICAM-1 
selection (see 3.2.2). A small sample was taken for a Giemsa-stained thin blood film 
to confirm trophozoite enrichment. 
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2.2 Nucleic acid techniques 
2.2.1 RNA extraction 
Parasite RNA extraction was performed by a method adapted from that originally 
described by Kyes et al. (2000). Parasite cultures were pelleted by centrifugation at 
600 x g for 5 minutes. The supernatant was aspirated and the pellet resuspended by 
tapping. Pre-warmed TRIzol® Reagent (Ambion) was added at 10 X pellet volume 
and mixed by pipetting until all clumps disappeared. Following incubation at 37 °C 
for at least 5 minutes, the TRIzol® lysed parasites were split into 1 ml aliquots and 
either frozen at -80 °C or RNA extraction continued immediately. To each 1 ml 
aliquot, 0.2 ml chloroform was added and the tube shaken vigorously for 15 
seconds, left to stand for 2-3 minutes and centrifuged at 1,200 x g for 30 minutes at 
4 °C. The upper aqueous layer was removed to a new 1.5 ml tube. 0.5 ml 
isopropanol was added and mixed by inverting the tube several times before 
incubation at 4 °C for at least 2 hours. The tube was mixed again by inverting 
several times and centrifuged at 16,200 x g for 30 minutes at 4 °C. The supernatant 
was carefully removed and the pellet washed in 0.5 ml 75% ethanol in DEPC-H2O 
(diethyl pyrocarbonate treated H2O, Sigma). After centrifugation at 16,200 x g for 5 
minutes, the supernatant was removed and the pellet left to air dry at room 
temperature. 50 µl DEPC-H2O was added to the pellet before incubation at 65 °C for 
10 minutes and then placed on ice. The RNA was mixed by pipetting and the 
concentration and purity measured by NanoDrop™ 1000 Spectrophotometer 
(Thermo Scientific). RNA was stored at - 80 °C. 
2.2.2 cDNA synthesis 
An RNase free environment was maintained throughout the following reactions. 1.2 
µg RNA was treated with DNase I (Amplification Grade, Sigma-Aldrich) according to 
manufacturer’s instructions. The reaction comprised 2 µl 10 X Reaction Buffer, 2 µl 
DNase I and 1.2 µg RNA made up to a final volume of 20 µl with DEPC-H2O. The 
reaction was incubated for 15 minutes at room temperature.  2 µl Stop Solution 
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(Sigma-Aldrich) was added and the reaction incubated at 70 °C for 10 minutes and 
then chilled on ice.  
cDNA synthesis was performed with Tetro cDNA Synthesis Kit (Bioline) following the 
manufacturer’s instructions. The reaction comprised 8 µl DNase treated RNA (~480 
ng, above), 1 µl Oligo (dT)18 primer,  dNTP at 0.5 mM final concentration, 4 µl 5X RT 
Buffer, 10 U RiboSafe RNase Inhibitor, 200 U Tetro Reverse Transcriptase and DEPC-
H2O up to 20 µl. The reaction was incubated at 45 °C for 30 minutes, followed by 85 
°C for 5 minutes to stop the reaction and chilled on ice. A control without reverse 
transcriptase (no-RT) was carried out to assess DNase I efficiency. cDNA was stored 
at -20 °C.  
2.2.3 Primer design and polymerase chain reaction (PCR) 
All novel primer sequences were designed with the aid of OligoCalc (Kibbe, 2007). 
Primer sequences from previously published work are reproduced with the 
appropriate citation. All primers are listed in Appendix A. 
All PCR reactions were carried out with the proofreading TaKaRa LA Taq® DNA 
polymerase (Clontech, TaKaRa Bio Inc) according to the manufacturer’s 
instructions. Each reaction comprised 10 X LA PCR Buffer II, magnesium chloride 
(MgCl2) at 2.5 mM final concentration, deoxyribonucleotide triphosphates (dNTP) at 
1 mM final concentration, primers at 0.3 mM final concentration each, 2.5 units of 
TaKaRa LA Taq®, 2 µl template and sterile water up to 50 µl final volume unless 
otherwise stated. Specific PCR cycling conditions are stated for each primer set in 
the appropriate chapter and annealing temperatures are listed in Appendix A. 
2.2.4 PCR product purification  
PCR products were visualised by gel electrophoresis on a 2% agarose gel in 1X TBE 
(89 mM Tris-borate, 2 mM EDTA, pH 8.3, Sigma) and stained with ethidium bromide 
at 3 µg/ml final concentration. Products were excised from the gel and purified 
using QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s instructions. 
The PCR product was eluted into a sterile 1.5 ml tube in 50 µl sterile H2O (Sigma). 
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The PCR product concentration was measured by NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific). 
2.2.5 Plasmid sequencing 
All plasmid sequencing was carried out by either the Core Genomic Facility, 
University of Sheffield or Source Bioscience Sequencing, Rochdale UK .  
 
2.3 Protein techniques 
2.3.1 SDS-PAGE 
Proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) on pre-cast PreciseTM Tris-HEPES 12% gels 
(ThermoFisher Scientific) in PierceTM 20X Tris-HEPES-SDS Buffer diluted to 1X to 
contain 0.1 M Tris, 0.1 M HEPES, 3 mM SDS at pH 8. Samples were prepared by 
adding an equal volume of 2X sample buffer (65.8 mM Tris-HCl, pH 6.8, 26.3% 
glycerol, 2.1% SDS, 0.01% bromophenol blue, 5% 2-mercaptoethanol) and boiling 
for 10 minutes before being placed on ice and briefly spun down in a bench-top 
centrifuge. Amersham Low Molecular Weight Marker (GE Healthcare) was used as a 
protein standard on each gel. SDS-PAGE was carried out at 90-150 V for 60-90 
minutes until the dye front was near the bottom of the gel. 
2.3.2 Coomassie staining 
Gels were stained with 0.16% Coomassie Brilliant Blue (ThermoFisher Scientific) in a 
solution of methanol, H2O and acetic acid in the ratio 5:5:1 for ~10 minutes and 
washed with hot water several times before addition of destain solution (methanol, 
H2O and acetic acid in the ratio 5:5:1). Gel images were taken using an InGenius 
Bioimager (Syngene). 
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2.3.3 Western blotting 
N-terminal histidine tagged proteins were detected by Western blot. Samples were 
separated by SDS-PAGE (see 2.3.1) and transferred to an Amersham Protran 0.45 
nitrocellulose membrane (GE Healthcare) in transfer buffer (25 mM Trizma-base, 
190 mM glycine, 20% methanol) at 200 V for 1 hour. The membrane was stained 
with 0.1% Ponceau S (Sigma) in 5% acetic acid until bands became visible. The 
protein marker was marked with pen and the stain washed out with TNT buffer (10 
mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20). The membrane was blocked with 5% 
milk (Sigma) in TNT buffer for 1 hour, shaking at room temperature. Primary Mouse 
anti-his antibody (H1029, Sigma) was diluted 1:1000 in SignalBoostTM 
Immunoreaction Enhancer Kit (Merck Millipore) Solution 1 for primary antibodies 
and incubated on the membrane for 1 hour, shaking at room temperature. The 
membrane was washed 3 x 5 minutes with TNT buffer. The secondary Goat Anti-
Mouse IgG-horseradish peroxidise (HRP) Conjugate antibody (Bio-Rad) was diluted 
1:5000 in SignalBoostTM Immunoreaction Enhancer Kit (Merck Millipore) Solution 2 
for secondary antibodies and incubated on the membrane overnight at 4 °C, 
shaking. The membrane was washed 3 x 5 minutes with TNT buffer and incubated 
for 5 minutes in SuperSignalTM West Pico Chemiluminescent Substrate 
(ThermoFisher Scientific) according to manufacturer’s instructions. The membrane 
was then exposed to CL-XPosureTM Film (Thermo Scientific) and developed on a 
photon imaging systems machine (AFP Imaging Corp).  
 
2.4 Software 
2.4.1 Analysis of plasmid sequences 
Plasmid sequences were initially visualised using Chromas Lite Version 2.1 
(Technelysium Pty Ltd, latest version available at http://technelysium.com.au/). 
Sequence alignments were carried out using ClustalX 2.1 (Larkin et al., 2007) unless 
otherwise stated.  
33  
2.4.2 Translation software 
Nucleic acid sequences were translated into amino acid sequence using either 
ExPASy Translate tool (Swiss Institute of Bioinformatics (SIB), available at: 
http://web.expasy.org/translate/) or EMBOSS Transeq (European Molecular Biology 
Laboratory-European Bioinformatics Institute (EMBL-EBI), available at: 
http://www.ebi.ac.uk/Tools/st/emboss_transeq/).  
2.4.3 BLAST® 
The National Centre for Biotechnology Information (NCBI) BLAST® resource 
(available at: http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to search for 
sequence similarities among the vast nucleotide database. The BLAST® align feature 
was also used to compare nucleotide sequences.  
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Chapter 3. Identifying dominantly expressed 
var genes of Plasmodium falciparum 
3.1 Introduction 
Sequestration of the malaria-causing parasite Plasmodium falciparum in the 
microvasculature of the human host is thought to be a key process in the 
pathogenesis of severe disease, including cerebral malaria (Newton et al., 1998, 
Taylor et al., 2004). Sequestration is mediated by the parasite protein family 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), encoded by var 
genes (Baruch et al., 1995, Smith et al., 1995, Su et al., 1995). The 50-60 var gene 
copies per genome are classified according to 5’ upstream sequence (UPS), 
chromosomal location and transcriptional orientation into three main groups A, B 
and C (Voss et al., 2000, Gardner et al., 2002). They are subject to mutually 
exclusive expression regulated by epigenetic mechanisms (Scherf et al., 1998). The 
large, highly variable, modular PfEMP1 proteins are made up of DBL (Duffy binding-
like) and CIDR (cysteine-rich interdomain region) domains  which are classified into 
types DBLα, β, γ, δ, ε, ζ and x and CIDRα, β, γ and δ based on sequence identity 
(Smith et al., 2000b, Lavstsen et al., 2003, Rask et al., 2010). These domains 
mediate binding to a variety of host endothelial cell receptors (Rowe et al., 2009, 
Turner et al., 2013), including intercellular adhesion molecule 1 (ICAM-1) (Berendt 
et al., 1989) which has been implicated in severe malaria. 
The link between ICAM-1 binding and disease severity has been studied in cultured 
field isolates with varying results. Some studies link ICAM-1 binding with severe 
malaria (Turner et al., 2013) and cerebral malaria specifically (Newbold et al., 1997, 
Ochola et al., 2011), whereas others found no association with disease (Rogerson et 
al., 1999, Heddini et al., 2001b). However, ICAM-1 has been associated with 
sequestered parasites at autopsy (Turner et al., 1994) and ICAM-1 binding is likely 
to act in synergy with other receptors to contribute to sequestration and disease 
progression (Yipp et al., 2000, McCormick et al., 1997). The nature of such a 
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complex host-parasite interaction makes it difficult to pinpoint the exact role of 
ICAM-1 binding but it appears to play a significant role in disease pathogenesis. 
The ICAM-1-PfEMP1 interaction has mainly been characterised in the reference 
strains of IT4 lineage and 3D7 (Howell et al., 2008, Janes et al., 2011, Oleinikov et 
al., 2009, Bengtsson et al., 2013b) and it is the DBLβ domain that mediates binding 
(Smith et al., 2000a, Brown et al., 2013). This focus on established reference strains 
is due to ease of culture, the knowledge of their var gene sequences and availability 
of qPCR primer sets targeting all var genes (Viebig et al., 2007), a requirement for 
confirmation of a culture’s dominantly expressed var gene. Sequencing the var 
genes of recently culture-adapted field isolates is a challenge. Primer sets designed 
to homology blocks within PfEMP1 domains are based on our knowledge from 
several P. falciparum genomes (Bull et al., 2005, Rask et al., 2010) and may not 
target all genes in the global population. Advances in whole genome sequencing 
(WGS) present a viable option but there is still difficulty in accurately assembling 
var genes due to low read coverage (Gardner et al., 2002, Manske et al., 2012). The 
Pf3k genome sequencing project 
(https://www.malariagen.net/projects/parasite/pf3k) aims to sequence 3,000 P. 
falciparum genomes worldwide and has generated a vast amount of data to date 
(Manske et al., 2012, Miotto et al., 2013), including a new database of ~62,000 var 
genes.  
In this chapter, we investigate the practical applications of the Pf3k var database by 
assessing whether a full length var gene can be predicted from a short sequence 
tag. The DBLα tag in question is a 350-400 bp section of the N-terminal DBLα 
domain amplified with primers designed by Bull et al. (2005) to short regions of 
homology. Our group has recently characterised the binding profile of several 
culture-adapted patient isolates that have been selected for ICAM-1 binding 
(Madkhali et al., 2014). This characterisation is extended to the molecular level by 
identifying the var genes responsible for ICAM-1 binding in these isolates and 
utilizing the Pf3k var database to obtain their full length sequences. We also test 
this approach on clinical samples from Malawi from which two var genes were 
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found to be expressed at a high level in the brains of multiple children who suffered 
fatal cerebral malaria (Tembo et al., 2014).  
 
3.2 Methods 
3.2.1 Parasite isolates 
Laboratory-adapted patient isolates PO69 and 8206, from Kenya, and BC12, J1 and 
PCM7, from UM patients in Thailand (Poyomtip et al., 2012), were collected with 
consent in previous clinical studies. All patient-derived material, such as white 
blood cells, have been removed during culture. All five patient isolates were used 
for the var gene analysis described below. The laboratory line ItG derived from the 
IT 4/25/5 lineage (Ockenhouse et al., 1992a) was used for DNA extraction and 
genotyping.  
3.2.2 Parasite selection on ICAM-1 
50 µl Protein A Dynabeads (Invitrogen) were washed three times with 500 µl 1% 
BSA/PBS, using a magnet to retain the beads each time. The beads were 
resuspended in 1% BSA/PBS and 2.5 µg ICAM-1D1D5 (an Fc fusion protein of ICAM-1 
domains 1-5 (Tse et al., 2004)) added to a final volume of 400 µl and incubated at 
room temperature with 15 rpm rotation using a stuart SB3 rotator (Bibby Scientific) 
for 1 hour. The beads were then washed three times with 500 µl 1% BSA/PBS using 
a magnet to retain the beads and resuspended in 200 µl 1% BSA/PBS. Parasite 
cultures were enriched for trophozoite stage using Plasmagel by standard 
techniques (see 2.1.4). Enriched parasites were resuspended in 200 µl 1% BSA/PBS 
and added to the ICAM-1 labelled Dynabead suspension. The mixture was rotated 
at 15 rpm using a stuart SB3 rotator (Bibby Scientific) for 45 minutes at room 
temperature. Two washes were carried out with 500 µl 1% BSA/PBS to remove 
unbound parasites. The beads were then transferred to a culture flask in complete 
medium with washed red blood cells (RBC) and cultured as standard (see 2.1.1).  
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3.2.3 DBLα tag polymerase chain reaction (PCR) of cDNA 
RNA was extracted from ICAM-1 selected parasites at peak var gene expression, 6- 
12 hours post invasion (Kyes et al., 2000), by a method modified slightly from Kyes 
et al (2000) and cDNA synthesised (see 2.2.1 and 2.2.2). The DBLα tag was amplified 
from parasite cDNA using the primers DBLαAF഻ and DBLαBR (Bull et al., 2005) 
(Appendix A) with the proofreading TaKaRa LA Taq® DNA polymerase (Clontech, 
TaKaRa Bio Inc) as described (see 2.2.3). Reaction conditions were an initial 
denaturing step of 95 °C for 3 minutes, followed by 30 cycles of 95 °C for 30 
seconds, 47 °C for 30 seconds, 65 °C for 30 seconds, and a final extension of 65 °C 
for 3 minutes. PCR products were purified as stated (see 2.2.4). A reaction was 
carried out with the no-RT control as template to show successful DNase treatment. 
3.2.4 DBLα tag cloning, plasmid preparation and sequencing 
DBLα tag PCR products were cloned into pCRTM4-TOPO® vector (Invitrogen) at 10:1 
insert to vector molar ratio. The reaction comprised 1 µl Salt Solution (1.2 M NaCl, 
0.06 M MgCl2), 1 µl pCRTM4-TOPO® (10 ng) with ~ 10 ng insert in a final reaction 
volume of 6 µl. The reaction was incubated for 30 minutes at room temperature 
then placed on ice. The plasmid was transformed into One Shot® TOP10 E. coli 
competent cells (Invitrogen). 2 µl of ligation reaction were added to 50 µl 
competent cells, incubated on ice for 10 minutes, heat shocked at 42 °C for 30 
seconds and kept on ice for 2 minutes before addition of 250 µl SOC medium (2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose). Cells were shaken for 1 hour at 37 °C before being spread 
on agar plates containing 100 µg/ml ampicillin and X-gal for selection of 
transformants. Two volumes were plated, 100 µl and 50 µl, and the plates were 
incubated at 37 °C overnight.  
Positive colonies were picked and cultured overnight in LB broth (1% tryptone, 0.5% 
yeast extract, 85.6 mM NaCl; Sigma) with 100 µg/ml ampicillin. Plasmids were 
isolated using GenElute Plasmid Miniprep Kit (Sigma) or QIAprep Spin Miniprep Kit 
(QIAGEN) following the manufacturer’s instructions. The culture was centrifuged at 
1,877 x g for 10 minutes. The pellet was resuspended, lysed and precipitated using 
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the kit solutions. The resulting lysate was spun through a column, washed and 
eluted in 70 µl sterile water. Plasmids were restriction digested with EcoRI (New 
England Biolabs) to confirm the expected size of the insert. The reaction comprised 
of 2 µl NEBuffer I (10 mM Bis-Tris-Propane-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.0 at 
25 °C), 20 U EcoRI, 5 µl plasmid and water up to 20 µl. The digest was incubated at 
37 °C for at least one hour before being visualised by gel electrophoresis on a 2% 
agarose gel in TBE subsequently stained with ethidium bromide. Twenty to twenty-
four plasmids per strain were sequenced as described (see 2.2.5). Sequences were 
visualised with Chromas Lite version 2.1 and alignments were carried out using 
ClustalX 2.1 on default settings (see 2.4.1). 
3.2.5 Reverse transcriptase quantitative PCR (RT-qPCR) 
RT-qPCR of the cDNA was carried out using Brilliant III Ultra-Fast SYBR® Green QPCR 
Master Mix (Agilent Technologies). Standard curves were generated for each new 
primer set (see Appendix A for primer sequences) by performing 10-fold serial 
dilutions of cDNA to produce five different concentrations of starting material. No-
RT and DPEC-H2O reactions were carried out as negative controls. All reactions 
were performed in triplicate. Each reaction comprised 10 µl 2X SYBR Green QPCR 
master mix, forward and reverse primers each at 0.5 µM final concentration, 2 µl 
template (cDNA, no-RT or DPEC-H2O) and DPEC-H2O to 20 µl final volume. 
Adenylosuccinate lyase (ASL) and seryl- tRNA synthetase (STS) were internal control 
genes (Viebig et al., 2005). Reactions were carried out on an MxPro-Mx3005P 
machine under the following conditions: 95 °C for 3 minutes, followed by 40 cycles 
of 95 °C for 10 seconds, 60 °C for 10 seconds, and a final cycle of 95 °C for 1 minute, 
55 °C for 30 seconds, 95 °C for 30 seconds. 
Primer efficiency was calculated from the gradient of the standard curve using the 
equation: 
E = 101/-m 
where E is efficiency and m is the gradient of the curve. 
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RT-qPCR was repeated on cDNA at a single concentration with the same reagents 
and conditions (as above) using all primer pairs designed to particular isolates on 
the same plate. Ct values were normalised against the internal control gene using 
the equation: 
     2-ΔCt 
where ΔCt is the mean Ct value of the gene of interest minus the mean Ct value of 
the internal control gene. 2-ΔCt values were transformed into percentage of the total 
for each parasite isolate.  
3.2.6 Genomic DNA extraction 
Genomic DNA (gDNA) was extracted from parasite cultures by saponin lysis of the 
RBC and the QIAamp® DNA Blood Mini Kit (Qiagen). Parasite cultures were 
centrifuged at 600 x g for 5 minutes and the resulting pellet was resuspended in 5 
ml 0.15 % saponin and incubated for 5 minutes on ice, mixing each minute. 
Parasites were centrifuged at 600 x g for 5 minutes and washed in PBS 2-3 times. 
Following the final centrifugation, the parasite pellet was resuspended in 200 µl PBS 
and transferred to a 1.5 ml tube containing 20 µl Qiagen protease. The QIAamp® 
DNA Blood Mini Kit (Qiagen) spin protocol was followed with a final elution of the 
parasite DNA in 100 µl Buffer AE (10 mM Tris- HCl, 0.5 mM EDTA, pH 9).  
3.2.7 Merozoite surface protein (MSP) and glutamate-rich protein (GLURP) 
genotyping 
MSP primary PCR 
Merozoite surface protein (MSP) genotyping was performed following 
Recommended Genotyping Procedures (Medicines for Malaria Venture, Amsterdam 
May 2007). An initial primary PCR reaction using both msp1 and msp2 primers 
comprised: 5 µl 10x NH4 reaction buffer, MgCl2 to 2 mM final concentration, dNTP 
to 0.2 mM final concentration, primers M1-OF, M2-OF, M1-OR, M2-OR (see 
Appendix A for primer sequences) to 0.3 µM final concentration, 2.5 U BIOTAQ 
(Bioline), 2 µl genomic DNA and sterile water up to 50 µl. Reaction conditions were 
an initial denaturing step of 94 °C for 2 minutes, followed by 30 cycles of 94 °C for 
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30 seconds, 54 °C for 1 minute, 72 °C for 1 minute, and a final extension of 72 °C for 
5 minutes. 
MSP2 secondary PCR 
Secondary MSP2 PCR was carried out using 2 µl of the primary PCR as template. The 
reaction comprised the same concentrations as the primary PCR except with 1.5 
mM final concentration of MgCl2. Primer S1TAILFW was used in combination with 
N5-3D7-RVVIC (see Appendix A for primer sequences) each to 0.2 mM final 
concentration. The reaction was carried out under the following conditions: 94 °C 
for 2 minutes, followed by 30 cycles of 94 °C for 30 seconds, 50 °C for 45 seconds, 
70 °C for 90 seconds, and a final extension of 70 °C for 5 minutes. All reactions were 
visualised by gel electrophoresis on a 3% agarose gel in TBE and stained with 
ethidium bromide. The reaction is referred to as “MSP2 N5 PCR” in Results 3.3.4. 
Restriction digest of MSP2 PCR product 
The MSP2 secondary PCR product underwent restriction digestion to further 
differentiate genotypes. The S1TAILFW/N5-3D7-RVVIC reaction product was 
digested with DdeI and ScrFI in separate reactions each comprising 7 µl PCR 
reaction product, 2 µl 10x NEB 2.1 buffer, 5 U of enzyme and sterile water up to 20 
µl. Digestion products were visualised by gel electrophoresis on a 3% agarose gel in 
TBE and stained with ethidium bromide. 
GLURP primary PCR 
GLURP genotyping was performed following Recommended Genotyping Procedures 
(Medicines for Malaria Venture, Amsterdam May 2007). An initial primary PCR 
reaction comprised: 5 µl 10x NH4 reaction buffer, MgCl2 to 2 mM final 
concentration, dNTP to 0.2 mM final concentration, primers G-F3 and G-F4 (see 
Appendix A for primer sequences) to 0.3 µM final concentration, 2.5 U BIOTAQ 
(Bioline), 2 µl genomic DNA and sterile water up to 50 µl. Reaction conditions were 
an initial denaturing step of 94 °C for 2 minutes, followed by 30 cycles of 94 °C for 
30 seconds, 54 °C for 1 minute, 72 °C for 1 minute, and a final extension of 72 °C for 
5 minutes. 
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GLURP secondary PCR 
Secondary GLURP PCR was carried out using 2 µl of the primary PCR as template. 
The reaction comprised the same components as the primary PCR but with primers 
G-NF and G-F4 (see Appendix A). Reaction conditions were the same but carried out 
for 25 cycles. PCR products were visualised by gel electrophoresis on a 2% agarose 
gel in TBE and stained with ethidium bromide. 
3.2.8 Pf3k var gene database search, primer design and sequencing 
Pf3k is a project set up as part of MalariaGEN which aims to sequence 3,000 
Plasmodium falciparum genomes and is led by the University of Oxford, the 
Wellcome Trust Sanger Institute and the Broad Institute 
(https://www.malariagen.net/projects/parasite/pf3k). As a result, a database of 
over 62,000 var genes has been assembled. The short DBLα tags generated in this 
study were sent to Thomas D. Otto at the Wellcome Trust Sanger Institute where 
he performed a BLAST search of the database with parameters of at least 99% 
identity and 95% overlap. The returned sequence hits were sent back in FASTA 
format. The hits were used as reference genes to design primers (see 2.2.3) with 
overlapping products of ~1 kb along the length of the gene (see Appendix A for 
primer sequences). Predicted melting temperatures of 50-53 °C were aimed for to 
allow simultaneous PCR. The primers were tested on parasite gDNA (3.2.6) and the 
products cloned into pCRTM4-TOPO® vector (Invitrogen) and sequenced as 
described (3.2.4). Overlapping sequences were assembled to reconstruct each var 
gene. 
3.2.9 UPS and exon 2 PCR 
5’ UPS PCR was carried out using primers unique to the three main UPS types A, B 
and C (Mugasa et al., 2012) (see Appendix A) in combination with the reverse DBLα 
specific primer designed for RT-qPCR (3.2.5). Reaction composition was as 
described (see 2.2.3) and reaction conditions were as follows: 95 °C for 3 minutes, 
followed by 30 cycles of 95 °C for 30 seconds, 52 °C for 30 seconds, 65 °C for 30 
seconds, and a final extension of 65 °C for 3 minutes. Downstream PCR was carried 
out using a primer designed to the more conserved exon 2 (Lavstsen et al., 2012) in 
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combination with an isolate specific forward primer (see Appendix A). Reaction 
composition was as described (see 2.2.3) and reaction conditions were as follows: 
96 °C for 1 minute, followed by 40 cycles of 98 °C for 6 seconds, 48 °C for 15 
seconds, 67 °C for 5 minutes, and a final extension of 68 °C for 10 minutes. 
 
3.3 Results Part I: ICAM-1 binding patient isolates 
3.3.1 Expressed DBLα tags of ICAM-1 binding patient isolates 
Five ICAM-1 selected, culture-adapted patient isolates – BC12, J1, PCM7, PO69, 
8206 – were re-selected on ICAM-1 and returned to culture to multiply before RNA 
extraction. As var genes are known to switch in culture (Recker et al., 2011), the 
number of cycles between selection and RNA extraction was kept to a minimum 
and is indicated in the nomenclature chosen e.g. BC12C2 refers to RNA extracted 
from isolate BC12 two cycles after ICAM-1 selection. “ukn” refers to parasite 
cultures that have previously been selected on ICAM-1 but have been cultured for 
an unknown number of cycles before and after cryopreservation. RNA quality and 
concentration was measured by NanoDrop™ before DNase I treatment and cDNA 
synthesis. Quality was defined as the absence of residual DNA, as detected by PCR 
of the no-reverse transcriptase (no-RT) cDNA synthesis reaction, suggesting 
successful DNase I treatment.  
DBLα tags were PCR amplified using universal primers DBLαAF഻ and DBLαBR (Bull et 
al., 2005) to the DBLα domain and cloned. Twenty four clones were sequenced per 
isolate with the exception of PCM7ukn for which 20 clones were sequenced. The 
number of unique sequences varied between isolates but all contained a prominent 
DBLα tag that was cloned at high frequency (Figure 3.1). DBLα tags were named 
after their patient isolate and lettered a, b, c, etc, in order of abundance. BC12 
displayed a similar distribution of DBLα tags regardless of the number of cycles 
after selection (2, 8 and unknown) showing a clearly prominent tag, BC12a. 
PCM7C3.1 and PCM7C3.2 cDNA samples were reverse transcribed from the same RNA  
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Figure 3.1. Distribution of expressed DBLα tags from ICAM-1 binding patient 
isolates. 
Twenty four DBLα tags were amplified and sequenced from parasite cDNA. Each pie 
chart represents the distribution of DBLα tag sequence variants from parasite 
isolates BC12 (A), PCM7 (B), J1 (C), PO69 (D) and 8206 (E). The number of cycles 
between ICAM-1 selection and RNA extraction are indicated in superscript (C_). 
“ukn”, unknown number of cycles. DBLα tags are named a, b, c, etc for each isolate. 
A high number of unique DBLα tags were sequenced from PCM7 and are referred to 
as N=1. 
 
sample (PCM7C3) and, although the same prominent DBLα tags were cloned from 
these two samples, the distribution varied. Most notable was the number of single 
DBLα tags detected: 9 in PCM7C3.2, the highest detected in all samples, and 5 in 
PCM7C3.1. J1C8 and PO69C8 showed a similar distribution of cloned DBLα tags, with 
the prominent tag cloned 13/24 and 15/24 times, respectively. Only two sequences 
were cloned from 8206C4: 23 of 8206a and 1 of 8206b.  
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3.3.2 Dominantly expressed DBLα tags confirmed by RT-qPCR  
Reverse transcriptase quantitative PCR (RT-qPCR) was performed to confirm that 
the most frequently cloned DBLα tags were in fact the dominantly expressed tags 
from each isolate. Specific primers to DBLα tags were designed (see Appendix A) 
and tested in a regular PCR reaction to confirm single band amplification (not 
shown). Primer efficiency was then tested by performing RT-qPCR on serially 
diluted cDNA to generate a standard curve (J1f example shown, Figure 3.2A and B, 
right panel) from which primer efficiency was calculated (see 3.2.5). Primer 
efficiencies were considered comparable if they were within 10% of each other 
(1.8-2.2) (Schmittgen and Livak, 2008) and any outside this range were re-designed. 
Two exceptions were primers to BC12e and BC12f for which expression was too low 
to generate a standard curve. However, each generated a single peak on the melt 
curve cycle of the RT-qPCR program (similar to dissociation curves shown in Figure 
3.2A and B), suggestive of a single amplification product. ASL and seryl- tRNA 
synthetase (STS) were used as internal control genes (Viebig et al., 2005). The no-RT 
and DPEC-H2O controls were included on each plate (example shown, Figure 3.2C 
and D, respectively).  
Having shown primer efficiencies to be comparable, RT-qPCR was repeated on each 
cDNA sample at a single concentration with all primer pairs designed to DBLα tags 
from that particular isolate on the same plate to minimise technical variation. Mean 
Ct values were normalised against the ASL internal control gene generating 2-ΔCt 
values and individual values are expressed as a percentage of the sum of 2-ΔCt values 
from each cDNA template (Figure 3.3). RT-qPCR data matches the expression 
patterns predicted from DBLα tag cloning of BC12, PO69 and 8206 (Figure 3.1), 
identifying BC12a, PO69a and 8206a as the dominantly expressed DBLα tags of 
these isolates (Figure 3.3). PO69b and PO69c are also expressed at high levels as 
predicted (Figure 3.1, Figure 3.3). PCM7, for which the predominant clone was 
PCM7a and for which clones PCM7b, PCM7c and PCM7d were represented at 
relatively high levels (Figure 3.1), in fact dominantly expresses PCM7a and 
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Figure 3.2. Example of RT-qPCR data output.  
Primer efficiency was tested on serially diluted cDNA from J1C8 using 217F+218R 
primers to J1f DBLα tag (A) and primers to internal control gene adenylosuccinate 
lyase (ASL, B). Amplification plots show the fluorescence signal detected over 40 
cycles of RT-qPCR amplification with each cDNA concentration colour-coded (A, B). 
Dissociation curves show the melting temperature of the reaction products with a 
single peak indicating specific amplification of a single RT-qPCR product (A, B). 
Standard curves plot the average Ct value of triplicate wells against concentration 
of cDNA (10-fold serial dilutions represented by an arbitrary log scale, A, B). 
Amplification plots and dissociation curves of no-reverse transcriptase (C) and 
DEPC-H2O (D) controls were carried out on the most concentrated cDNA to show a 
lack of specific amplification. Blue: triplicate wells of each control, red: triplicate 
wells with DEPC-H2O (C, D).  
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expresses only PCM7d at a high level, with PCM7b and PCM7c hardly detected 
(Figure 3.3). It is interesting to note that PCM7d DBLα tag was not cloned from 
PCM7ukn cDNA and yet is expressed at a relatively high level, highlighting a pitfall of 
this method of detection by cloning. Finally, J1 dominantly expresses J1a and has 
high levels of J1d and notable levels of J1b (> 10%, Figure 3.3).  
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Figure 3.3. Relative DBLα tag expression as determined by RT-qPCR.  
RT-qPCR was carried out with primers specific to each DBLα tag identified by 
cloning. Ct values were normalised against the ASL internal control gene to give 2-ΔCt 
values and are shown as percentage of total for each cDNA. a, b, c, etc refer to 
DBLα tags sequenced from each individual isolate as shown in Figure 3.1.  
 
3.3.3 Sequence comparison reveals PO69 and 8206 share DBLα tags with 
IT4 parasites 
We performed a sequence alignment of all DBLα tags (not shown) and found no 
overlap between BC12, J1 and PCM7 sequence tags. However, the dominant DBLα 
tags PO69a and 8206a share 100% sequence identity. Likewise 8206b shares 100% 
sequence identity with PO69b. A BLAST search of the NCBI database identified all 
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DBLα tags cloned from PO69 and 8206 to share identity with var genes from the 
lineage IT (IT4/ItG), a common reference strain cultured in our lab. Through 
sequence alignments we identified PO69a and 8206a as IT4var16, PO69b and 8206b 
as IT4var12 and PO69c as IT4var41. This result prompted merozoite surface protein 
(MSP) and glutamate-rich protein (GLURP) genotyping.  
3.3.4 MSP and GLURP genotyping of all isolates 
MSP genotyping was carried out on gDNA from all five ICAM-1 selected patient 
isolates and the reference strain ItG (Figure 3.4). gDNA from an original, unselected 
sample of PO69 was included for comparison. An original sample of 8206 was 
unavailable. MSP2 N5 PCR shows ItG, PO69 ICAM-1 selected and 8206 share a band 
pattern which is consistent after both DdeI and ScrFI digest (Figure 3.4A, lanes 1, 3 
and 4, respectively). This is corroborated by identical length of products in the 
GLURP PCR (Figure 3.4B, lanes 1, 3 and 4). PO69 unselected has a unique band 
pattern compared to PO69 ICAM-1 selected, ItG and 8206 suggesting that it began 
as a distinct genotype (Figure 3.4A and B, lane 2). PO69 unselected has a similar 
band pattern to PCM7 by both MSP2 N5 and GLURP PCR (Figure 3.4, lanes 2 and 7, 
respectively) but differs after MSP2 N5 restriction digests (Figure 3.4A, right gel, 
lanes 2 and 7). BC12 and J1 have a similar pattern in MSP2 N5 PCR and are only 
subtly different after digestion (Figure 3.4A, lanes 5 and 6, respectively). However, 
the size difference by GLURP PCR confirms they are unique genotypes (Figure 3.4B, 
lanes 5 and 6).  No further work was carried out on PO69 ICAM-1 selected and 8206 
as both cultures were shown to share the genotype of ItG parasites. Repeating 
ICAM-1 selection of PO69 unselected cultures could not be undertaken due to time 
constraints. Our objective to identify novel ICAM-1 binding var genes from patient 
samples continues with isolates BC12, J1 and PCM7. 
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Figure 3.4. Genotyping of all parasite isolates.  
MSP2 (A) and GLURP (B) genotyping was carried out as described in Methods 
section 3.2.7 on 1: ItG, 2: PO69 unselected, 3: PO69 ICAM-1 selected, 4: 8206, 5: 
BC12, 6: J1 and 7: PCM7 DNA. M: HyperLadderTM 1 kb (Bioline), sizes indicated are 
in kilobases (kb).  
 
3.3.5 Reconstructing full length var genes 
This section now focuses on three Thai isolates – BC12, J1 and PCM7 – and their 
highly expressed DBLα tags. Six genes are analysed: the three dominantly expressed 
tags of each isolate, BC12a, J1a and PCM7a, and the secondary tags J1b, J1d and 
PCM7d which were expressed at a relatively high level. We first performed 5’ 
upstream (UPS) typing of the six genes and made use of the new var gene database 
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generated by the Pf3k genome sequencing project to test whether you can predict 
a full length var gene sequence from a short DBLα tag. Sequence predictions of this 
kind that are easily tested experimentally could lead to faster sequencing of these 
highly variable genes, thus making it easier to analyse and test the predicted 
binding properties of the resulting PfEMP1 proteins. 
5’ UPS type classification 
UPS typing performed using UPS primers A, B and C (Mugasa et al., 2012) revealed 
BC12a, J1d, PCM7a and PCM7d to be UPS B type and J1a UPS C type. Two 
sequences were amplified from J1b with the UPS B primer but neither shared 
sequence identity with J1b DBLα. Another set of UPS primers (Kaestli et al., 2006) 
tested on J1b DNA also failed to produce the correct sequence (data not shown). 
We were therefore unable to UPS type J1b (represented by red bar in Figure 3.6C).  
Pf3k var gene database search yields variable number of hits 
Highly expressed DBLα tags were BLAST searched against the Pf3k var gene 
database with parameters of at least 99% identity and 95% overlap. Five of the six 
DBLα tags resulted in ≤ 10 hit sequences each, whereas J1a resulted in 153 hits 
(Table 3.1).  
 
Table 3.1. The number of hits to each DBLα tag in the Pf3k var gene database detected by BLAST search. 
DBLα tag # database hits 
BC12a 2 
J1a 153 
J1b 1 
J1d 3 
PCM7a 4 
PCM7d 10 
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The returned sequences to the DBLα tags with the fewest hits, BC12a, J1d and 
PCM7a, shared 99% sequence identity and are therefore essentially the same 
genes. Sequence hits to PCM7d (N=10) shared 97-99% identity, with one hit 
containing an additional ~200 bp insertion. The 153 hits to J1a share sequence 
similarity over ~3 kb at the 5’ end but are variable downstream. Therefore, the 
more sequence hits that are returned from the DBLα tag search, the more likely it is 
that they will be of varying full length sequence, at least in our small sample set. 
 
Novel primers to Pf3k hits successfully amplify products in vitro 
Returned sequence hits to each DBLα tag were chosen as reference sequences for 
primer design based on length and consensus sequence. Primers were designed 
every ~1 kb to produce overlapping products (see Figure 3.5 for BC12a example) 
which were cloned and sequenced.  
 
 
Figure 3.5. BC12a PCR fragments amplified with primers designed to XX0156-
C.g40 Pf3k database hit. 
Pf3k database sequence XX0156-C.g40 was returned to the BC12a DBLα tag. 
Primers were designed along the length of the returned sequence to produce 
overlapping products and used to PCR amplify BC12 gDNA. Primer pairs are 1: 227F-
228R, 2: 229F-230R, 3: 231F-232R, 4: 233F-234R, 5: 235F-236R, 6: 237F-238R, 7: 
239F-240R, 8: 241F-242R, see Appendix A for primer sequences. M: 1 kb DNA 
Ladder (NEB). 
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Schematics of the reference sequence match and the amplified PCR fragments are 
shown for each DBLα tag in Figure 3.6. Remarkably, BC12a, J1a and J1b fragments 
shared ≥ 99% identity with their respective reference sequences (Figure 3.6A, B, C). 
J1d fragments downstream of the DBLα tag shared ≥ 99% identity with its reference 
sequence but the upstream fragment had no significant similarity (Figure 3.6D, 
obtained by UPS PCR). PCM7a fragments amplified across three quarters of the 
length of the reference gene with ≥ 99% identity but the remaining fragments failed 
to amplify (Figure 3.6E). PCM7d fragments also shared ≥ 99% identity with their 
reference sequence with the exception of two 3’ fragments whose sequences were 
highly AT rich, suggesting that priming occurred within the intron (Figure 3.6F, 
denoted by question marks).  
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Figure 3.6. Schematic of DBLα tags and their reference gene matches from the 
Pf3k var database.  
DBLα tags from each dominantly expressed var gene were searched against the 
Pf3k var database and the resulting match was treated as a reference gene for PCR 
primer design. Reference gene names are shown below each schematic. PCR 
fragments amplified from parasite gDNA are indicated by dark grey bars. Sequence 
coverage and identity to the reference are shown, as determined by BLAST 
Alignment. Upstream fragments were amplified using published primers to UPS A, B 
and C types (Mugasa et al., 2012). Red bars indicate fragments that fail to amplify. 
“?” in F indicate that both fragments appeared to prime in intron sequence and 
could not be assembled.  
 
3’ sequences obtained/predicted by exon 2 PCR  
A conserved primer to exon 2 (Lavstsen et al., 2012) was used to fully sequence 
genes PCM7a and J1b (Figure 3.7A and B, respectively). We were unable to gain the 
complete sequence of genes BC12a, J1a, J1d and PCM7d due to either multiple 
products of the exon 2 PCR or cloning difficulty. The exon 2 PCR of these genes, 
shown in Figure 3.7C, provides some insight into the length of the genes yet to be 
sequenced. The amplification products are of size 1.9 kb for BC12a, 2.5 kb for J1a 
and 1.4 kb for J1d (Figure 3.7C, lanes 1, 2 and 3, respectively). PCM7d produced 
multiple products and therefore no size predictions can be made (Figure 3.7C, lane 
4). This is likely due to the low annealing temperature of 48 °C, required for the 
reverse Ex2-reg primer, affecting the priming of the forward primer 297F (see 
Appendix A for primer sequences). Considering the introns of var genes are 
between 0.17-1.2 kb (Gardner et al., 2002), the maximum coding sequence we are 
yet to obtain from BC12a and J1d is 1.73 kb and 1.23 kb, respectively. It is therefore 
likely that BC12a and J1d are sequenced up to the final extracellular domain with 
the average DBL domain between 0.96-1.5 kb and the average CIDR domain 
between 0.77-0.83 kb (Rask et al., 2010). Additionally, the TM region of ATS which 
is encoded 5’ prime to the splice site is 0.08 kb (Rask et al., 2010). J1a has between 
1.3-2.33 kb yet to be sequenced, likely encoding two or three additional 3’ domains.  
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Figure 3.7. Exon 2 PCR of ICAM-1 binding genes.  
PCR was carried out using a conserved primer to exon 2 (Ex2-reg) in combination 
with a gene specific primer (see Methods 3.2.9). PCM7a, primer 73F (A), and J1b, 
primer 253F (B), products were successfully cloned and sequenced. Unrelated lanes 
have been removed (A, B). C, DNA gel showing exon 2 PCR products of the ICAM-1 
binding genes that could not be sequenced. 1: BC12a, primer 241F, 2: J1a, primer 
310F, 3: J1d, primer 285F, 4: PCM7d, primer 297F. See Appendix A for primer 
sequences. M: HyperLadderTM 1 kb (Bioline), sizes indicated are in kilobases (kb). 
 
Sequence reconstruction 
Overlapping sequence fragments were assembled to reconstruct these six highly 
expressed var genes from ICAM-1 binding parasite isolates: BC12a_1-7764, J1a_1-
4254, J1b_1-5362, J1d_1-6884, PCM7a_1-6926 and PCM7d_1-4369.  
 
J1d and PCM7a differential sequences present in Pf3k var database 
The differential sequences obtained from J1d upstream of the DBLα tag (J1d_1-567) 
and PCM7a at the 3’ end of the gene (PCM7a_4798-6762) were searched against 
the Pf3k var gene database for any sequence hits. J1d_1-567 sequence was present 
in the database within a gene that differed from J1d_1-6884 downstream from 
base 567. PCM7a_4798-6762 sequence was present in the database within a gene 
that differed from PCM7a_1- 6762 upstream from base 4798. Interestingly, 
PCM7a_4798-6762 was also present in a gene that matched the full length 
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PCM7a_1- 6762 completely, suggesting that in the time between our initial 
database search and carrying out the experiments, the sequence was added to the 
database.  
 
3.4 Results Part II: Brain-specific var genes in fatal cerebral 
malaria 
Having shown proof of concept in Results section 3.3, we went on to test this 
method of searching the var gene database for hits with two sequences detected in 
the brains of multiple patients who had died of cerebral malaria (Tembo et al., 
2014). Sequences 28B1-1 (DBLα tag, 0.4 kb, accession number KC678110) and 
62B1-1 (DBLα- DBLβ, 2.5 kb, accession number KC678109) were searched against 
the Pf3k var database by Thomas D. Otto, as above. A notable difference with these 
samples is that only gDNA extracted from tissue biopsies was available for testing. 
3.4.1 Pf3k var database search and attempted reconstruction of 62B1-1 
There were no hits to 28B1-1 sequence in the Pf3k var database. 62B1-1 resulted in 
two hits which share 99% identity with 62B1-1 and 96% identity with each other. 
The longer of the two hits, PF0311-C.g26 (10.3 kb) was used to design PCR primers 
along the length of the gene (see Appendix A). These primers were tested on gDNA 
samples from patients in which 62B1-1 sequence was dominantly expressed in the 
brain. PCR often resulted in multiple bands, making cloning difficult. An example of 
PCR products obtained is shown in Figure 3.8A with details of the resulting cloned 
and sequenced fragments shown in Figure 3.8B. Only minimal PCR optimisation 
could be carried out due to the low quantity of the sample.  
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Figure 3.8. Example of 62B1-1 PCR using primers designed to PF0311-C.g26.  
A, Primers designed to the Pf3k var gene database hit PF0311-C.g26 were used to 
PCR 62B1-1 gDNA. White arrows indicated bands that were purified and cloned for 
sequencing. M: HyperLadderTM 1 kb (Bioline), sizes indicated are in kilobases (kb). B, 
Details of PCRs 1-7. “*” primer details can be found in Appendix A. # P.f/total seq. 
refers to the number of P. falciparum fragments sequenced out of the total 
fragments successfully cloned. Coverage and identity of each fragment to PF0311-
C.g26 are listed. A summary of all P. falciparum fragments sequenced is shown in 
Figure 3.9. 
 
Overall, of the 37 primer combinations tested, only 7 primer pairs resulted in 
amplification of Plasmodium DNA and these displayed either low coverage or 
sequence identity of only 83% (summarised in Figure 3.9). Two exceptions are 
overlapping fragments which share 87 and 97% identity with the reference 
sequence and 93% when combined (Figure 3.9, black bar). However, these 
fragments are not in the overlap area with 62B1-1 and, without overlapping  
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Figure 3.9. Schematic of 62B1-1 database match and successfully amplified PCR 
fragments from clinical gDNA samples.  
PCR primers were designed to the 62B1-1 Pf3k var database match PF0311-C.g26 
and tested on gDNA from tissue biopsies. Successfully amplified P. falciparum 
fragments are indicated by grey bars with their sequence coverage and identity to 
the reference shown, as determined by BLAST Alignment. Black bar indicates 
consensus in overlapping sequence between two fragments. The majority of 
fragments amplified were human host DNA (not shown). 
 
upstream fragments, we cannot be sure that they originate from the same var 
gene. The remaining fragments sequenced were human host DNA, as confirmed by 
BLAST search.  
3.4.2 Parasite DNA enrichment 
In an attempt to isolate parasite DNA from the 62B1-1 gDNA sample, we used 
NEBNext® Microbiome DNA Enrichment Kit which separates microbial DNA from 
that of the human host. The kit control reaction successfully separated the target E. 
coli DNA from the human IMR-90 host DNA (Figure 3.10, faint band), whereas the 
62B1-1 target DNA is not visible on the gel and the host DNA band is comparable to 
the input DNA (Figure 3.10). This result was confirmed by NanoDrop® measurement 
of 62B1-1 target DNA which was below accurate levels of quantitation. Further 
optimization of this method was not carried out due to low sample volume. 
Therefore, due to the very low abundance of parasite DNA and lack of material for 
reaction optimisation, we did no further work with these samples.  
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Figure 3.10. Parasite DNA enrichment of 62B1-1 gDNA sample.  
NEBNext® Microbiome DNA Enrichment was carried out on kit Control, human IMR-
90/E.coli DNA at 10:1 ratio, and 62B1-1 Sample at unknown ratio. Input: mixture of 
microbial and human DNA. Target: enriched microbial DNA. Host: human host DNA 
minus microbial DNA. The same gel is shown visualised with different exposure 
times. 
 
3.5 Discussion 
This Chapter describes the use of the new Pf3k var gene database of > 62,000 var 
genes to test whether a full length var gene can be predicted from a short DBLα tag. 
We tested this method on two different sample types: cDNA from ICAM-1 selected 
culture-adapted patient isolates whose binding profiles have been recently 
characterised (Madkhali et al., 2014), and genomic DNA samples from a previous 
study that identified brain-specific var genes in Malawian children who died of 
cerebral malaria (Tembo et al., 2014).  
In the case of the ICAM-1 selected patient isolates, we first identified the expressed 
var genes using DBLα tag primers (Bull et al., 2005) which target conserved 
homology blocks of the DBLα domain and are thought to amplify the majority of var 
genes. Indeed, such primers are frequently used in surveys of var gene diversity 
(Sulistyaningsih et al., 2013, Mugasa et al., 2012, Chen et al., 2011, Albrecht et al., 
2010). However, universal amplification by these primers cannot be known for 
certain due to the high variability of var genes. This, combined with reliance on 
cloning, which can carry bias towards some sequences, results in uncertainty that 
all expressed DBLα tags have been identified. This is highlighted with PCM7ukn cDNA 
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from which DBLα tag PCM7d was not cloned but was shown to be expressed at a 
high level by RT-qPCR (Figure 3.1, Figure 3.3). However, the most frequently cloned 
tag did prove to be the dominantly expressed tag in all isolates indicating that any 
bias only affects secondary tags, at least in these culture-adapted isolates. The 
over-representation of some minor tags identified by cloning has been observed 
previously (Gatton et al., 2006) and highlights the importance of the more 
quantitative RT-qPCR method. Repeating ICAM-1 selection and RNA extraction 
increases confidence in this method as seen with the reproducible results of three 
different BC12 RNA extractions. Replicates can also identify DBLα tags that may 
have been missed as with PCM7d. However, this proved difficult with isolate J1 
which tended to produce gametocytes. This was also the case with several other 
isolates from the initial characterisation study (Madkhali et al., 2014) from which 
sufficient RNA could not be extracted due to gametocytogenesis (data not shown).  
We performed ICAM-1 selection of these isolates to identify new ICAM-1 binding 
var genes. This is not necessarily selecting for a clonal population as multiple var 
genes can be expressed within a culture. Therefore, expression of secondary tags in 
J1, PCM7 and PO69 can be explained by multiple var genes within an isolate with 
the ability to bind ICAM-1, as seen with multiple IT4 var genes (Howell et al., 2008). 
Alternatively, var gene switching may have occurred after selection which occurs in 
an ordered manner and involves initially switching to numerous genes before a 
single dominant gene emerges (Recker et al., 2011). We minimised the effect of 
switching by extracting RNA as quickly as possible after ICAM-1 selection. Whether 
these secondary genes also have the ability to bind ICAM-1 is yet to be determined.  
Our finding that PO69 and 8206 isolates are in fact ItG parasites highlights the 
importance of regularly checking genotypes of patient isolates and comparing them 
to any reference strain cultured in the lab. A low level contamination with such an 
established strain will likely outcompete any patient isolates which are less adapted 
to culture conditions. An additional disadvantage lies in the propensity for these 
patient isolates to switch to gametocytes in culture, a phenotype not displayed by 
ItG parasites.  
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Classification of var genes is based on a combination of upstream sequence, 
genomic location and direction of transcription (Voss et al., 2000, Gardner et al., 
2002) (see Figure 1.3). Group A genes have been associated with severe disease 
(Jensen et al., 2004, Kyriacou et al., 2006, Rottmann et al., 2006) as well as group B 
in some studies (Rottmann et al., 2006, Kaestli et al., 2006). The majority of ICAM-1 
binding var genes identified in the reference strains IT4 and 3D7 are group B and C 
type (Janes et al., 2011, Howell et al., 2008) with only two group A ICAM-1 binders 
identified in 3D7: PF11_0521 (Oleinikov et al., 2009, Gullingsrud et al., 2013) and 
PFD1235w (Jensen et al., 2004, Bengtsson et al., 2013b). Both UPS A ICAM-1 
binding genes have been shown to induce adhesion blocking (rat) antibodies to 
their recombinant domains (Gullingsrud et al., 2013, Bengtsson et al., 2013b), with 
PFD1235w specific antibodies additionally able to block binding of other DC4 
expressing parasites, displaying cross-reactivity (Bengtsson et al., 2013b). The 
dominantly expressed var genes of our ICAM-1 binding patient isolates are UPS B 
type and one UPS C type, an unsurprising result given that group A var genes are 
seldom expressed in vitro (Peters et al., 2007, Janes et al., 2011, Ye et al., 2015). 
This is related to high switching bias towards centrally located short var genes (4 
extracellular domains), all of which are UPS B or C, rather than the specific 
avoidance of UPS A gene expression (Noble et al., 2013). Assuming IT4 and 3D7 
strains are representative of all parasites then we expect only 0-2 group A ICAM-1 
binding var genes per genome and their identification from these patient isolates 
would require alternative methods to those employed here. For example, whole 
genome sequencing would identify the full var repertoires of these isolates and 
allow analysis of their predicted binding functions. However, sequence predictions 
alone cannot predict ICAM-1 binding, particularly of the UPS A genes, discussed 
further in Chapter 4. 
The var gene database, which is a result of the Pf3k genome sequencing project, is a 
new resource with the potential to provide valuable information on an 
unprecedented scale. However, the copious amount of ‘omics’ data now being 
generated presents the challenge of interpretation and of identifying practical 
applications. We wanted to test whether this vast resource can predict full length 
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var genes from their short ~400 bp DBLα tag. The results obtained for the ICAM-1 
binding patient isolates were remarkable with the majority of successfully cloned 
fragments sharing ≥ 99% identity with the reference sequence (Figure 3.6). The two 
cases of differential sequence (J1d_1-567 and PCM7a_4798-6762) occurred at a 
single point in the sequence suggesting a gene recombination event or possibly a 
sequence assembly error. The former is likely as it has been reported that mitotic 
recombination frequently occurs in the var genes (Bopp et al., 2013, Claessens et 
al., 2014). Interestingly, recombination occurs between domains of the same type 
resulting in in-frame genes and domain structure preservation which produces 
viable genes (Claessens et al., 2014), concordant with our results. Our finding that 
PCM7a_1-6762 full length sequence was present in the database in our second 
search is perhaps unsurprising as the Pf3k project is ongoing and the database is 
constantly expanding. It does, however, raise the interesting question of whether 
we are close to sequencing the worldwide var gene repertoire. If this is the case, it 
must be kept in mind that these genes are constantly undergoing recombination 
events, both mitotic (Bopp et al., 2013, Claessens et al., 2014) and meiotic in the 
mosquito vector (Ranford-Cartwright and Mwangi, 2012). Therefore, although the 
sequence might be known, the order in which they are combined in any one gene is 
still unpredictable.  
Limitations of the database are highlighted by the varying number of hits to each 
DBLα tag, in particular 28B1-1 for which there was no hit and J1a for which there 
were 153 hits. The length of contiguous sequence also varies in the database and 
may only provide partial sequence. We utilised a primer to the conserved exon 2 
(Lavstsen et al., 2012) in an attempt to sequence the 3’ end of the genes. However, 
this can result in long PCR products that are difficult to clone and sequence, a 
problem avoided in the original study by using the long PCR products to create a 
library for whole genome sequencing (Lavstsen et al., 2012). We were able to 
sequence the full length genes of J1b and PCM7a using this primer. However, we 
were unable to clone and sequence exon 2 PCR products of BC12a, J1a, J1d or 
PCM7d but were able to make size predictions of all but PCM7d products. The un-
sequenced region of J1a is the longest and is the result of having 153 returned 
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database hits which differed significantly in the 3’ end making specific primer 
design impossible in this region. 
Our attempts to apply this approach of targeted sequencing of a single var gene to 
gDNA collected from cases of fatal cerebral malaria were unsuccessful. This is 
mainly due to the vast amount of human host DNA in the samples (Figure 3.10). In 
the original study, DNA was extracted from half of a biopsy of approximately 0.4 x 
0.4 x 1 cm tissue which contained a majority of human DNA which contributed to 
the failure of genotyping in many of the extractions, shown in Tembo et al Figure S1 
(2014). Human DNA in the sample was also thought to be responsible for difficulties 
with reproducibility of the RT-qPCR (Tembo et al., 2014). This is unsurprising when 
taking into account the respective sizes of the human and P. falciparum genomes 
(3,200 Mb and 22.9 Mb, respectively), the fact that the majority of biopsy cells are 
human and the uncertainty of the number of parasites in the biopsy. For example, 
consider that a ratio of 100: 1 human to parasite cells would consist of 320,000 Mb 
of human and 22.9 Mb P. falciparum genetic material, a ratio of 14,000: 1. This 
presents a challenge for even the best of PCR primers to gain access to the correct 
complementary sequence. Of the fragments that were successfully sequenced, only 
one shared > 90% identity with the database match (Figure 3.9) and we cannot be 
certain this fragment originates from the same gene as the original 62B1-1 
sequence.  
Therefore, having shown this method to be successful in section 3.3 with pure DNA 
samples, failure to amplify PCR fragments can be attributed to vast quantities of 
human DNA in the sample and a lack of material for either purification of parasite 
DNA or extensive optimisation of PCR conditions. As a result, we were unable to 
sequence the full length of these var genes that were found specifically in cerebral 
malaria. A major failing of the original study was in not collecting parasite blood 
samples from these patients on hospital admission. This could have resulted in 
purer gDNA samples, through well established nucleated cell depletion techniques 
followed by DNA extraction, or in establishing stable parasite lines upon successful 
culture adaptation, allowing their detailed characterisation. An alternative method 
would have been to perform laser capture microdissection (for review see Datta et 
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al. (2015)) of the tissue biopsies to isolate individual parasites, a technique that has 
been used to isolate liver stage parasites (Semblat et al., 2005). However, the short 
sequences of 28B1-1 and 62B1-1 that are available, found specifically in the brains 
of fatal cerebral malaria cases (Tembo et al., 2014), could still be used in 
surveillance of parasites causing CM to assess the distribution of these sequences.  
 
3.6 Summary 
We have successfully identified and sequenced the dominantly expressed var genes 
of patient isolates BC12, J1 and PCM7 which have been selected for binding to the 
human endothelial receptor ICAM-1. The sequences were identified using universal 
DBLα tag primers which result in products of around 400 bp. These tags were then 
searched against the new Pf3k var gene database for sequence matches. We found 
that these sequence matches were a useful starting point for primer design in this 
targeted sequencing approach but that some sequences amplified from the 
parasites differ from the database hits. Therefore, returned sequence matches to 
short DBLα tags are useful predictors of full length var gene sequences but require 
experimental validation. We were unable to successfully apply this approach to the 
62B1-1 sequence identified specifically in the brains of patients who died of CM 
mainly due to low sample volume and the majority of the sample consisting of 
human DNA. Extensive analysis of sequences identified from the ICAM-1 selected 
isolates and the predicted 62B1-1 sequence is carried out in the next Chapter 4 to 
characterise their predicted binding abilities.   
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Chapter 4. Sequence analysis of Plasmodium 
falciparum var genes 
4.1 Introduction 
Plasmodium falciparum var genes are responsible for antigenic variation and 
cytoadhesion of the parasite IEs, both of which are major virulence factors that 
contribute to pathogenicity, resulting in the most severe form of human malaria. 
The 50-60 var gene copies per genome can be classified into three main groups A-C 
and two subgroups B/A and B/C (Gardner et al., 2002, Lavstsen et al., 2003, 
Kraemer and Smith, 2003). Groupings are based on the 5’ upstream sequence 
(UPS), chromosomal location and direction of transcription (see Figure 1.3). In 
addition, group A genes are characterised by DBLα1 domains, while groups B and C 
are characterised by DBLα0 domains (Gardner et al., 2002, Lavstsen et al., 2003, 
Kraemer and Smith, 2003). Groups B/A and B/C represent transitional genes with 
criteria from more than one group (Gardner et al., 2002, Lavstsen et al., 2003, 
Kraemer and Smith, 2003). The conserved var2csa gene is unique among the var 
genes and is flanked by UPS E sequence (Salanti et al., 2003). See Introduction 
section 1.6 for more details. 
The var genes encode modular PfEMP1 proteins which are made up of DBL (Duffy 
binding-like) and CIDR (cysteine-rich interdomain region) domains  which are 
classified into types DBLα, β, γ, δ, ε, ζ and x and CIDRα, β, γ and δ based on 
sequence identity (Smith et al., 2000b, Lavstsen et al., 2003, Rask et al., 2010). The 
landmark analysis carried out by Rask et al. (2010) of var genes from seven distinct 
genomes redefined domain boundaries and identified domain subtypes based on 
sequence similarity, which is remarkably low at 31-45% identity among domains of 
the same type. Domain combinations that are frequently found together were 
identified and termed domain cassettes (DCs) (Rask et al., 2010). Since their 
description, several of these DCs have been associated with specific binding 
capabilities (Avril et al., 2012, Claessens et al., 2012, Lavstsen et al., 2012, Turner et 
al., 2013, Bengtsson et al., 2013b, Berger et al., 2013). Despite the low sequence 
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identity between PfEMP1 proteins, they consists of short conserved sequence 
blocks, interspersed amongst stretches of highly variable sequence, which have 
been identified as homology blocks (HBs) (Rask et al., 2010). HBs provide an 
alternative to sequence comparison by alignment and distance tree analysis which 
determine sequence relatedness based on the whole domain, instead focussing on 
short sequence similarities. The VarDom 1.0 Server is an online resource which 
stores the sequence information described above for the seven genomes dataset 
and can perform analysis of new PfEMP1 sequences (Rask et al., 2010). 
We identified and reconstructed the dominantly expressed var genes of the ICAM-1 
binding patient isolates BC12, J1 and PCM7 in Chapter 3. This chapter aims to 
characterise these var gene sequences by identifying their domain structure and 
analysing their predicted binding phenotypes. We perform in-depth analysis of the 
newly identified DBLβ domains, which mediate ICAM-1 binding, and investigate 
their similarity to known ICAM-1 binding sequences. Analysis of the non-dominant 
genes identified in these isolates is also carried out along with the Pf3k var gene 
database matches to the brain-specific var genes, 28B1-1 and 62B1-1, identified in 
fatal cases of cerebral malaria. Due to the nature of the data in this chapter, the 
Results and Discussion sections have been combined to avoid repetition.  
 
4.2 Methods 
4.2.1 Characterising PfEMP1 domain structures 
Amino acid sequences of var genes were entered into the VarDom 1.0 Server (Rask 
et al., 2010) (available at http://www.cbs.dtu.dk/services/VarDom/) in FASTA 
format to define domain boundaries. The corresponding nucleic acid sequences 
were then separated into domains and BLAST searched against the entire 7 
genomes dataset (Rask et al., 2010). The top six hits were analysed and domain 
subtypes were identified by searching Figure S4 from Rask et al. (2010). Subtypes 
were included if a consensus between the six hits was reached or if the top hits had 
appropriate coverage. Where multiple subtypes were identified, they were included 
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if there were two of equal standing (separated by “/”) or excluded if there were 
more than two matches with similar coverage.  
4.2.2 DBLα tag cysteine/position of limited variability (cys/PoLV) analysis 
DBLα tags were classified using a Perl script (kindly provided by Peter Bull) to 
identify positions of limited variability and the number of cysteines (cys/PoLV) 
present as described (Bull et al., 2007). DBLα tag amino acid sequences beginning 
with DIGDI and ending with PQFLR were analysed based on 4 anchor points: a, b c 
and d. PoLV1 is identified as the 4 amino acids starting 10 amino acids downstream 
of anchor point a, the N-terminal D residue. PoLV2 and 3 are based around anchor 
point b which is a WW motif or anchor point c, a VW motif, in the absence of 
anchor point b. In relation to anchor point b, PoLV2 is defined as the 4 amino acids 
directly upstream of point b and PoLV3 as 4 amino acids starting 9 amino acids 
downstream of point b. In relation to anchor point c, PoLV2 is defined as the 4 
amino acids beginning 12 amino acids upstream of point c and PoLV3 as the 4 
amino acids directly downstream of point c. PoLV4 is fixed in relation to anchor 
point d, the C-terminal R residue, and is defined as 4 amino acids beginning 11 
amino acids upstream of point d (Bull et al., 2007). The output of the Perl script 
consists of the cys/PoLV group number and a distinct sequence identifier in the 
format “PoLV1-PoLV2-PoLV3-number of cysteines-PoLV4-sequence tag length” (Bull 
et al., 2007).  
4.2.3 Phylogenetic comparison by maximum likelihood method 
Amino acid sequences were aligned using ClustalX 2.1 (Larkin et al., 2007). Aligned 
files were opened in MEGA 6.06 (Tamura et al., 2013), converted to MEGA files and 
analysed by maximum likelihood method with 100 bootstrap replications. The 
Jones-Taylor-Thornton (JTT) substitution model was used. The resulting tree was 
exported as a Newick file and uploaded to iTOL (interactive Tree of Life, available 
at: http://itol.embl.de/itol.cgi) (Letunic and Bork, 2007, Letunic and Bork, 2011) for 
aesthetic editing.  
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4.2.4 Homology block analysis 
Homology blocks (HBs) of DBLβ domains were downloaded from the VarDom 1.0 
Server (Rask et al., 2010) and analysed in relation to a maximum likelihood tree 
generated as described (see section 4.2.3). Information on ICAM-1 binding ability 
was obtained from the following references: Howell et al. (2008), Janes et al. (2011) 
and Bengtsson et al. (2013b).  
4.2.5 Sequence alignments 
Initial sequence alignments were carried out with ClustalX 2.1 (Larkin et al., 2007). 
Short peptide sequences were then aligned with T-Coffee, available at: 
http://tcoffee.crg.cat/apps/tcoffee/index.html (Di Tommaso et al., 2011, 
Notredame et al., 2000), and the resulting fasta_aln files were copied into the 
BoxShade Server, created by K. Hoffman and M. Baron and available at: 
http://www.ch.embnet.org/software/BOX_form.html.  
 
4.3 Results and Discussion 
4.3.1 PfEMP1 domain structures of ICAM-1 binding patient isolates 
The dominantly expressed var gene sequences of three ICAM-1 binding patient 
isolates, BC12, J1 and PCM7, were characterised in detail. Domain boundaries and 
types were defined by the VarDom 1.0 Server (Rask et al., 2010) and each domain 
was BLAST searched against the 7 genomes data set (Rask et al., 2010) to identify 
subtypes. Domain structures are represented schematically in Table 4.1. Three of 
the six genes contain domain cassettes (DCs) as indicated by dashed lines. BC12a 
contains DC14 (DBLα0.6-CIDRα3.1-DBLβ5) and J1a and J1d each contain DC22 
(DBLα0.4/18-CIDRα6-DBLβ5). All are of DBLα type 0 with varying sub-classifications 
(DBLα0.6, 0.4, etc). J1b and PCM7a DBLα0 domains generated diverse hits from the 
BLAST search and could not be further classified. DBLα0 is almost exclusively 
associated with UPS B and C var genes (Rask et al., 2010) and is therefore not 
associated with rosetting, an UPS A virulence phenotype associated with DBLα 
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subtypes 1.5, 1.8, 1.6 and 2 (Ghumra et al., 2012). The CIDRα domains from each 
gene are of a variety of subtypes, 2-4 and 6 (Table 4.1), all of which, along with 
CIDRα5, are predicted to bind CD36 (Robinson et al., 2003, Turner et al., 2013). This 
prediction is in agreement with the ability of antibodies against CD36 to block 
binding of these parasites to HDMEC cells by > 60% under flow conditions 
(Madkhali et al., 2014). CD36 binding is mainly observed in UPS B and C var genes 
which are associated with uncomplicated malaria (Kirchgatter and del Portillo, 
2002, Kyriacou et al., 2006, Rottmann et al., 2006, Warimwe et al., 2009). 
 
Table 4.1. Schematic representation of the domain structures of the dominantly 
expressed var genes of ICAM-1 binding patient isolates. 
Gene name NTS PfEMP1 domain structure DC # 
BC12a B4/3 DBLα0.6 CIDRα3.1 DBLβ5 DBLγ5 DBLδ1 CIDRβ1 14 
J1a B3 DBLα0.4/12 CIDRα6 DBLβ5 22 
J1b - DBLα0 CIDRα3.1/2 DBLδ1 CIDRβ1 
J1d ND DBLα0.4 CIDRα6 DBLβ5 DBLγ11/15 DBLζ3/6 DBLε12 22 
PCM7a B3 DBLα0 CIDRα2.5/9 DBLβ5/8 DBLδ1 CIDRβ1/3 
PCM7d B6/3 DBLα0.18 CIDRα4 DBLβ3/5 
 ND – not defined, no hits in Rask dataset. Dashed lines outline domain cassettes (DCs). “/” indicates similarity to two subtypes.  
 
BC12a, J1a and J1d contain DBLβ5 which is predicted to mediate binding to ICAM-1 
(Howell et al., 2008, Janes et al., 2011). Indeed, all DBLβ5 domains tested to date 
bind to ICAM-1 (Janes et al., 2011). The DBLβ domains of PCM7a and PCM7d had 
BLAST hits to two different domain subtypes: 5/8 for PCM7a and 3/5 for PCM7d. 
These could be predicted to bind ICAM-1 if they are more similar to DBLβ5 type. In 
addition, three DBLβ3 domains tested have been shown to bind ICAM-1 but several 
others do not (Howell et al., 2008, Janes et al., 2011, Bengtsson et al., 2013b). 
Interestingly, J1b does not contain a DBLβ domain, suggesting that it is not involved 
in ICAM-1 binding. This gene was detected at notable levels of expression (12% of 
the overall 2-ΔCt value, Figure 3.3) from the J1 isolate. A switching event may have 
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taken place in the culture after ICAM-1 selection as RNA was extracted from this 
isolate 8 cycles after selection. Given that the parasite isolates in this study have 
been selected on ICAM-1 (Chapter 3), the DBLβ subtypes identified though this 
sequence analysis provide confidence that these dominantly expressed var genes 
are in fact mediating ICAM-1 binding. However, experimental validation is required 
to confirm and to provide more data to increase confidence in these sequence 
predictions.  
Three of the genes, BC12a, J1b and PCM7a, contain the C-terminal domain tandem 
DBLδ1-CIDRβ1. No role for this tandem has been identified to date. Indeed, specific 
roles of individual C-terminal domain sequences have not been extensively 
described. Domains DBLζ3/6 and DBLε12 of J1d could have a known role in binding 
and pathogenesis as these domains have been identified as IgM binding domains, 
often accompanied by an upstream DBLγ domain. However, IgM binding cannot be 
predicted by sequence and therefore the subtype of DBLζ/ε domain (Pleass et al., 
2016). This would require experimental testing. This domain structure in 
combination with DBLα types 1 and 2 is specifically associated with IgM binding 
mediated rosetting (Ghumra et al., 2012). The other C-terminal domains may act as 
extenders to allow the N-terminal domains freer access to receptors away from the 
IE membrane. Alternatively, these C-terminal domains may act in tandem to bind as 
yet unidentified receptors as is the case with DC5 (DBLγ12-DBLδ5-CIDRβ3/4-
DBLβ7/9) mediating PECAM-1 binding, for which no individual domain was clearly 
identified as responsible (Berger et al., 2013). Other receptors that have been 
suggested to bind PfEMP1 but for which no specific binding domains have been 
identified, include VCAM-1, E-selectin (Ockenhouse et al., 1992b) and P-selectin 
(Senczuk et al., 2001). 
Note that the full extracellular domain sequence of only J1b and PCM7a was 
obtained. BC12a, J1a, J1d and PCM7d may encode additional C-terminal domains 
that we were unable to sequence by exon 2 PCR (see Results section 3.3.5). 
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4.3.2 In silico analysis of non-dominant and brain specific var genes 
In the previous chapter, a number of DBLα tags were identified from the ICAM-1 
binding patient isolates BC12, J1 and PCM7 by cloning but were not expressed at a 
high level when tested by RT-qPCR (Figure 3.1, Figure 3.3). We will refer to these 
tags as the non-dominant var genes of these isolates. We searched these DBLα tags 
against the Pf3k var gene database and analysed the top four hit sequences in an 
attempt to extend our knowledge of the var repertoires of these isolates and to 
further test the prediction capabilities of the Pf3k database. We also repeated the 
search for a hit to the brain-specific sequence 28B1-1 with the hope that, similarly 
to the case of PCM7a, there may now be a match in the ever expanding database. 
There were two hits to 28B1-1 upon the second search. One hit is very short and 
consists of only the NTS and an incomplete DBLα, whereas the second hit is much 
longer. This sequence, along with the PF0311-C.g26 hit to 62B1-1, was included in 
this in silico analysis in an attempt to understand their importance in the 
pathogenesis of cerebral malaria.  
Pf3k database hits to non-dominant DBLα tags of ICAM-1 binding patient isolates 
The non-dominant DBLα tags were searched against the database with parameters 
of at least 99% identity and 95% coverage (Thomas D. Otto). Hits were obtained for 
4/5 BC12 tags, 3/4 J1 tags and 15/18 PCM7 tags. The absence of hits in the 
database to 5 of the tags highlights that sequencing of the global var repertoire is 
yet to be achieved. The domain structure and subtypes of the top four hits to each 
tag was identified, as above, using the VarDom 1.0 Server and the 7 genomes 
dataset (Rask et al., 2010). Schematics of the domain structures are shown in Table 
4.2.  
 
Table 4.2. Schematic representation of the domain structures of Pf3k database 
hits to non-dominant and brain-specific var genes. 
See pages 71-73 below. 
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The length of the hits was variable with the sequences of two tags, BC12f and J1e, 
encoding only the NTS-DBLα-CIDRα head structure. Of the non-dominant hits, only 
4 sequences include the ATS region indicating the complete extracellular domain 
structure is present. The remaining hits are therefore partial sequences and cannot 
provide information on gene length which has previously been linked to sequence 
conservation (Buckee and Recker, 2012). Sixteen of the 22 non-dominant tags 
which had database hits had one apparent PfEMP1 domain structure (Table 4.2). 
However, of these, 4 had only one database hit (J1e, PCM7e, PCM7i and PCM7l). 
Five of the non-dominant tags had hits with 2 apparent domain structures with the 
differences occurring downstream of the NTS-DBLα-CIDRα head structure (BC12e, 
J1c, J1f, PCM7b and PCM7c). One tag had 3 different domain structures apparent in 
the database hits, two of which differed after the NTS-DBLα-CIDRα-DBLβ domains 
and one which differed downstream of the NTS-DBLα domains (BC12d, Table 4.2). 
The presence of genes in the database which share a DBLα tag but which have 
different PfEMP1 domain compositions reduces the reliability of the database as a 
predictive power and highlights the need for experimental validation of these 
predictions. This is perhaps unsurprising considering the constant recombination, 
both mitotic and meiotic, which occurs between var genes (Bopp et al., 2013, 
Claessens et al., 2014, Ranford-Cartwright and Mwangi, 2012).  
The only DC present in the hits to the non-dominant tags is DC1 which is present in 
all hits analysed to PCM7h indicating this gene is the conserved VAR1 gene. Hits to 
BC12e have a domain structure similar to DC8 (BC12e: DBLα2/0.9-CIDRα1.8/1-
DBLβ12-DBLγ6/4, DC8: DBLα2-CIDRα1.1-DBLβ12-DBLγ4/6) and are the only non-
dominant tag hits to contain a predicted EPCR binding domain, CIDRα1.8/1 (Turner 
et al., 2013, Lau et al., 2015). The remaining sequences, with the exception of 
PCM7h VAR1 hits, contain CIDRα2-4 which are predicted to bind CD36 (Robinson et 
al., 2003, Turner et al., 2013).  
Pf3k database hits to brain-specific var gene sequences 28B1-1 and 62B1-1 
Two sequences were recently identified as brain-specific var genes in several cases 
of fatal cerebral malaria, 28B1-1 and 62B1-1 (Tembo et al., 2014). In the previous 
chapter we attempted to reconstruct the 62B1-1 sequence from gDNA extracted 
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from tissue samples using primers to the Pf3k var gene database hit, PF0311-C.g26, 
to no avail (see Results section 3.4). Here, we identify the PfEMP1 domain structure 
of PF0311-C.g26 along with the newly identified XX0072-C.g6 database hit to 28B1-
1 (Table 4.2) and analyse their binding predictions.  
62B1-1_PF0311-C.g26 contains NTSA7, a class that is exclusively found in UPSA type 
var genes and contains DBLα1 which is also associated with UPS type A (Rask et al., 
2010). 28B1-1_XX0072-C.g6 contains NTSB3 which could be either UPS B or C type 
but has DBLα0/1 and so had BLAST matches of both type 0 and 1 suggesting a 
possible chimera (Rask et al., 2010). Both genes contain CIDRα types that are 
predicted to bind EPCR (1.1 and 1.7) (Turner et al., 2013, Lau et al., 2015), a 
receptor that has recently been identified as the receptor for DC8 and DC13 (Turner 
et al., 2013), cassettes which were found to be associated with severe malaria 
(Lavstsen et al., 2012). 62B1-1_PF0311-C.g26 is unusual in that it contains three 
consecutive DBLγ domains. The function of these domains is unknown. The DBLζ3-
DBLε6 domains of 62B1-1_PF0311-C.g26 may have the ability to bind IgM which is 
mediated by these domain types but cannot be predicted by sequence (Pleass et 
al., 2016). Both genes are large with 62B1-1_PF0311-C.g26 containing 8 
extracellular domains and 28B1-1_XX0072-C.g6 containing 6 extracellular domains. 
Neither hit includes an ATS region indicating they are not full length sequences.  
The sequence predictions for these brain-specific var genes provide insight into 
possible mechanisms for disease pathogenesis. Both sequences are predicted to 
bind EPCR, an endothelial receptor involved in anti-coagulation and anti-
inflammatory pathways (Gleeson et al., 2012). It is thought that EPCR binding blocks 
the native function of this receptor, resulting in loss of cytoprotective effects 
(Turner et al., 2013). In addition to EPCR binding, 62B1-1_PF0311-C.g26 has the 
structure of a rosette mediating var gene. Specifically, it contains a DBLα1 domain 
which has been shown to bind to uninfected erythrocytes via complement receptor 
1 (CR1) (Rowe et al., 1997, Rowe et al., 2000), blood group A and B trisaccharides 
(Vigan-Womas et al., 2012, Barragan et al., 2000) and heparin sulphate (Carlson and 
Wahlgren, 1992, Vogt et al., 2003). It also contains the C-terminal domain structure 
of IgM binding var genes (Ghumra et al., 2012) which is thought to strengthen 
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interactions between infected and uninfected erythrocytes (Clough et al., 1998, 
Somner et al., 2000). However, these are predictions which could not be 
experimentally validated with the samples available. In depth study of the Pf3k var 
gene database will provide more information on var gene structure and sequence 
relationships and will likely identify new domain cassettes which could be useful in 
picking apart the pathogenic mechanisms observed experimentally.  
4.3.3 DBLα tag analysis by cysteine/Positions of Limited Variability 
(cys/PoLV) 
Many studies, including the present one (see Results section 3.3.1 and Discussion in 
3.5), use the DBLα tag to identify the highly variable var genes within a population. 
This strategy is effective due to (i) all var genes, except the unique var2csa (Rask et 
al., 2010), containing an N-terminal DBLα domain, (ii) suspected universal primers 
designed to relatively conserved homology blocks within the DBLα domain (Bull et 
al., 2005), and (iii) the short length of the DBLα tag which can easily be cloned in 
large numbers from a single PCR per sample. The short DBLα tag has been classified 
using the number of cysteine residues present, positions of limited variability (PoLV) 
and length to generate distinct sequence identifiers which are reported to provide 
relevant biological information (Bull et al., 2005, Bull et al., 2007). We performed 
this analysis on the dominantly expressed DBLα tags of ICAM-1 binding patient 
isolates, the non-dominant tags from these isolates and the DBLα tag sequences of 
the brain-specific var genes 28B1-1 and 62B1-1.  
DBLα tag sequences were checked for N-terminal DIGDI and C-terminal PQFLR 
motifs before analysing with a Perl script (kindly provided by Peter Bull, (Bull et al., 
2007)) which uses 4 anchor points within the sequence to identify the number of 
cysteines and PoLV1-4 (see Methods 4.2.2). These are described as belonging to 
one of six groups which are defined as follows: Group 1 – cys2, PoLV1 (MFK*); 
Group 2 – cys2, PoLV2 (*REY); Group 3 – cys2 not groups 1 or 2; Group 4 – cys4 not 
group 5; Group 5 – cys4, PoLV2 (*REY); Group 6 – cys1, 3, 5, >5 (Bull et al., 2005). 
These groupings are based on findings that cys2, PoLV1 MFK* and PoLV2 *REY are 
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all independently associated with short DBLα tag length and that MFK* and *REY 
are mutually exclusive (Bull et al., 2005). 
All of the dominantly expressed var genes of the ICAM-1 binding patient isolates 
belong to PoLV Group 4, i.e. they are all cys4 and do not contain the *REY motif at 
PoLV2 (Table 4.3). The UPS type of each gene, as identified in the previous chapter, 
is included in Table 4.3 and is in keeping with observations that Group 4 DBLα tags 
are associated with group B/A, B, and B/C var genes but never group A in the 
reference parasite strains 3D7, HB3 and IT4 (Bull et al., 2005, Bull et al., 2007).  
 
Table 4.3. DBLα tag cys/PoLV classification and UPS type of dominantly expressed 
var genes.  
DBLα tag PoLV group Distinct ID sequence UPS type 
BC12a 4 LYIR-LRED-KAIT-4-PTYF-121 B 
J1a 4 LFLG-LRND-NAIT-4-LTNF-119 C 
J1b 4 LYLG-LRND-NAIT-4-LTNF-119 - 
J1d 4 LYFG-LRED-KAIT-4-PTYF-124 B 
PCM7a 4 LYRG-LRED-KAIT-4-PTYF-122 B 
PCM7d 4 LYRG-LRED-KAII-4-PTNF-117 B 
 
Groups 1-6 are all represented in the non-dominant and brain-specific var genes. 
68B1-1 and PCM7h DBLα tags are the only PoLV Group 1 tags which are exclusive to 
group A var genes and those encoding more than 5 extracellular domains (Bull et 
al., 2007). This is in agreement with the Pf3k database hits to these sequences 
predicting them to be UPS A type var genes, each with 8 domains (Table 4.2). The 
only tags belonging to Group 2 are 28B1-1 and BC12e. These are the only tags, 
other than 62B1-1, whose hits contain predicted EPCR binding domains. BC12e hits 
are those whose domain structure is similar to DC8 which has been associated with 
severe malaria (Lavstsen et al., 2012). Group 2 tags are associated with rosetting 
(Bull et al., 2005), another phenotype linked to disease pathogenesis. More 
generally, cys2 tags are found more frequently in CM than hyperparasitaemic 
patients (Kyriacou et al., 2006) and are also found to be independently associated  
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Table 4.4. DBLα tag cys/PoLV classification of non-dominant and brain-specific var 
genes. 
DBLα tag PoLV group Distinct ID sequence 
28B1-1 2 LYLD-VREY-KAIT-2-VPTN-109 
62B1-1 1 MFKS-LRND-KAIT-2-PTYL-114 
BC12b 4 MFKS-LREA-EAIT-4-PTYF-115 
BC12c 4 LYLG-LRED-RAIT-4-PTYF-120 
BC12d 4 LFYG-LRED-RAIT-4-PTYF-130 
BC12e 2 LYLG-LREY-KAIT-2-QTYL-122 
BC12f 4 LYLG-LRED-KAIT-4-PTYF-127 
J1c 4 LFIG-LRED-KAIT-4-PTYF-126 
J1e 4 LYLG-LRED-KAIT-4-PTYF-133 
J1f 3 LYRR-LRED-KAIT-2-PTNL-117 
J1g 4 LYRR-LRED-KAIT-4-PTYF-118 
PCM7b 3 LYRR-LRED-KAIT-2-PTNL-117 
PCM7c 5 LFLG-IREY-KAIT-4-PTNF-111 
PCM7e 4 LYLG-LRED-KAIT-4-PTNL-120 
PCM7f 4 LYLG-LRED-KAMI-4-PTNL-122 
PCM7g 4 LYSG-LRED-KAIT-4-PTYF-125 
PCM7h 1 MFKP-LREA-EAIT-2-PTNL-116 
PCM7i 4 LYRG-LRED-KAIT-4-PTYF-124 
PCM7j 4 LYRG-LRED-KAIT-4-PTYF-125 
PCM7k 4 LHLG-LRED-KAMT-4-PTYF-122 
PCM7l 4 LYLG-LRED-KAIT-4-PTYF-125 
PCM7m 5 LFLG-IREY-KAIT-4-PTYF-116 
PCM7n 4 LYRG-LRED-EAIT-4-PTYF-118 
PCM7o 4 LFLG-LRED-KALT-4-PTYF-129 
PCM7p 4 LFLG-LRED-KALT-4-PTYF-121 
PCM7q 4 LFLG-LRED-KAIT-4-PTYF-126 
PCM7r 5 IFRG-VREY-KALT-4-PTYF-122 
PCM7s 6 LFLG-VREY-KAIT-5-PTYF-117 
PCM7t 4 LYIG-LRED-NAIT-4-PTYF-138 
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with SM, young host age and parasite pathogenicity in multiple linear regression 
models (Warimwe et al., 2009). Two additional cys2 tags were identified as 
belonging to Group 3, J1f and PCM7b, which upon closer inspection actually share 
identical database hits (Table 4.2, Table 4.4). A sequence alignment of these tags 
shows only two amino acid differences between them (not shown).  
The remaining non-dominant DBLα tags are mainly PoLV Group 4 (N=19) and just 
three belonging to Group 5 (cys4, PoLV *REY) and one to Group 6 which has 5 
cysteine residues (Table 4.4). The original reasoning behind this grouping according 
to tag length was that if sequences are recombining within a restricted subset, then 
the length of the sequence will stay similar after multiple recombination events, 
suggesting that the different functions of these distinct groups are desirable to be 
maintained within the var repertoire (Bull et al., 2007). We compared the length of 
the tags from each Group in Figure 4.1A with the Group definitions included in 
Figure 4.1B. This generally follows the patterns observed previously (Bull et al., 
2005, Bull et al., 2007) with cys2 tags and those containing either PoLV1 MFK* or 
PoLV2 *REY (Groups 1-3 and 5) having shorter tag sequence than Groups 4 and 6 
(Figure 4.1). However, there are not enough sequences in our comparison to show 
meaningful associations. It will be interesting to perform this analysis on the entire 
Pf3k var gene database when it becomes publically available. This will not only 
provide many DBLα tags (which many studies have analysed, including those 
studies mentioned above (Bull et al., 2007, Warimwe et al., 2009)) but will also 
include longer sequence information, including domain structures, and sequences 
from a worldwide distribution, thus allowing a more comprehensive analysis.  
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Figure 4.1. DBLα tag length comparison of PoLV Groups.  
A, The cys/PoLV Group of all DBLα tags analysed is plotted against tag length. B, 
PoLV Group 1-6 definitions (Bull et al., 2005). 
 
The cys/PoLV method of sequence classification has been shown to predict some 
aspects of disease phenotypes which is remarkable for such a short sequence (350-
400 bp) within a much larger gene (3.5-9 kb, exon 1). Here we have used two 
predictive methods: the Pf3k database search and the cys/PoLV classification of 
DBLα tags. The methods are in agreement in relation to var genes that are 
predicted to be associated with severe malaria, as discussed above. This is likely 
correct in relation to the 28B1-1 and 62B1-1 sequences important in cerebral 
malaria but we have no indication of the role of the non-dominant var genes as 
these were identified from the culture-adapted patient isolates after selection on 
ICAM-1. Therefore, their function in vivo is unknown. Classification methods to date 
can generally only predict var genes important in severe malaria which can aid 
efforts to produce anti-disease therapies. However, it is often assumed that the role 
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of those not associated with severe disease is less significant. In the absence of 
sterilising immunity (McGregor, 1964) parasites causing mild and asymptomatic 
malaria persist in the human population. Further study of var genes expressed in 
these infections will be required to understand the role of parasite sequestration in 
these patients. This may become increasingly important if we are to progress 
towards malaria elimination goals (Hemingway et al., 2016).  
4.3.4 Phylogenetic analysis of DBLβ domains predicted to bind ICAM-1 
ICAM-1 binding by PfEMP1 proteins is mediated by a subset of DBLβ domains, 
namely all DBLβ5 domains tested, three DBLβ3 domains and one DBLβ1 domain 
have been identified to date (Howell et al., 2008, Janes et al., 2011, Bengtsson et 
al., 2013b). We analysed the newly identified DBLβ domains of the ICAM-1 binding 
patient isolates in more detail by comparing them to known DBLβ sequences using 
the maximum likelihood method. A comparison with DBLβ domains of all subtypes 
identified in the Rask et al (2010) dataset shows that the dominantly expressed 
DBLβ domains from BC12a, J1a, J1d, PCM7a and PCM7d group relatively closely 
together but do not form a distinct cluster (Figure 4.2, red). Known ICAM-1 binding 
DBLβ domains (Howell et al., 2008, Janes et al., 2011, Bengtsson et al., 2013b) are 
highlighted in orange to show their wide distribution. However, note that bootstrap 
support of ≥ 70% is present in relatively few nodes (black dots, Figure 4.2). Lower 
values indicate the unreliability of the groupings which reflects the recombination 
that we know to occur between the DBLβ domains (Bopp et al., 2013, Claessens et 
al., 2014). The DBLβ domains encoded by the Pf3k database hits to the non-
dominant genes of these patient isolates are included.  
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Figure 4.2. Phylogenetic comparison of all DBLβ domains in the VarDom 1.0 
Server and BC12, J1 and PCM7 DBLβ domains.  
A maximum likelihood tree was constructed from all DBLβ domains in the Rask et 
al. (2010) dataset, accessed via the VarDom 1.0 Server, and the DBLβ domains of 
the ICAM-1 binding patient isolates BC12, J1 and PCM7. Orange: known ICAM-1 
binding DBLβ domains. Red: dominantly expressed var genes of BC12, J1 and PCM7. 
Black dots indicate bootstrap values ≥ 70%. 
 
The dominantly expressed var genes of the ICAM-1 binding patient isolates encode 
DBLβ domains of subtype 5 (BC12a, J1a, J1d), 5/8 (PCM7a) and 3/5 (PCM7d). We 
therefore constructed a maximum likelihood tree of all DBLβ3, 5 and 8 domains 
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along with our newly identified DBLβ sequences (Figure 4.3). The majority of β3 
sequences cluster together (purple) and are of UPS A type. Two exceptions 
(IGHvar10 and PFCLINvar68) fall within a cluster of β5 sequences (orange) of mainly 
UPS B type. PCM7d (DBLβ3/5) falls within the DBLβ3 group suggesting it is more 
similar to DBLβ3. DBLβ8 sequences (turquoise) form two clades in the midst of the 
DBLβ5 sequences. PCM7a (DBLβ5/8) falls in the middle of these two clades with the 
HB3var10 DBLβ5 sequence (Figure 4.3), suggesting it was accurately classified by 
BLAST analysis as falling between two types. The majority of DBLβ5 sequences are 
of UPS B type with a small cluster of UPS C sequences which include J1a (Figure 
4.3). J1d forms a single branch in between the DBLβ3 clade and the other 
sequences, suggesting it is more distantly related to the other DBLβ5 sequences.  
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Figure 4.3. Phylogenetic comparison of type 3, 5 and 8 DBLβ domains.  
A maximum likelihood tree was constructed from all DBLβ domains of subtype 3, 5 
and 8 in the Rask et al. (2010) dataset and the DBLβ domains of the dominantly 
expressed var genes of the ICAM-1 binding patient isolates BC12, J1 and PCM7. 
Purple: DBLβ3, orange: DBLβ5, turquoise: DBLβ8, black: PCM7a and PCM7d which 
have similarities to two subtypes. The UPS type A-C or unknown (?) is indicated. 
Black dots indicate bootstrap values ≥ 70%. 
 
The tree displayed in Figure 4.3 was re-analysed in relation to ICAM-1 binding, with 
ICAM-1 binding DBLβ in red, non-binders in blue and untested DBLβ domains in 
black (Figure 4.4). The sequences identified in this thesis are also in red as they are 
assumed to be responsible for ICAM-1 binding. There are seven DBLβ5 sequences 
that bind ICAM-1, ten if BC12a, J1a and J1d are included, and they are spread across 
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the DBLβ5 containing branches of the tree (Figure 4.4). Only IT4var16 and IT4var41 
group very closely together.  J1a groups with two other UPS C sequences of DBLβ5 
type with a bootstrap value of 100% (indicated by black dot, Figure 4.4). One of 
these sequences is the ICAM-1 binder IT4var01 and the other is the untested 
sequence of HB3var34. It is possible that these very closely related sequences all 
have the ability to bind ICAM-1 specifically. However, the binding ability of 
HB3var34 would need to be tested to confirm this. There are three DBLβ3 ICAM-1 
binders, two of which are of UPS A type and one UPS B. PCM7d groups with the UPS 
B IT4var31 DBLβ3 ICAM-1 binding domain (Figure 4.4). As described above, PCM7a 
falls between two DBLβ8 clusters, none of which are known to bind ICAM-1, 
although only two have been tested. Indeed, only 19 out of the 70 domains 
included in this tree have been tested for binding to ICAM-1 and the majority of 
those belong to the IT4 parasite strain.  
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Figure 4.4. Phylogenetic comparison of type 3, 5 and 8 DBLβ domains in relation 
to ICAM-1 binding.  
The maximum likelihood tree shown in Figure 4.3 (constructed from all DBLβ 
domains of subtype 3, 5 and 8 in the Rask et al. (2010) dataset and the DBLβ 
domains of the dominantly expressed var genes of the ICAM-1 binding patient 
isolates BC12, J1 and PCM7). DBLβ domains that bind ICAM-1 (red), do not bind 
ICAM-1 (blue) and have not been tested for ICAM-1 binding (black) are indicated. 
The UPS type (A-C or unknown (?)) and DBLβ subtype is indicated. Black dots 
indicate bootstrap values ≥ 70%. 
 
Since the majority of work on ICAM-1 binding has been carried out on the IT4 
parasite strain, we constructed a maximum likelihood tree of our DBLβ domains 
and all those from the IT4 sequences (Figure 4.5). The majority of the ICAM-1 
binding DBLβ domains fall on one side of the tree, forming two clades. J1d groups 
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with an untested sequence, IT4var11, and PCM7a branches with two non-binders 
but is close to ICAM-1 binders IT4var13 and IT4var27. IT4var31 and PCM7d form a 
separate clade with a bootstrap value of 100%. As in Figure 4.4, J1a and IT4var01 
group together with a bootstrap value of 100%. BC12a groups with IT4var27 with a 
bootstrap value of 83%. The relatedness of BC12a, J1a and PCM7d to known ICAM-
1 binding DBLβ domains could be interpreted as further evidence that these 
domains are truly mediating ICAM-1 binding. This could also suggest that the 
untested sequences grouped with these ICAM-1 binding domains in Figure 4.4 can 
also mediate binding to ICAM-1. However, the fact that these sequences are known 
to recombine (Claessens et al., 2014, Bopp et al., 2013) weakens the reliability of 
phylogenetic analysis. 
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Figure 4.5. Phylogenetic comparison of IT4 and BC12, J1 and PCM7 DBLβ domains. 
A maximum likelihood tree constructed from all IT4 DBLβ domains and those of the 
dominantly expressed var genes of the ICAM-1 binding patient isolates BC12, J1 and 
PCM7. DBLβ domains that bind ICAM-1 (red), do not bind ICAM-1 (blue) and have 
not been tested for ICAM-1 binding (black) are indicated. The UPS type (A-C or 
unknown (?)) and DBLβ subtype is indicated. Black dots indicate bootstrap values ≥ 
70%. 
 
The results of our phylogenetic comparisons of the DBLβ domains show that there 
are some groupings of sequences known to mediate ICAM-1 binding. However, it is 
clear that there are also a number of exceptions which reduces the reliability of 
using sequence comparisons as predictors of domain function. Experimental 
validation is still necessary to test any predictions from sequence comparisons. In 
addition, the sequence of the entire DBLβ domain is compared when it may be 
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more informative to focus on key areas of the sequence such as homology blocks 
(Rask et al., 2010) or areas specifically involved in contact with ICAM-1 (Lennartz et 
al., 2015). These comparisons are addressed below. 
4.3.5 Homology block analysis of DBLβ domains predicted to bind ICAM-1 
One downside of studying the relatedness of entire domain sequences is that small 
conserved sequences may be missed if the overall sequence groups elsewhere. 
This, along with the high frequency of recombination of the var genes, was the 
reasoning behind the definition of short sequence homology blocks (HBs) by Rask et 
al. (2010). We analysed the DBLβ domain HB structure of the ICAM-1 binding 
patient isolates, the IT4 var genes, and the individual var genes PF11_0521, 
PFD1235w, DD2var32, HB3var10, HB3var34 and AAQ73926, which either bind 
ICAM-1 or grouped closely with ICAM-1 binding sequences, in an attempt to 
identify shared HBs that indicate ICAM-1 binding ability.  
Figure 4.6A shows a maximum likelihood tree of these DBLβ domains and their HB 
composition. Note the low bootstrap values of many of the branches, indicating the 
unreliability of the groupings which reflects the recombination that occurs between 
the DBLβ domains (Claessens et al., 2014, Bopp et al., 2013). The core DBL HBs 1-5 
are found in all the DBLβ domains with the exception of IT4var22 which does not 
contain HB4. HB13, which is found in all DBLα, β, and ζ domains, and HB18, which is 
found in all DBLβ and ζ domains (Rask et al., 2010), are present in all domains 
(Figure 4.6). DBLβ specific HB53 and HB61 are also present in all domains except 
IT4var22 which does not contain HB53. The close proximity of HB53 to HB4, which 
is also missing in IT4var22, suggests that this section of IT4var22 DBLβ is 
significantly different from the other domains, likely as a result of a recombination 
event. HB59 is present in all the domains and HB52, HB65 and HB14 are present in 
all but one of the DBLβ domains (HB52 and HB14 absent from IT4var35 and HB53 
absent from IT4var22). With the exception of the HBs mentioned above, no clear 
pattern emerges that could suggest specific HBs in ICAM-1 binding DBLβ domains. 
Only very closely related sequences share a HB pattern: IT4var16 identical to 
IT4var41 and IT4var19 identical to IT4var32b. 
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We separated the DBLβ domain HB compositions into ICAM-1 binding and non-
binding groups in an attempt to see any significant pattern (Figure 4.6B). The 
majority of HBs appear in both groups with some exceptions. HB231 and HB408 
appear only in the ICAM-1 binding DBLβ domains from IT4var01 and J1a. HB375 and 
HB382 also only appear in ICAM-1 binding domains. Four HBs are only found in non-
binding DBLβ domains in this dataset: HB317, HB272, HB48 and HB614. However, 
these ‘specific’ HBs are only found in 2-4 domains and there are no clear 
associations between ICAM-1 binding and non-binding DBLβ domains (Figure 4.6B).  
This lack of association is perhaps unsurprising when you consider that these 
defined HBs would need to include the specific contact residues necessary for 
ICAM-1 binding. The HB analysis was performed on linear sequences and HBs have 
an average length of 19 resides with the most common length 10 residues (Rask et 
al., 2010). However, protein structures are not linear and binding sites can be 
formed from a number of secondary structures which may be some distance away 
in terms of primary structure. However, a recent study found that some HBs of the 
DBLα domain had a stronger association with certain disease phenotypes than the 
commonly used DBLα tag (Rorick et al., 2013). The authors found HB expression to 
be significantly different in SM and UM and found that some HBs could distinguish 
different forms of severe disease. Specifically, they found that HB204 is associated 
with SM but is not associated with rosetting, suggesting that another mechanism 
for disease pathogenesis is responsible for the SM (Rorick et al., 2013). IT4var13 
contains HB204 and is known to bind CD36 (Robinson et al., 2003) and ICAM-1 
(Howell et al., 2008) which is mediated by the CIDRα and DBLβ domains, 
respectively, resulting in its ability to bind endothelial cells (Madkhali, 2015). It is 
possible that this DBLα domain predictor reflects downstream sequences. A major 
impediment to our ability to associate specific sequences to disease phenotypes is 
that the underlying cause of many of those phenotypes is poorly understood. 
Indeed, disease phenotypes can overlap making it incredible difficult to disentangle 
cause and effect. A much larger dataset than that studied here is required to 
identify any specific associations between HBs, and indeed whole DBLβ domain 
sequences, and ICAM-1 binding.   
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Core S1 S2a S2b S2c S3a S3b 
  HB4   HB52   HB278   HB146   HB231   HB48   HB119   Other 
  HB3   HB65   HB189   HB174   HB297   HB59   HB614 
  HB5   HB17   HB584   HB317   HB183   HB382   HB129 
  HB2   HB375   HB290   HB272   HB187   HB523 
  HB1   HB53   HB13   HB14   HB408 
  HB234   HB199   HB62 
  HB266   HB255 
  HB396 
  HB61 
  HB18  
Figure 4.6. Homology block structure of DBLβ domains (Figure begins on page 91).  
A (Page 91), left, maximum likelihood tree of ICAM-1 binding (red), non-binding (blue) and untested (black) DBLβ domains. Numbers indicate 
the bootstrap support. Right, homology block (HB) structure of each DBLβ sequence. Common HB numbers are indicated above the figure. B 
(Page 92), HB structure of DBLβ domains grouped into ICAM-1 binding (red) and non-binding (blue). Above, colour key to HBs split into the 
following sections: Core: HBs shared with all DBLβ domains; S1: HBs N-terminal to HB4; S2a: HBs located between HB4 and HB3; S2b: HBs 
located between HB3 and HB5; S2c: HBs located between HB5 and HB2; S3a: HBs located between HB2 and HB1; S3b: HBs C-terminal to HB1; 
Other: HBs which appear >3 times in the sequences analysed. Sections are indicated below the HB structures with brackets. 
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4.3.6 Comparison of peptides important in DC4 DBLβ3∷ICAM-1 binding 
DC4-containing PfEMP1 are unusual among ICAM-1 binders in that they belong to 
group A (Bengtsson et al., 2013b), suggesting that they may be more important in 
the development of SM. Evidence that this set of group A ICAM-1 binders may have 
a distinct binding site compared to group B and C binders is provided by differential 
blocking of binding by an antibody against domain 2 (D2) of ICAM-1 (Anja Jensen, 
personal communication). DC4 DBLβ binding is blocked by this antibody whereas 
group B and C DBLβ domains are not, suggesting the involvement of D2 in DC4 DBLβ 
ICAM-1 binding. A recent study has characterised a monoclonal antibody, 24E9, 
that blocks the interaction between the DBLβ3 domain of DC4 containing var genes 
and ICAM-1 and is effective against distinct parasite strains that also express DC4 
(Lennartz et al., 2015). The authors used 24E9 bound to PFD1235w DBLβ3 in 
hydrogen/deuterium exchange mass spectrometry (HDX MS) to identify key 
peptides that are masked by this antibody (Lennartz et al., 2015). We performed a 
sequence comparison of these DBLβ peptides, P1-P3, to the dominantly expressed 
DBLβ domains of the ICAM-1 binding patient isolates (Figure 4.7) with particular 
interest in region P3a which was shown to be essential for 24E9 binding (Lennartz 
et al., 2015).  
P1 and P2a are relatively conserved which is in agreement with observations that 
these regions are conserved between both 24E9 binding (PFD1235w DBLβ3) and 
non-binding (Dd2var32 DBLβ1, IT4var13 DBLβ5 and IT4var16 DBLβ5) DBLβ domains 
and were likely identified due to steric hinderence (Lennartz et al., 2015). There is 
very little conservation in the essential P3b region, although the DBLβ3 domains all 
share the A*NGG motif (Figure 4.7). However, this motif is also present in Dd2var32 
DBLβ1 which does not bind 24E9 (Lennartz et al., 2015). This sequence comparison 
suggests that the newly identified ICAM-1 binding DBLβ domains will not be 
inhibited by this DC4 specific antibody and that ICAM-1 binding is mediated by 
different peptides. They are, however, likely to be located on the same convex 
surface of the DBLβ domain (Lennartz et al., 2015, Brown et al., 2013, Howell et al., 
2008, Oleinikov et al., 2009) which mainly consists of subdomain 3. Similar studies  
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    Protein               P1                        P2 
     PFD123w_DBLb3      FYLPPRRQHMCTSNL   ADLGDIIRGKDMWNINSDAKDLQDRLEK     PCM7d_DBLb3_5      VYLPPRRQHMCTSNL   ADIGDIIRGRDMWDKNSGEVTTQNVLIN     IT4var31_DBLb3     VYLPPRRQHMCTSNL   ADIGDIIRGTDMWDKDEGSKKMDVILKK     PF11_0521_DBLb3    VYLPPRRQHFCTSNL   ADIGDIIKGTDLWDKDGGEIKTQNHLVT     AAQ73928_DBLb3     VYMPPRRQHFCTSNL   ADLGDIIKGTDLWDKDGGEIKTQNHLVT     Dd2var32_DBLb1     LYLPPRRQHICTSNL   ADIGDIIRGRDMWSKNGDEQRTQGRLKT     BC12a_DBLb5        VFLPPRREHMCTSNL   ADLGDIIRGRDMWDLDDGSQKIEKNLKD     J1a_DBLb5          VIMPQRREHMCTSNL   ADLGDIIRGRDMWDLNDGSQKIEKNLKD     J1d_DBLb5          VFLPPRREHMCTSNL   ADIGDIIRGTDMWDKDGGSTDMQNNLKT     IT4var01_DBLb5     VFLPPRREHMCTSNL   ADLGDIIRGRDMWDLNDGSQKIEKNLKD     IT4var13_DBLb5     AYIPPRRQHMCTSNL   ADLGDIIRGRDLWEHGD-QTKLQGHLQI     IT4var14_DBLb5     VFLPPRREHMCTSNL   ADLGDIIKGTDLWDKDSGEQKTQRNLVT     IT4var16_DBLb5     VFLPPRRQHMCTSNL   ADLGDIIRGRDLWDLDEGSKKMEGHLKK     IT4var27_DBLb5     VFLPPRREHMCTSNL   ADLGDIIRGRDMWDEDKSSTDMETRLIT     IT4var41_DBLb5     VFLPPRRQHMCTSNL   ADLGDIIRGRDLWDLDEGSKKMEGHLKK     PCM7a_DBLb5_8      IYMPPRREHMCTSNL   ADLGDIIRGRDLWDHRDNKKKLQSNLKD                        ...*.**.*.*****   **.****.*.*.*...... ... .*.                                                             P2a               P2b          Protein                   P3 
     PFD123w_DBLb3      TVSAIYQILYAKARIV-A-SNG-GPGYYNTEVQKK     PCM7d_DBLb3_5      AISDKYQILYWQAKTA-A-ANG-GLNTSVGAVNNE     IT4var31_DBLb3     AISDKYQFLYLQAKTA-A-ANG-GPHASSGDVGEK     PF11_0521_DBLb3    AISYKYLMLYAKARIT-A-ING-GPGYYNTEVQEE     AAQ73928_DBLb3     KIRAKYKTLYSSALVDIA-ANG-GLNTSTAIKDNE     Dd2var32_DBLb1     IISAKYKELYKEAEIY-A-RNG-GPGYYNTEVQKE     BC12a_DBLb5        KIKDKYEELYLQAQTT-A-AGT-VLGD----V--S     J1a_DBLb5          KMQLKYLYFYHEAKTT-S-RHG-IDAY-SGAVEPK     J1d_DBLb5          QMDEKYQKLYLQAEVD-AAANG-GPHASSAIQKDK     IT4var01_DBLb5     KMQLKYLYFYHEAKTT-S-RHG-IDAY-SGAVEPK     IT4var13_DBLb5     KIKDKYEELYLQAKIA-F-AGT-SFGG-------G     IT4var14_DBLb5     KLELEYALSYLHAKND-S-RRM-AFGG----TDPD     IT4var16_DBLb5     TMEIKYLTLYAYAQMA-S-NNKGDMSIFGNAVGPK     IT4var27_DBLb5     KISDKYNLLYLQAKTT-S-TNP-GRTV-LGDDDPD     IT4var41_DBLb5     TMEIKYLTLYAYAQMA-S-NNKGDMSIFGNAVGPK     PCM7a_DBLb5_8      TMEIKYLTLYMQAKNG-S-AGM---AFLDA----D                         .  .*  .*  *..  .  .. . .   . .    
                                                                                  P3a                      P3b 
Figure 4.7. Sequence comparison of three peptides of DBLβ that are masked by a 
mAb specific to DC4 DBLβ3.  
Sequences were aligned with T-Coffee (see Methods 4.2.5). P1-P3 were identified in 
HDX MS experiments with PFD1235w DBLβ3 as being masked by mAb binding and 
further characterised to show that region P3a is essential for this mAb to block 
ICAM-1 binding (Lennartz et al., 2015).  
 
are required to identify peptides from other DBLβ domains important in ICAM-1 
binding.  
The finding of remarkable sequence conservation between DC4 DBLβ3 domains 
(Bengtsson et al., 2013b) could suggest that var gene classification at DC level is 
more informative than shorter sequence comparisons of single domains or tags. It 
may be that these common domain compositions represent desirable binding 
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functions that are maintained in the global var repertoire. This is supported by data 
on DC5 binding to PECAM-1 for which no single domain is clearly responsible 
(Berger et al., 2013). However, the DC13 and DC8 binding EPCR story (Turner et al., 
2013, Lau et al., 2015) is complicated by the inability of other research groups to 
replicate the results of binding experiments ((Gillrie et al., 2015) and Alex Rowe, 
unpublished data). In particular, the findings of Gillrie et al. (2015) that the binding 
of DC13 and DC8 expressing parasites was not attributed to EPCR in all endothelial 
cell types tested, suggesting the involvement of other receptors. The highly variable 
nature of var genes, their constant recombination and their combined role in host 
receptor binding and antigenic variation make them very difficult to classify. This is 
exacerbated by the presence of exceptions in the majority of classification 
predictions which highlights the fact that sequence variability is on a continuous 
scale for which cut off points are required but are arbitrary.  
4.3.7 Antigenic variation, receptor binding and the evolution of var genes 
Pathogen-host interactions are the complex evolutionary result of centuries old 
battles for dominance. Many diverse pathogens, including viral, bacterial, 
protozoan and fungal examples, have independently developed mechanisms to 
avoid the host immune system with the ultimate goal of onward transmission. In 
this section we consider broader ideas of the evolution behind the var genes and 
the reason for their immense diversity at both the single parasite level and at the 
level of population genetics.  
The dynamics of infection at population level follow different patterns which are 
largely dictated by host susceptibility and pathogen virulence and persistence 
within a population. Different strategies are implemented by different pathogens 
and lead to a range of population structures which can be modelled 
mathematically. An example of differential strategies and outcomes is found among 
the RNA viruses. Measles virus infects young hosts and emphasis is placed on 
transmission, resulting in a virus of one antigenic type for which an effective 
vaccine is available (Frank and Bush, 2007). Influenza, on the other hand, is a virus 
which infects a whole range of host ages and regularly produces new antigenic 
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types which can infect previously exposed individuals. Here, emphasis is on 
persistence in the population, rather than high transmissibility, resulting in the 
need for new vaccines each season (Frank and Bush, 2007). Cause and effect of 
such infection dynamics are inherently difficult to disentangle due to co-evolution 
and are not discussed here.  
The P. falciparum parasite is a much more complex organism which utilises an 
antigenic variation strategy, as opposed to the random mutagenesis of RNA viruses, 
but parallels can be drawn with both situations. The different groups of var genes 
appear to act in different ways. The UPS A type var genes are similar to the measles 
example in that they are expressed in young children and immunity is quick to 
develop, whereas UPS B and C var genes follow the influenza pattern of persistence 
within the population.  The presence of both strategies could be related to the 
trade off between what is beneficial in an individual infection versus what is 
beneficial to the population as a whole, as discussed by Holding and Recker (2015). 
Through modelling, they demonstrated that a parasite in an individual infection 
benefits from having multiple antigenic phenotypes which prolong infection by 
avoiding the immune response. However, population var repertoires would benefit 
from having a diverse set of parasites each with a single phenotype to reduce the 
chance of cross-reactivity between distinct infections (Holding and Recker, 2015). In 
reality, P. falciparum parasites have developed diverse individual var repertoires 
which have minimal overlap with other genetically distinct parasites, gaining the 
benefit of both scenarios.  
The strategy of antigenic variation to avoid the host immune system is found in 
many pathogens. Bacterial examples include Borrelia hermsii, Neisseria spp. and 
Trepomena pallidum (Deitsch et al., 2009). Protozoal examples include Giardia 
lamblia (Prucca et al., 2011), Babesia bovis (Allred and Al-Khedery, 2004) and the 
extensively studied Trypanosoma brucei (Horn, 2014). An interesting aspect to 
consider for P. falciparum is the need to maintain receptor binding while producing 
antigenically distinct PfEMP1 proteins. This is thought to restrict the evolution and 
diversification of these genes (Holding and Recker, 2015), which is not the case in 
gene families with a role solely in antigenic variation, such as T. brucei and G. 
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lamblia. Clues as to how receptor binding ability is retained are found in var gene 
recombination mechanisms. Recombination mainly occurs between domains of the 
same type, is initiated in HBs and can involve multiple crossovers between the two 
genes in question (Claessens et al., 2014, Kraemer et al., 2007). HBs contain 
conserved amino acids important in the maintenance of protein structure (Kraemer 
et al., 2007, Rask et al., 2010) and they flank the three structural subdomains of DBL 
domains and the two structural subdomains of CIDR domains (Rask et al., 2010), 
suggesting that their function in recombination initiation allows recombination 
while maintaining structure. In addition, the HBs shared between domain subtypes 
allow for multiple crossovers to occur, presumably maintaining receptor binding 
ability within a subtype. However, it is likely that the situation is, or was once, more 
complex to allow for generation of new domain types. The chromosomal location 
and orientation of transcription is thought to be responsible for the restriction of 
var gene recombination to mainly within the groups A, B and C (Gardner et al., 
2002, Kraemer and Smith, 2003, Kraemer et al., 2007, Claessens et al., 2014). Thus, 
resulting in specific adhesion phenotypes of gene groups e.g. CD36 binding of group 
B and C genes but not group A (Robinson et al., 2003). In this manner, the groups 
are separate and preserve the specialisation of specific receptor binding, 
particularly between group A and C genes. However, the potential for 
recombination between groups is present, as evidenced by group B/A genes 
(Lavstsen et al., 2003, Rask et al., 2010), allowing the relatively rare generation of 
new gene types.  
 
4.4 Summary 
In this chapter, we further tested the predictive powers of the Pf3k var gene 
database by analysing the returned sequences to the non-dominant DBLα tags of 
the ICAM-1 binding patient isolates and the short sequences identified specifically 
in cases of fatal cerebral malaria, 28B1-1 and 62B1-1. We found that the domain 
structure and predicted group type of the database sequence hits were in 
agreement with predictions made from PoLV analysis of the DBLα tag. Together 
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these analyses identified group A and B/A virulence associated genes, which 
included the two genes identified as important in CM. We characterised the 
PfEMP1 domain structure of the dominantly expressed var genes of BC12, J1 and 
PCM7. The DBLβ domains of BC12a, J1a and J1d are all of subtype 5 and are 
predicted to bind ICAM-1. PCM7a and PCM7d DBLβ domains fell between two 
subtypes: 5/8 and 3/5, respectively. Phylogenetic comparisons showed that these 
DBLβ domains generally grouped with ICAM-1 binding domains but the presence of 
exceptions reinforces the need for experimental validation to confirm, and increase 
the reliability of, sequence predictions. HB analysis did not reveal any patterns 
specific to ICAM-1 binding DBLβ domains, although the relatively small number of 
sequences analysed may not detect such patterns.  Finally, comparisons with DBLβ 
peptides identified as important in ICAM-1 binding of DC4-containing PfEMP1, 
suggest that binding of group A proteins and group B and C proteins to ICAM-1 
involves distinct peptides. Mechanisms of var gene recombination provide clues as 
to how such differences in host receptor binding are maintained within var gene 
groups.  
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Chapter 5. Recombinant DBLβ ICAM-1 
molecular interactions 
5.1 Introduction 
ICAM-1 is an endothelial receptor involved in transmigration of leukocytes to sites 
of inflammation. Ligands for this receptor include the native lymphocyte function 
associated molecule 1 (LFA-1) (Marlin and Springer, 1987) and fibrinogen (Languino 
et al., 1993), and the pathogens rhinovirus (Greve et al., 1989) and P. falciparum IEs 
(Berendt et al., 1989). ICAM-1 consists of five Ig domains (D1-D5) with the N-
terminal D1 mediating binding to LFA-1 and P. falciparum IEs at distinct but 
overlapping sites (Berendt et al., 1992, Ockenhouse et al., 1992a). The crystal 
structure of D1 has been known for some time (Casasnovas et al., 1998) and 
comprises a number of β-sheets named A-G (Figure 5.1). The P. falciparum binding 
site has been identified via mutagenesis studies as the BED side of ICAM-1 (Berendt 
et al., 1992, Ockenhouse et al., 1992a, Tse et al., 2004), indicated in Figure 5.1.  
Importantly, different parasite strains have been shown to be differentially affected 
by some of the mutations tested (Tse et al., 2004), including the culture-adapted 
patient isolates that are the subject of this study (Madkhali et al., 2014), indicating 
subtle contact residue differences. One such mutation is the naturally occurring 
homozygous K29M mutation known as ICAM-1Kilifi which reduced binding of A4 
parasites but had minimal effect on ItG (Tse et al., 2004, Madkhali et al., 2014). 
These results could help explain differences in studies which found ICAM-1Kilifi to be 
either associated with CM (Fernandez-Reyes et al., 1997), have no association to 
SM (Bellamy et al., 1998, Ohashi et al., 2001) or be protective of SM (Kun et al., 
1999), depending on the predominant PfEMP1s expressed in these geographically 
diverse populations.  
PfEMP1 proteins are made up of a number of DBL and CIDR domains that mediate 
binding to a variety of host endothelial cell receptors. They belong to a wider family 
of Plasmodium proteins that also have DBL domains as their building blocks,  
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Figure 5.1. Crystal structure of the N-terminal domain 1 (D1) of ICAM-1.  
The binding sites of LFA-1 and P. falciparum-infected erythrocytes are shown. β-
sheets are labelled A-G and the four mutated residues assessed in this study are 
highlighted in yellow and labelled. Structure accessed via Protein Data Bank, 
deposited by Casasnovas et al. (1998).  
 
including the EBL and RBL invasion proteins (Culleton and Kaneko, 2010). Although 
they are all α-helical proteins with a conserved overall fold, they share just 4% 
sequence identity and 15% similarity (Higgins and Carrington, 2014). Crystal 
structures of several PfEMP1 DBL (Higgins, 2008b, Khunrae et al., 2009, Vigan-
Womas et al., 2012) and CIDR (Klein et al., 2008, Lau et al., 2015) domains have 
been solved. These, along with small angle x-ray scattering (SAXS) data, have 
revealed two different strategies of PfEMP1 organisation and receptor binding. 
VAR2CSA mediates IE binding to chondroitin sulphate A (CSA) on placental 
syncytiotrophoblasts and has been shown to have a compact structure where the 
domains are folded together, with the DBL2X domain mainly responsible for binding 
(Clausen et al., 2012). In contrast, the ICAM-1 binding IT4var13 has been shown to 
have a rigid, elongated structure whereby binding is mediated by the DBLβ5 domain 
only (Brown et al., 2013). This elongated, modular structure is predicted to be the 
norm, based on the uniqueness of VAR2CSA as a semi-conserved protein with a 
very specific binding phenotype (Salanti et al., 2003) and evidence from an EPCR 
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binding gene that the CIDRα1.1 domain binds its receptor with affinity comparable 
to the full length protein (Turner et al., 2013). There are no crystal structures of an 
ICAM-1 binding DBLβ domain to date. Mutagenesis of multiple residues of DBLβ 
domains have been shown to decrease ICAM-1 binding, however, it is unclear 
whether these are residues of the contact site or if they are important for protein 
folding (Howell et al., 2008).  
The majority of data on the DBLβ∷ICAM-1 interaction is from parasites of the IT 
lineage. In the absence of structural information on which to model sequences, a 
more diverse set of DBLβ domains need to be characterised, especially since ICAM-
1 binding cannot be solely predicted by sequence comparison (Howell et al., 2008). 
This chapter aims to recombinantly express the DBLβ domains of ICAM-1-binding 
patient isolates identified in Chapter 3 and analysed in Chapter 4, and characterise 
their binding ability to wild type ICAM-1 and four mutant proteins (mutated 
residues indicated in Figure 5.1). 
 
5.2 Methods 
5.2.1 Expression plasmid preparation 
Full length DBLβ domains were PCR amplified with the proofreading TaKaRa LA 
Taq® DNA polymerase (Clontech, TaKaRa Bio Inc), as described (see 2.2.3), from 
parasite gDNA using primers listed in Appendix A. Reaction conditions were an 
initial denaturing step of 95 °C for 3 minutes, followed by 30 cycles of 95 °C for 30 
seconds, 52 °C for 30 seconds, 65 °C for 40 seconds, and a final extension of 65 °C 
for 3 minutes. PCR products were purified as stated (see 2.2.4). PCR products were 
restriction digested in a reaction comprising 2 µl CutSmart® Buffer (NEB), 20 U each 
of BamHI and XhoI (NEB), 5 µl purified PCR product and made up to 20 µl with 
sterile water. The reaction was incubated overnight at 37 °C. A modified pET15b 
plasmid (kindly provided by the Higgins group, Oxford) was digested with the same 
reagents and incubated at 37 °C for 2 hours. Restriction digests of both vector and 
product were run on a 1% agarose gel, visualised with ethidium bromide and 
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purified as described (see 2.2.4). Purified digested PCR products were ligated into 
the pET15b vector using T4 DNA Ligase (NEB) in a reaction comprising 2 µl 10x T4 
DNA Ligase Buffer, 10:1 ratio of product to vector, 1 µl T4 DNA Ligase (NEB) and 
nuclease- free water up to 20 µl. The ligation was incubated overnight at 16 °C and 
heat inactivated at 65 °C for 10 minutes. 
5.2.2 Transformation of E. coli 
Expression plasmids were transformed into One Shot® TOP10 E. coli competent 
cells (Invitrogen) as described (see 3.2.4). Overnight cultures were grown and 
Miniprep performed to isolate the plasmid as described (see 3.2.4). Plasmids were 
sent for sequencing (see 2.2.5) to confirm correct in frame sequence.  
Expression plasmids were then transformed into SHuffle® T7 Express lysY 
competent E. coli (C3030) (NEB), a cell line optimized to form proteins containing 
disulphide bonds. Competent cells were thawed on ice for 10 minutes and 5 µl 
plasmid DNA added, mixed and incubated for 30 minutes on ice. Cells were heat- 
shocked at 42 °C for 30 seconds and placed on ice for 5 minutes. 950 µl SOC was 
added and the cells were incubated at 30 °C for 1 hour with agitation. 10- fold serial 
dilutions were carried out and 100 µl spread on agar plates containing 100 µg/ml 
ampicillin before incubating overnight at 30 °C. Ten colonies were picked and 
cultured overnight at 30 °C in 2-YT broth (1.6% tryptone, 1% yeast extract, 0.5% 
NaCl) before plasmid preparation as described (see 3.2.4). Plasmids were PCR 
amplified to confirm presence of the insert. Glycerol stocks were made by adding 
800 µl 80% glycerol to 500 µl overnight culture and freezing at – 80 °C.  
5.2.3  Recombinant protein expression 
Optimisation 
Expression clones were grown in 3 ml 2-YT broth (1.6% tryptone, 1% yeast extract, 
0.5% NaCl) at 30 °C to an optical density at 600 nm (OD600) of 0.8 or 1.2 before 
induction with 0.4 mM or 1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside, 
Sigma). Following induction, cultures were grown at 25 °C for 16- 20 hours. Un-
induced cultures at each OD600 were also grown.  Cultures were centrifuged at 5000 
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x g for 20 minutes and the pellet resuspended in Lysis Buffer (20 mM Tris- HCl, 150 
mM NaCl, 30 mM imidazole, 2% glycerol, 0.9% Triton X-100, pH 7.4) and placed at -
80 °C overnight. Cells were thawed on ice and cΘmplete EDTA-free protease 
inhibitors (Roche) were added before sonication with a VibraCellTM sonicator 
(Jencons Scientific Ltd) at 80 Amp, 10 second pulse, 10 second pause, repeated until 
cells are disrupted. Disrupted cells were spun down at 16,200 x g for 20 minutes in 
a bench-top centrifuge and samples of the supernatant and pellet were taken for 
SDS-PAGE and Western blot analysis (see 2.3.1, 2.3.2, 2.3.3). Optimal conditions for 
each DBLβ domain are show in Table 5.1. 
 
Table 5.1. Optimal DBLβ expression conditions in SHuffle® C3030 cells. 
DBLβ:pET15b OD600 [IPTG] (mM) Temperature (°C) 
BC12a clone #1  1.2 1 25 
J1a clone #8 1.2 1 25 
PCM7a clone #5 1.2 0.4 25 
 
5.2.4 Recombinant protein purification 
Affinity purification 
N-terminal His-tagged DBLβ domains were purified by affinity chromatography 
using nickel-nitrilotriacetic acid agarose (Ni-NTA, Qiagen) under native conditions. 
100 ml test cultures were induced in optimal conditions (Table 5.1) and cells 
disrupted by a freeze-thaw and sonication as described in section 5.2.3 above. 
Disrupted cells were spun down at 30,000 x g in a Beckman Avanti J25 centrifuge 
for 20 minutes. The supernatant was added to 1 ml Ni-NTA agarose pre-
equilibrated in Lysis Buffer (20 mM Tris- HCl, 150 mM NaCl, 30 mM imidazole, 2% 
glycerol, 0.9% Triton X-100, pH 7.4) and incubated at 4 °C for 1 hour with gentle 
shaking. The mixture was loaded onto a polypropylene column (Qiagen) and the 
flow-through collected. The column was washed twice with 2.5 ml Wash Buffer (20 
mM Tris-HCl, 150 mM NaCl, 30 mM imidazole, pH 7.4). Protein was eluted from the 
column with Elution Buffer (20 mM Tris-HCl, 150 mM NaCl, 200 mM imidazole, pH 
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7.4) in four elutes, followed by a final elute with elution buffer containing 500 mM 
imidazole. Samples were taken at each step for SDS-PAGE analysis (see 2.3.1).  
Affinity purification of larger cultures followed the same protocol with volumes 
appropriately adjusted. A major difference was that the initial cell supernatant was 
passed over the Ni-NTA agarose 3 times and allowed to drip by gravitational flow. 
Protein was eluted in 10 fractions with Elution Buffer (20 mM Tris-HCl, 150 mM 
NaCl, 200 mM imidazole, pH 7.4). Samples were taken at each step for SDS-PAGE 
analysis (see 2.3.1).  
Concentrating protein, buffer exchange and measurement of concentration 
Elution fractions containing the desired protein were pooled and concentrated 
using an Amicon ultracell 30 kDa concentrator (Merck Millipore) to ~ 2.5 ml. Buffer 
exchange into 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 was performed using a PD-10 
column (GE Healthcare) by gravity protocol. Protein concentration was then 
measured by absorbance at 280 nm (A280) on a NanoDrop® using the molar 
extinction coefficient and molecular weight of each domain.  
Stability test 
Affinity purified DBLβ domains were incubated at 4 °C or room temperature for 48 
hours. Samples of each were analysed by SDS-PAGE (see 2.3.1, 2.3.2) along with a 
sample before incubation. All subsequent purification was carried out at 4 °C. 
Gel filtration 
Samples were further purified on a HiLoad 16/600 Superdex 75 prep grade column 
(GE healthcare). Samples were concentrated to approximately 3.5 ml before 
loading onto a column pre-equilibrated with running buffer (20 mM HEPES, 200 
mM NaCl, pH 7.2, filtered (0.2 µm Filter), degassed). The running speed was 0.75 
ml/minute and fractions were collected between 38 and 100 ml. Fractions were 
checked by SDS-PAGE (see 2.3.1, 2.3.2).  
5.2.5 CD spectroscopy 
Protein was concentrated to ~ 200 µl using an Amicon ultra 0.5 ml centrifugal filter 
10 k (Merck Millipore) and dialyzed into 100 mM sodium phosphate buffer with 200 
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mM sodium fluoride, pH 7.4 using Slide-A-Lyzer 3.5 k Dialysis Cassettes (Thermo 
Scientific) overnight at 4 °C. The far-UV CD spectroscopy experiments were carried 
out (by Frank Lennartz) in a J-815 Spectropolarimeter (Jasco) equipped with a 
computer-controlled Peltier temperature control unit. Measurements were carried 
out at a protein concentration of 0.3 mg/ml using a 1 mM path cell. All 
measurements were taken at 20 °C between 195 and 260 nm wavelengths. Four 
spectra were recorded for each sample, averaged and corrected for buffer 
absorption. 
5.2.6 Surface plasmon resonance (SPR) 
SPR was carried out on a Biacore T200 machine (GE Healthcare). Protein A was 
immobilised onto a CM5 chip (GE Healthcare) by amine coupling. All experiments 
were carried out in buffer containing 10 mM HEPES, pH 7.2, 250 mM NaCl and 
0.05% Tween- 20, filter sterilised and degassed. ICAM-1 proteins fused to the Fc 
region of human IgG1 (ICAM-1D1D5 (Lennartz et al., 2015), ICAM-1Kilifi, ICAM-1S22A, 
ICAM-1L42A, ICAM-1L44A (Tse et al., 2004)) were captured onto the Protein A surface. 
Coupling of the different ICAM-1 proteins to the chip was kept comparable at 1108 
± 108 response units (RU). DBLβ domains were flowed over the chip in a 
concentration series (1000 nM – 7.81 nM) at a flow rate of 30 µl/min with an 
association time of 240 seconds and a dissociation time of 600 seconds. The chip 
was regenerated after each concentration with the injection of 10 mM Glycine- HCl, 
pH 1.7 for 120 seconds at a flow rate of 10 µl/min which breaks the Protein A- Fc 
interaction. The signal from a flow channel without ICAM-1 was subtracted from all 
measurements. Single stranded DNA (ssDNA, Salmon Sperm DNA sodium salt, 
AppliChem) was added to BC12aDBLβ to 1 mg/ml final concentration prior to 
injection to minimise background binding observed during test runs. Injection of 
ssDNA only had no effect on the signal (data not shown). Sensorgrams were fitted 
to a global 1:1 interaction model allowing calculation of kinetic values ka, kd and KD 
using BIAevaluation software 2.0.3 (GE Healthcare).  
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SPR competition assay 
Competition assays were carried out with ICAM-1D1D5 under the same conditions 
outlined above except that only one concentration of DBLβ was used (adjusted to 
give the same molar ratio of each protein). The first domain was injected at a flow 
rate of 30 µl/min with an association time of 240 seconds. The second domain was 
then injected at a flow rate of 30 µl/min with an association time of 240 seconds 
and a dissociation time of 600 seconds. 
5.2.7 Flow adhesion assay 
Flow adhesion assays were carried with the VenaFlux semi-automated microfluidic 
system and VenaFlux software (Cellix). The Vena8 Fluoro+TM protein biochips 
(Cellix) used contain 8 channels which allow several proteins to be tested in 
immediate succession. Individual biochip channels were coated with 4 µl of 50 
µg/ml of either ICAM-1D1D5, ICAM-1S22A, ICAM-1Kilifi, ICAM-1L42A or ICAM-1L44A 
protein and incubated at 37 °C for 1 hour in a humidified petri dish. The protein was 
then aspirated and the channel blocked with 1% BSA/PBS for either 1 hour at 37 °C 
or overnight at 4 °C. Channels were warmed to 37 °C before use. IE were prepared 
in binding buffer (RMPI 1640 powder (Invitrogen) dissolved in H2O, pH 7.2) at 3% 
parasitaemia and 2% haematocrit. The assay followed the Cellix protocol. The 
protein coated biochip was attached to a microscope stage within a plastic chamber 
whose temperature was 37 °C. The IE were drawn through the channel at a flow 
rate of 0.04 Pa for 8 minutes before washing with binding buffer. Bound parasites 
were counted in 7-10 microscope fields and the numbers adjusted to IE/ mm2.  
5.2.8 RT-qPCR 
RNA was extracted from parasite cultures and cDNA synthesised as described (see 
2.2.1, 2.2.2). Reverse transcriptase, quantitative PCR (RT-qPCR) was carried out as 
described using primers to DBLα tags of BC12 and J1 (see 3.2.5) and previously 
published primers to IT4 ICAM-1-binding var genes (Viebig et al., 2007) , Appendix 
A.  
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5.3 Results 
5.3.1 Optimisation of recombinant DBLβ domain expression 
DBLβ domains from BC12a, J1a, J1d, PCM7a and PCM7d were tagged with an N-
terminal hexa-histidine motif (His-tag) by cloning into a modified pET15b expression 
vector. Plasmids were sequenced to confirm the insert was correct and in-frame. 
J1d_DBLβ:pET15b and PCM7a_DBLβ:pET15b contain the correct sequence and 
BC12a_DBLβ:pET15b contained one silent (synonymous) mutation, not affecting 
the amino acid sequence (CTC > CTT, L166). J1a_DBLβ:pET15b contained one serine 
to threonine mutation near the N-terminus which we predict to have minimal effect 
on the fold of the protein and is not in the predicted binding region (Howell et al., 
2008). However, PCM7d_DBLβ:pET15b contained two mutations to amino acids 
with markedly different side chains which would have an unknown effect on the 
protein fold. Repeated efforts to clone this DBLβ sequence proved difficult and two 
additional clones also contained point mutations. We did not pursue this further 
due to time constraints. 
Initial expression conditions were tested on PCM7a_DBLβ:pET15b clones in a range 
of bacterial strains, IPTG concentrations and temperatures (not shown). Based on 
these initial studies and previous experience with these domains (Frank Lennartz, 
personal communication), we tested clones of each DBLβ for inducibility and 
solubility at OD600 0.8 or 1.2 with IPTG concentration of 0.4 or 1 mM (Figure 5.2) to 
determine the optimal expression conditions for each DBLβ domain. Shown in 
Figure 5.2 are examples of inducible clones for each construct and one example of a 
clone which constitutively expressed the recombinant DBLβ domain (Figure 5.2B, 
BC12a_DBLβ:pET15b clone #2). J1dDBLβ protein was highly degraded (Figure 5.2D) in 
all clones tested. We reduced the induction time in an attempt to improve the 
stability of this domain but observed the same levels of degradation. Further 
optimisation was not undertaken due to time constraints. Some degradation of 
PCM7aDBLβ (Figure 5.2E) at OD600 0.8 was apparent with overexposure of the 
membrane (not shown). Optimal conditions for BC12aDBLβ, J1aDBLβ and PCM7aDBLβ 
are summarised in Table 5.1, Methods section 5.2.3. 
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Figure 5.2. Examples of DBLβ expression optimisation.  
SHuffle® C3030 were grown in 3 ml 2-YT broth at 37 °C to OD600 0.8 or 1.2 and 
induced with 0.4 mM or 1 mM ITPG and grown at 25 °C for 16-20 hours. Cells were 
harvested, sonicated and samples taken of the supernatant (S) and pellet (P) and 
analysed by Western blot. DBLβ proteins were detected by α-His antibody. A, 
BC12a_DBLβ:pET15b clone #1, expected size 54.6 kDa. B, BC12a_DBLβ:pET15b 
clone #2, expected size 54.6 kDa. C, J1a_DBLβ:pET15b clone #8, expected size 54 
kDa. D, J1d_DBLβ:pET15b clone #4, expected size 57 kDa. E, PCM7a_DBLβ:pET15b 
clone #5, expected size 44 kDa. “*” indicates a sample shared between two wells. 
 
5.3.2 Optimisation of affinity purification and scale-up  
DBLβ proteins were purified by affinity chromatography on Ni-NTA agarose, first in 
a small scale test from 100 ml culture, followed by scaling-up to 2 L culture. We 
observed varying results for each DBLβ domain. BC12aDBLβ was successfully purified 
from both the small scale and large 2 L cultures with minimal carryover of non-  
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Figure 5.3. Ni-NTA purification of BC12aDBLβ.  
A, Initial purification trial of 100 ml culture expressing BC12aDBLβ, visualised by 
coomassie (left) and Western blot (right). Protein was eluted with 200 mM 
imidazole in four fractions (E1-4) and finally with 500 mM imidazole (E500). B, Large 
scale 2 L culture expressing BC12aDBLβ eluted with 200 mM imidazole, visualised by 
coomassie. Fractions pooled for further purification are shown (black bar) and 
consist of 7 mg total protein. S, supernatant. P, pellet. FT, flow-through. W, wash. E, 
elute. Mx, sample of Ni-NTA agarose matrix after elution.  
 
specific proteins (Figure 5.3A and B, respectively). Seven elution fractions were 
pooled and contained ~ 7 mg total protein.  
J1aDBLβ purified in the small scale test culture (Figure 5.4A) but appeared as a 
double band in the 2 L culture with the majority of protein in the first elute (Figure 
5.4B). A similar pattern was observed when purifying from 500 and 250 ml cultures 
(Figure 5.4C and D, respectively). Therefore, J1aDBLβ was purified from four 100 ml 
cultures and pooled, producing ~ 3.7 mg total protein (one example shown, Figure 
5.4E).  
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Figure 5.4. Ni-NTA purification of J1aDBLβ.  
A, Initial purification trial of 100 ml culture expressing J1aDBLβ, visualised by 
coomassie. Protein was eluted with 200 mM imidazole in four fractions (E1-4) and 
finally with 500 mM imidazole (E500). Larger scale cultures expressing J1aDBLβ of 2 L 
(B), 500 ml (C) and 250 ml (D) eluted with 200 mM imidazole. E, 1 of 4 purifications 
from 100 ml cultures that were pooled for further purification (black bar and data 
not shown). S, supernatant. P, pellet. FT, flow-through. W, wash. E, elute. Mx, 
sample of Ni-NTA agarose matrix after elution.  
 
PCM7aDBLβ purified from small scale culture appeared as a double band and slightly 
degraded, although it was unclear if this was simply a diffuse gel run (Figure 5.5A). 
Purification from a 2 L culture resulted in the majority of protein in the first elute 
which appears highly degraded (Figure 5.5B). A 250 ml culture produced very little 
protein which was similarly degraded (Figure 5.5C). A repeat of purification from a  
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Figure 5.5. Ni-NTA purification of PCM7aDBLβ.  
A, Initial purification trial of 100 ml culture expressing PCM7aDBLβ, visualised by 
coomassie (left) and Western blot (right). Protein was eluted with 200 mM 
imidazole in four fractions (E1-4) and finally with 500 mM imidazole (E500). 
Expression in larger scale 2 L (B) and 250 ml (C) cultures, visualised by coomassie. S, 
supernatant. P, pellet. FT, flow-through. W, wash. E, elute. Mx, sample of Ni-NTA 
agarose matrix after elution.  
 
100 ml culture also resulted in degraded protein (data not shown). PCM7aDBLβ 
production was not pursued further due to time constraints.  
BC12aDBLβ and J1aDBLβ stability test 
Due to the apparent sensitivity of the DBLβ domains, we performed a stability test. 
Samples of BC12aDBLβ and J1aDBLβ Ni-NTA purified proteins were incubated at 4 °C or 
room temperature (RT) for 48 hours. Extensive degradation of RT samples occurred 
and a slight shift in molecular weight of 4 °C samples indicates some instability 
(Figure 5.6). All steps in further purification were carried out at 4 °C to minimise 
protein degradation. 
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Figure 5.6. DBLβ domain stability test.  
Ni-NTA purified BC12aDBLβ and J1aDBLβ were incubated at either 4 °C or room 
temperature (RT) for 48 hours. Samples are run alongside pre-incubated protein 
(Pre) in a coomassie stained SDS-PAGE gel.  
 
5.3.3 Purification of BC12aDBLβ and J1aDBLβ by gel filtration 
BC12aDBLβ and J1aDBLβ were further purified by gel filtration. Much of BC12aDBLβ 
formed aggregates which eluted first, along with the majority of non-specific 
proteins (Figure 5.7A, left gel). However, sufficient protein subsequently eluted in 
fractions containing ~ 93% BC12aDBLβ which were pooled as indicated in Figure 5.7A 
(right gel). A smaller proportion of J1aDBLβ formed aggregates (Figure 5.7B, left gel), 
with the majority of protein eluting in subsequent fractions which were pooled as 
indicated to produce ~ 97% pure protein (Figure 5.7B, right gel).  
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Figure 5.7. Purification of BC12aDBLβ and J1aDBLβ by gel filtration.  
DBLβ domains were passed through a HiLoad 16/600 Superdex 75 prep grade 
column (GE healthcare) and 1 ml fractions collected between 38 and 100 ml. A, 
BC12aDBLβ gel filtration and SDS-PAGE of samples from fractions 11-22 (left) and 23-
35 (right). Fractions pooled for use in SPR and CD spectroscopy are indicated (black 
bar). B, J1aDBLβ gel filtration and SDS-PAGE of samples from fractions 11-21 (left) 
and 22-34 (right). Fractions pooled for use in SPR and CD spectroscopy are indicated 
(black bars). 
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5.3.4 Circular dichroism (CD) spectroscopy of BC12aDBLβ and J1aDBLβ 
Circular dichroism (CD) spectroscopy was carried out (by Frank Lennartz, University 
of Oxford) to determine whether the purified DBLβ domains are folded correctly. 
Recombinant DBLβ domains from both BC12a and J1a resulted in spectra typical of 
α-helical proteins, as expected (for review and typical spectra see (Greenfield, 
2006)).  
 
 
Figure 5.8. CD spectroscopy of BC12aDBLβ and J1aDBLβ recombinant domains.  
CD spectra were recorded between 195 and 260 nm at 20 °C. For each protein, four 
measurements were averaged and corrected for buffer absorption. 
 
5.3.5 Recombinant DBLβ interactions with ICAM-1 
DBLβ binding kinetics to ICAM-1D1D5  
Surface plasmon resonance (SPR) was carried out to measure DBLβ∷ICAM-1 binding 
kinetics. ICAM-1D1D5 was coupled to a Protein A chip via its Fc region, ensuring 
correct orientation and binding site availability on the chip surface. DBLβ domains 
were injected over the chip surface in a concentration series (flow channel 2, shown 
for J1aDBLβ in Figure 5.9B). ICAM-1D1D5 was removed after each DBLβ concentration 
by low pH, regenerating the chip before an equivalent amount of ICAM-1D1D5 was  
116  
 
Figure 5.9. J1a SPR data from flow channels 1 and 2 showing that binding is 
specific to ICAM-1D1D5. 
A, J1aDBLβ is injected over flow channel 1 in the absence of ICAM-1-D1D5. There is a 
slight response due to a small change in the buffer containing the DBLβ domain 
which remains constant throughout the injection time (indicated with arrows). 
Multiple red lines represent the concentration series of J1aDBLβ (see Methods 5.2.6 
for details). B, ICAM-1D1D5 is injected over flow channel 2 where it binds throughout 
the injection time, indicated by the increase in response units (RU). RU remains 
constant until injection of the DBLβ domain, indicating stable binding of ICAM-1D1D5 
to the channel. A concentration dependant response is observed when J1aDBLβ is 
injected over flow channel 2, indicating specific binding to ICAM-1D1D5. Flow channel 
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1 RU is subtracted from flow channel 2 RU to adjust for any background binding 
before analysis. 
 
captured for the next concentration. DBLβ domains were also injected over a 
channel without ICAM-1 to test for unspecific binding (flow channel 1, see Figure 
5.9A and legend for details). Data were fitted globally to a 1:1 interaction model 
based on previous studies of DBLβ∷ICAM-1 interaction by SPR (Brown et al., 2013, 
Lennartz et al., 2015).  
We performed SPR on the known ICAM-1D1D5 binder, IT4var13DBLβ, for comparison 
and as an experimental control. Binding kinetics of IT4var13DBLβ to ICAM-1D1D5 
display a fast association rate and a slow dissociation rate, with a KD of 3.45 nM 
(Figure 5.10A, D), comparable to published values for this domain (Brown et al., 
2013). BC12aDBLβ has a slow association rate and relatively fast dissociation rate, 
with the overall response much lower than IT4var13DBLβ (100 RU compared to 550 
RU, Figure 5.10B and A, respectively). BC12aDBLβ has a high KD of 197 nM indicating 
a low affinity for binding ICAM-1D1D5. J1aDBLβ also has an overall low response of 150 
RU but has very interesting kinetics which are apparent in the shape of the 
sensorgram in Figure 5.10C. J1aDBLβ association rate is fast and comparable to 
IT4var13DBLβ at 2.96 X 104 M-1 s-1 but it has a very fast dissociation rate of 15.3 X 10-4 
s-1 resulting in a higher KD of 51.7 nM (Figure 5.10D).  
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Figure 5.10. DBLβ:ICAM-1D1D5 binding kinetics.  
ICAM-1D1D5 was coupled to a sensor chip surface (1000 RU) and DBLβ domains were 
injected at 30 µl/min with an association time of 240 seconds and a dissociation 
time of 600 seconds. Shown are sensorgrams for the binding to ICAM-1D1D5 of 
IT4var13DBLβ (A), BC12aDBLβ (B) and J1aDBLβ (C). Data (black lines) are modelled to a 
1:1 global interaction model (red lines). Note the difference in scale of the y-axes. 
D, Kinetic parameters derived from SPR experiments. 
 
DBLβ domains tested for binding to ICAM-1 mutants 
We used SPR to test binding of recombinant BC12aDBLβ, J1aDBLβ and IT4var13DBLβ to 
four ICAM-1 mutant proteins that have been shown to have differential effects on 
binding of different parasite isolates (Tse et al., 2004, Madkhali et al., 2014). ICAM-
1S22A, ICAM-1Kilifi, ICAM-1L42A and ICAM-1L44A are all produced as Fc fusion proteins 
and were captured onto a Protein A chip following the protocol for ICAM-1D1D5 SPR 
experiments. Each of the four ICAM-1 mutations obliterated binding of BC12aDBLβ 
with only minimal signal detected (Figure 5.11B-E. A, binding to ICAM-1D1D5  
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Figure 5.11. BC12aDBLβ response to ICAM-1 mutant proteins.  
ICAM-1 proteins were coupled to a sensor chip surface (1000 RU) and the DBLβ 
domain injected at 30 µl/min with an association time of 240 seconds and a 
dissociation time of 600 seconds. Shown are sensorgrams for the binding of 
BC12aDBLβ to ICAM-1D1D5 (A), ICAM-1S22A (B), ICAM-1Kilifi (C), ICAM-1L42A (D) and 
ICAM-1L44A (E). Data (black lines) are modelled to a 1:1 global interaction model (red 
lines). The y-axis scale is kept constant for comparison. F, Response units measured 
to each ICAM-1 mutant protein expressed as a percentage of wild type ICAM-1D1D5 
binding.  
 
included for comparison). Binding to all mutants is < 8% of the ICAM-1D1D5 binding 
(Figure 5.11F), although it should be noted that signals are close to background  
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Figure 5.12. J1aDBLβ response to ICAM-1 mutant proteins.  
ICAM-1 proteins were coupled to a sensor chip surface (1000 RU) and the DBLβ 
domain injected at 30 µl/min with an association time of 240 seconds and a 
dissociation time of 600 seconds. Shown are sensorgrams for the binding of J1aDBLβ 
to ICAM-1D1D5 (A), ICAM-1S22A (B), ICAM-1Kilifi (C), ICAM-1L42A (D) and ICAM-1L44A (E). 
Data (black lines) are modelled to a 1:1 global interaction model (red lines). The y-
axis scale is kept constant for comparison. F, Response units measured to each 
ICAM-1 mutant protein expressed as a percentage of wild type ICAM-1D1D5 binding.  
 
noise levels and, therefore, may not be accurate and are presented as 
representative values only.  
121  
Similarly, J1aDBLβ only minimally interacted with the ICAM-1 mutant proteins (Figure 
5.12B-E). Binding to ICAM-1Kilifi, ICAM-1L42A and ICAM-1L44A is ≤ 5% of wild type 
ICAM-1D1D5 binding. ICAM-1S22A binding is slightly higher at 11% of wild type binding 
(Figure 5.12F) but is still very low.  
IT4var13DBLβ also had minimal interaction with ICAM-1Kilifi, ICAM-1L42A and ICAM-
1L44A which is ≤ 10% of ICAM-1D1D5 binding (Figure 5.13C-F). However, IT4var13DBLβ 
did bind to ICAM-1S22A with 9.82 nM affinity (carried out by Frank Lennartz, 
University of Oxford, Figure 5.13B). A repeat of this experiment resulted in a similar 
sensorgram profile and a KD of 9.96 nM, confirming the result (Frank Lennartz, data 
not shown). Therefore, the S22A mutation decreases IT4var13DBLβ binding affinity 
for ICAM-1 but only by 5% (Figure 5.13F). This is a minor effect compared to 
BC12aDBLβ and J1aDBLβ for which binding is reduced by ≥ 90% (Figure 5.11B and 
Figure 5.12B, respectively), suggesting that this residue is not critical for 
IT4var13DBLβ binding. 
Taken together, the results of the mutant ICAM-1 binding assays suggest that the 
DBLβ domains share an overlapping but not identical binding surface in the area of 
the mutations. The Kilifi, L42A and L44A mutations dramatically reduce the binding 
ability of all three DBLβ domains. The S22A mutation has a similarly dramatic effect 
on BC12aDBLβ and J1aDBLβ binding but has minimal effect on IT4var13DBLβ binding, 
suggesting a specific difference in contact residues in this area.  
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Figure 5.13. IT4var13DBLβ response to ICAM-1 mutant proteins.  
ICAM-1 proteins were coupled to a sensor chip surface (1000 RU) and the DBLβ 
domain injected at 30 µl/min with an association time of 240 seconds and a 
dissociation time of 600 seconds. Shown are sensorgrams for the binding of 
IT4var13DBLβ to ICAM-1D1D5 (A), ICAM-1S22A (B), ICAM-1Kilifi (C), ICAM-1L42A (D) and 
ICAM-1L44A (E). Data (black lines) are modelled to a 1:1 global interaction model (red 
lines). The y-axis scale is kept constant for comparison. F, Response units measured 
to each ICAM-1 mutant protein expressed as a percentage of wild type ICAM-1D1D5 
binding.  
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Competition assays confirm DBLβ domains share an overlapping binding surface 
In addition to the mutant ICAM-1 data, we performed a competition SPR assay to 
confirm that the DBLβ domains share a binding surface. One DBLβ domain is 
injected over an ICAM-1D1D5 coated chip, followed immediately by a second DBLβ 
domain with the expectation that if the domains have separate binding sites, an 
additive response will be observed. Conversely, if the domains share a binding 
surface, the response of the second domain will not be higher than that of the first. 
We performed this experiment with the injection of IT4var13DBLβ followed by 
BC12aDBLβ and, in a separate experiment, with the injection of IT4var41DBLβ followed 
by J1aDBLβ. In each case, the injection of the second domain did not result in 
additional response units to that of the first domain (Figure 5.14), suggesting that 
the overall binding surface is shared between IT4var13DBLβ and BC12aDBLβ and 
between IT4var41DBLβ and J1aDBLβ. However, it should be noted that this technique 
will not pick up subtle differences in specific amino acid contact residues which do 
exist due to the high sequence variation between DBLβ domains. Therefore, we can 
conclude only that the overall binding surface is conserved between these domains.  
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Figure 5.14. Competition assays confirm DBLβ domains share an overlapping 
binding site.  
ICAM-1D1D5 protein was coupled to a sensor chip surface (1000 RU) and the first 
DBLβ domain injected at 30 µl/min with an association time of 240 seconds 
(indicated above the graph with bracket beginning at time -336 s), followed by 
injection of the second domain at 30 µl/min with an association time of 240 
seconds (indicated above the graph with bracket beginning at time 0) and a 
dissociation time of 600 seconds. Shown are sensorgrams for the binding of A, 
IT4var13DBLβ followed by BC12aDBLβ to ICAM-1D1D5 and B, IT4var41DBLβ followed by 
J1aDBLβ to ICAM-1D1D5, blue lines. The response to the second domain alone is 
shown in red.  
 
5.3.6 Flow adhesion assay 
The initial parasite binding study (Madkhali et al., 2014) assessed the ability of 
different isolates to bind to ICAM-1 and the mutant ICAM-1 proteins in static 
adhesion assays (see discussion in 5.4 below for comparison). Our SPR experiments 
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with recombinant protein occur in channels with a constant flow of buffer. 
Although there are many differences between whole parasite and recombinant 
protein assays, we wanted to test parasite binding to the mutant ICAM-1 proteins 
under flow adhesion assay conditions which may be more comparable to those of 
SPR than the static adhesion assays. Results of parasite adhesion to ICAM-1D1D5 and 
the four ICAM-1 mutant proteins are presented in Figure 5.15A. Interestingly, BC12 
and J1 parasites bind more strongly to the wild type ICAM-1D1D5 than IT4var13 
parasites. In the majority of cases, the ICAM-1 mutations resulted in a 16-56% 
reduction in binding of all three parasite lines. Exceptions are the L42A and L44A 
mutations. ICAM-1L42A resulted in a 78 and 76% reduction of J1 and IT4var13 
binding, respectively, and ICAM-1L44A resulted in an 88% reduction of IT4var13 
binding (Figure 5.15A). RT-qPCR confirmed the dominantly expressed var gene of 
BC12 to be BC12a and IT4var13 to be var13 (Figure 5.15B). The dominant var of J1 
is J1a which represents 62% of expressed vars with a number of other var genes 
making up the remaining 38% (Figure 5.15B). This includes the previously identified 
secondary tags J1d and J1b and also includes J1f which is represented at a higher 
level than previously observed (Figure 3.3).  
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Figure 5.15. BC12, J1 and IT4var13 flow adhesion assays to ICAM-1 proteins.  
A, Channels were coated with 4 µl of 50 µg/ml ICAM-1D1D5. Recently ICAM-1-
selected IEs were passed through the channel at 3% parasitaemia, 2% haematocrit 
for 8 minutes. Bound parasites were counted in 7-10 fields and adjusted to IE/mm2. 
Bars represent the mean of 3 (BC12, J1) or 4 (IT4var13) independent experiments 
with the standard error of the mean (SEM) shown (error bars). B, RT-qPCR of cDNA 
from each parasite culture. RT-qPCR was carried out using BC12 and J1 DBLα tag 
primers (a-e and a-f, respectively) and primers to IT4 ICAM-1 binding var genes (a: 
01, b:13, c:14, d:16, e:27, f:31, g:41). Ct values were normalised against the ASL 
internal control gene to give 2-ΔCt values and are shown as percentage of total for 
each isolate. The mean of 3 (BC12, J1) or 4 (IT4var13) independent experiments are 
shown. 
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5.4 Discussion 
Here, we present data detailing the expression and purification of two newly 
identified DBLβ domains from the ICAM-1 selected patient isolates BC12 and J1. We 
have obtained kinetic information on their interaction with ICAM-1D1D5, along with 
the previously studied DBLβ domain of IT4var13, and tested the binding of all three 
recombinant DBLβ domains to four ICAM-1 mutant proteins that have been 
previously shown to have differential effects on parasite binding assays (Tse et al., 
2004, Madkhali et al., 2014). Preliminary data of flow adhesion assays to the wild 
type ICAM-1D1D5 and the four ICAM-1 mutants are also presented. 
We successfully expressed and purified two of the five newly identified DBLβ 
domains to > 90% purity. BC12aDBLβ and J1aDBLβ are from the dominantly expressed 
var genes of the ICAM-1 selected patient isolates BC12 and J1, respectively. The 
remaining DBLβ domains are from the var genes J1d, PCM7a and PCM7d. We were 
unable to generate a plasmid containing the correct PCM7dDBLβ sequence due to 
time constraints. J1d and PCM7a DBLβ domains appeared highly sensitive to 
degradation (Figure 5.2D and Figure 5.5, respectively). Alternative approaches to 
expression should be tested to improve stability of these domains. This could 
include testing of expression in alternative bacterial strains or expression in insect 
cell lines which has previously been successful for PfEMP1 domains (Brown et al., 
2013, Lau et al., 2015). A possible explanation for failure to express P. falciparum 
proteins in E. coli is codon bias. This has previously been overcome by codon 
optimisation and subsequent synthesis of the resulting synthetic gene for the 
expression of the full length var2csa gene (Khunrae et al., 2010). The current study 
was limited by time constraints and these strategies could not be pursued. 
However, the differential behaviour of these domains of the same type, and the 
same subtype in the case of BC12a, J1a, and J1d (DBLβ5), highlights the diversity of 
the PfEMP1 domains, reflected in their low sequence identity. It is unfortunate that 
neither J1dDBLβ nor PCM7dDBLβ could be expressed to test whether these secondary 
expressed genes can truly bind to ICAM-1. However, successful expression of 
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BC12aDBLβ and J1aDBLβ proteins allowed us to test two new DBLβ domains for ICAM-
1 binding by SPR, along with the previously tested IT4var13DBLβ. 
BC12aDBLβ, J1aDBLβ and IT4var13DBLβ all bind ICAM-1D1D5 with nanomolar affinity. 
IT4var13DBLβ has the strongest interaction, followed by J1aDBLβ and BC12aDBLβ (KD 
values: 3.45, 51.7, 197 nM, respectively, Figure 5.10). These KD values are similar to 
those found for five IT4 DBLβ domains, tested in comparable SPR assays, which 
ranged from 2.6 nM for IT4var13DBLβ (comparable to our 3.45 nM value for this 
domain) to 144 nM for IT4var31DBLβ (Brown et al., 2013). The UPS A type, DC4 DBLβ 
domain was also found to bind ICAM-1 with nanomolar affinity (7.9 nM) in an SPR 
assay where the DBLβ domain was immobilised on the chip and ICAM-1D1D2 passed 
over (Lennartz et al., 2015). All three domains studied here are DBLβ5 type and 
these findings fit with previous observations that, to date, all domains of this type 
mediate ICAM-1 binding (Janes et al., 2011). The difference in binding kinetics 
between IT4var13DBLβ and J1aDBLβ is very interesting. They have a similar fast 
association rate which can be thought of as necessary to overcome the flow rate of 
the capillaries to mediate IE binding. Indeed, ICAM-1 has been shown to improve 
efficiency of IE capture under flow conditions (Gray et al., 2003). However, they 
differ in their dissociation rates. IT4var13DBLβ has a slow dissociation rate which fits 
with stationary adhesion of the IE. J1aDBLβ, however, has a very fast dissociation rate 
which suggests that this domain could mediate rolling adhesion, in which the IE 
constantly attaches and detaches from the capillary wall in a rolling motion (Cooke 
et al., 1994, Gray et al., 2003).  
The KD value is calculated based on the association and dissociation rates and is 
therefore based on the shape of the sensorgram rather than the overall height of 
the response. In this case, the kinetic parameters fit with the response units 
recorded for each domain, i.e. the highest response was by IT4var13DBLβ, followed 
by J1aDBLβ then BC12aDBLβ. The low responses recorded for J1aDBLβ and BC12aDBLβ are 
in agreement with the initial parasite binding study which found both parasite 
isolates to be low avidity ICAM-1-binders, with BC12 having a lower binding rate 
than J1 (1362 and 2391 IE/mm2, respectively) (Madkhali et al., 2014). Interestingly, 
the IT4var13 parasite line has a lower binding rate (900 IE/mm2) than both BC12 
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and J1 in static adhesion assays (Madkhali, 2015), a result that is also apparent in 
our preliminary flow adhesion assays (Figure 5.15), highlighting differential results 
between IEs and recombinant protein. Great care must be taken when comparing 
data from, not only two different experimental techniques, but two different 
components, namely whole IEs and recombinant protein domains. There is no clear 
correlation between KD values of DBLβ domains and the number of bound IEs in 
static adhesion assays. For example, IT4var16DBLβ has the same KD as J1aDBLβ (51.1 
and 51.7 nM, respectively) but parasites expressing var16 have more than twice the 
binding rate of J1 parasites in static assays (5000 and 2391 IE/mm2, respectively) 
(Brown et al., 2013, Madkhali et al., 2014, Madkhali, 2015). For further discussion 
of differential results between assays see pages 131 and 132 below. 
The DBLβ binding site on ICAM-1 has been identified by mutagenesis studies and a 
number of ICAM-1 blocking antibodies as the BED side of D1 (Tse et al., 2004, 
Berendt et al., 1992, Ockenhouse et al., 1992a). The four ICAM-1 mutants utilized in 
this study have been shown to have differential effects on the binding of different 
parasite strains (Tse et al., 2004, Madkhali et al., 2014). We studied the effects of 
these mutations on the ability of the recombinant DBLβ domains to bind ICAM-1 
using SPR assays. The Kilifi (K29M), L42A and L44A mutations dramatically reduce 
the binding ability of all three recombinant DBLβ domains by ≥ 90%. The S22A 
mutation similarly reduces BC12aDBLβ and J1aDBLβ binding by ≥ 90% but has minimal 
effect on IT4var13DBLβ binding, suggesting a specific difference in contact residues in 
this area (Figure 5.11, Figure 5.12, Figure 5.13). This reduction of recombinant 
protein binding is more marked than that observed in parasite adhesion assays 
(summarised in Figure 5.16). BC12 parasite static adhesion studies found a 43-66% 
reduction in binding to ICAM-1S22A, ICAM-1Kilifi and ICAM-1L42A and actually saw an 
increase to 147% of ICAM-1D1D5 binding to ICAM-1L44A (Madkhali et al., 2014). J1 IE 
static binding to ICAM-1S22A, ICAM-1Kilifi and ICAM-1L44A was 43, 58 and 86% of wild 
type binding, respectively, with only ICAM-1L42A showing a reduction in binding 
comparable to the recombinant protein to 4% of wild type in static assays 
(Madkhali et al., 2014). Indeed, reductions in binding to ICAM-1L42A are the most 
consistent results across all assays (Figure 5.16). ICAM-1S22A had a major effect on  
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  S22A Kilifi L42A L44A Static  (Madkhali et al., 2014) A4         ItG            Static  (Tse et al., 2004) A4         ItG            Flow  (Tse et al., 2004) A4         ItG             Static assay  (Madkhali et al., 2014, Madkhali, 2015) 
BC12         
J1         IT4var13            
Flow assay BC12         J1         IT4var13            
Recombinant DBLβ domain – SPR 
BC12         
J1         IT4var13          
  No effect or increase (% ref binding > 80) 
  Minor effect (% ref binding 50-79) 
  Moderate effect (% ref binding 25-49) 
  Major effect (% ref binding < 25)  
Figure 5.16. Summary of ICAM-1 mutant binding data across assays. 
The effects of the ICAM-1 mutant proteins on binding are presented as a 
percentage of reference ICAM-1D1D5 binding. The results of the present study and 
previous studies (Tse et al., 2004, Madkhali et al., 2014, Madkhali, 2015) are 
summarised. The assay type is indicated. 
 
IT4var13 binding in static assays, a minor effect in our preliminary flow assays and 
no effect on recombinant protein, as discussed. Any explanation for these 
differences is speculative and likely relates to assay set-up and the components 
being tested (discussed further below). Tse et al. (2004) proposed that any negative 
effect of the mutant proteins on binding is amplified in flow assays due to a greater 
strain on the interaction under flow and this is in keeping with their data on A4 and 
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ItG (Figure 5.16). However, different results were obtained for A4 and ItG static 
binding to L42A and L44A by Madkhali (2015), which brings into question the 
reproducibility of IE binding assays. It is worth noting that the expressed var genes 
of A4 and ItG were not confirmed in either study but are presumed to be 
predominantly IT4var14 and IT4var16, respectively. This raises the possibility that 
the expression of other genes within the culture may be influencing the outcome of 
binding assays and these could be variable between studies. 
There are a number of factors to consider when comparing such data sets. The SPR 
assays allow us to study the specific protein-protein interaction of different DBLβ 
domains to ICAM-1, utilising the mutant ICAM-1 proteins to identify specific contact 
residues. This is a highly sensitive, automated technique. However, both proteins 
are taken out of the context of the full length protein which is membrane bound on 
the surface of a cell with numerous additional components. Static adhesion assays 
are performed by panning IEs over fixed recombinant ICAM-1, allowing testing of 
DBLβ domain binding in the context of the full length PfEMP1 on its native cell 
surface. However, assays rely on technical consistency and many replicates are 
required to reduce the standard error. Similarly, flow adhesion assays test binding 
of whole IEs to recombinant ICAM-1 but have the advantage of mimicking 
conditions of flow in the capillaries and are thought to be more physiologically 
relevant. 
 A potential area of variability in IE studies is the amount of PfEMP1 exported to the 
cell surface. This is inherently difficult to measure due to the highly variable nature 
of these proteins and, therefore, a lack of a universal PfEMP1 antibody. One 
method of detecting PfEMP1 is by Western blot using an antibody against the 
relatively conserved ATS region (Waterkeyn et al., 2000, Maier et al., 2007). Our 
study measures var gene expression to identify an isolate’s dominantly expressed 
gene with an assumed correlation to PfEMP1 abundance but, with the exception of 
VAR2CSA (Bancells and Deitsch, 2013), post-transcriptional control is poorly 
understood. In addition, global var gene transcription in known to decrease upon 
parasite adaptation to culture (Peters et al., 2007), which may affect surface 
protein abundance. The absence of knobs has also been shown to affect PfEMP1 
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expression (Horrocks et al., 2005). However, all parasites in this study are amenable 
to Plasmagel floatation, indicating the presence of knobs.  
Both static and flow assays spot ICAM-1 Fc fusion protein onto plastic surfaces in an 
unknown orientation, presumably with a consistent number of binding sites 
available between assays to allow comparison. However, SPR assays capture ICAM-
1 via the Fc receptor, mediated by Protein A. Future studies should test the spotting 
of Protein A into flow channels, followed by ICAM-1 capture in an attempt to make 
SPR and flow assays more comparable.  Recombinant ICAM-1 forms dimers via the 
Fc region (Bengtsson et al., 2013a), the effect of which on parasite binding is 
unknown. ICAM-1 can also form dimers mediated by D4∷D4 (Yang et al., 2004) and 
D1∷D1 (Casasnovas et al., 1998) binding and has been suggested to exist in an 
intermediate monomeric-dimeric state on the endothelial cell surface (Oh et al., 
2011). However, the native state of ICAM-1 on the cell surface is unknown in the 
absence of direct visualisation. D1∷D1 dimers form via the same area involved in 
DBLβ binding, the BED side, but the effect on DBLβ binding is unknown, as is the in 
vivo relevance of this dimer. Therefore, flow adhesion assays which test IE binding 
to induced endothelial cells (Gray et al., 2003, Madkhali et al., 2014) are perhaps 
the most physiologically relevant assays available since both proteins are in the 
context of their native cell. However, these assays are technically very difficult due 
to the need to combine two independently challenging cell cultures. Each assay 
provides important information and a combination of results obtained from all 
assays should be considered to build a picture of ICAM-1 binding. For example, IE 
binding to recombinant ICAM-1 informs us of their binding ability, protein-protein 
interactions are useful for analysing the kinetics of the binding and the sites 
involved, and IE binding to endothelial cells, in combination with receptor blocking 
antibodies, provide information on the contribution of different host receptors to 
overall IE binding.  
Our SPR results show that J1a, BC12a and IT4var13 DBLβ domains bind ICAM-1D1D5 
with nanomolar affinity, in agreement with previous studies (Brown et al., 2013, 
Lennartz et al., 2015). This has important implications for the design of antibody 
therapies which would require higher affinities to outcompete the DBLβ∷ICAM-1 
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interaction. Binding to the ICAM-1 mutant proteins indicates subtle differences in 
contact residues between the different DBLβ domains. When the surface 
architecture of ICAM-1 is considered (Figure 5.17), the S22 residue is near the edge 
of the area identified as important for DBLβ binding. It is likely that IT4var13DBLβ has 
a structural difference in the area that contacts here, resulting in the lack of effect 
of this mutation. This has implications for development of therapeutics such as 
drugs or antibody therapy, which should focus around the L42 and L44 residues and 
possibly extend to K29 (mutated in ICAM-1Kilifi) to confer a cross-blocking effect. A 
co-crystal is required to fully understand the DBLβ∷ICAM-1 bound structure and 
further guide the design of cross-acting therapeutics (discussed in Chapter 6). The 
difference in contact residues between DBLβ domains is also important when 
considering anti-disease vaccine development targeting ICAM-1 binding DBLβ 
domains.  
 
 
Figure 5.17. The crystal structure of ICAM-1 D1, showing the surface architecture. 
Residues of the mutated proteins tested in this study are labelled and coloured 
yellow. K29 residue is mutated to M in ICAM-1Kilifi. Structure accessed via Protein 
Data Bank, deposited by Casasnovas et al. (1998).  
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5.5 Summary 
In this chapter, we analysed the binding of two newly identified DBLβ domains to 
ICAM-1. Using SPR assays, we show that the recombinant DBLβ domains of J1a and 
BC12a bind ICAM-1D1D5 with nanomolar affinity. We compared their binding to the 
previously characterised IT4var13DBLβ and studied the binding of all three DBLβ 
domains to four ICAM-1 mutant proteins. Residues K29, L42 and L44 are essential 
for ICAM-1 binding of all three DBLβ domains, whereas S22 is essential for J1aDBLβ 
and BC12aDBLβ binding but not IT4var13DBLβ binding. This has important implications 
for the design of therapies targeting severe malaria, topics discussed in the final 
Chapter 6.  
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Chapter 6. Conclusions and implications for 
therapeutic targeting of PfEMP1 
An estimated 438,000 deaths worldwide were attributed to severe malaria in 2015 
(WHO, 2015). A key process in the development of SM is the sequestration of P. 
falciparum IE in the microvasculature which involves the interaction of numerous 
parasite and host factors. The most extensively studied interaction is that of the 
highly variable PfEMP1 protein family with various endothelial cell receptors. 
Evidence that SM is caused by a subset of PfEMP1 variants has led to hope of an 
anti-disease therapeutic targeting these interactions. The need for such therapeutic 
adjuncts to current drug treatment is evidenced in the ~ 10% mortality rate among 
SM patients in spite of effective anti-parasite treatment (Dondorp et al., 2010). 
Extensive understanding of the mechanisms involved in IE sequestration is required 
to inform on the feasibility of adjunct therapies and vaccines targeted against 
PfEMP1 proteins. 
The current study has extended our understanding of PfEMP1 interactions with the 
host endothelial receptor ICAM-1. The majority of studies of ICAM-1 binding have 
focussed on the parasite reference strains IT4 and 3D7 (Howell et al., 2008, Janes et 
al., 2011, Brown et al., 2013, Bengtsson et al., 2013b). Recent work characterised 
the ICAM-1 binding ability of a panel of ICAM-1-selected culture-adapted patient 
isolates, conducted at the cellular level of IEs (Madkhali et al., 2014). The current 
study extends that characterisation to the molecular level, with the aim of 
identifying novel ICAM-1 binding PfEMP1 proteins and providing insight into a 
broader range of DBLβ∷ICAM-1 interactions. We have identified and sequenced 
five new predicted ICAM-1 binding PfEMP1 proteins from three patient isolates, 
BC12, J1 and PCM7. Validation of ICAM-1 binding ability was carried out for two of 
these PfEMP1 proteins (BC12a and J1a) by recombinantly expressing their DBLβ 
domains and demonstrating ICAM-1D1D5 binding by SPR experiments. SPR 
experiments with the mutant ICAM-1 proteins ICAM-1S22A, ICAM-1Kilifi, ICAM-1L42A 
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and ICAM-1L44A showed an almost complete loss of binding of both BC12aDBLβ and 
J1aDBLβ, confirming the importance of these residues in binding. The IT4var13DBLβ 
domain bound ICAM-1D1D5 with high affinity, as previously described (Brown et al., 
2013), did not bind  ICAM-1Kilifi, ICAM-1L42A or ICAM-1L44A, in a similar result to 
BC12aDBLβ and J1aDBLβ domains, but did retain binding ability to ICAM-1S22A. These 
results suggest overlapping but distinct ICAM-1 binding sites.  
A key component of this study was to test the practical application of the new Pf3k 
var gene database in a targeted sequencing approach. The global var gene 
repertoire was once considered endless but, with advances in WGS methods, it is 
becoming apparent that the organisation of PfEMP1 proteins into DCs (Rask et al., 
2010) and the occurrence of recombination mainly within groups (Kraemer and 
Smith, 2003, Kraemer et al., 2007, Claessens et al., 2014), results in limitations on 
the extent of diversity compared to a situation of completely random domain 
associations. Therefore, if enough parasites genomes are sequenced globally, it is 
feasible that we may have access to the majority of possible var sequences.  A 
number of the non-dominant DBLα tags queried against the database did not yield 
any matches, suggesting that this has yet to be achieved. Our limited analysis of the 
returned database sequences, in conjunction with PoLV analysis, suggests that they 
are an invaluable resource in predicting virulent group A var genes from short DBLα 
tag sequences. The wealth of information held in this database will likely lead to 
identification of new DCs, improve current classification techniques, aid our 
understanding of var gene recombination, and reveal the global distribution of var 
gene sequences. Together, this information is likely to enhance our understanding 
of these highly variable genes and their role in pathogenesis of SM. We look 
forward to the full analysis and public availability of this database. 
The mechanism by which IE sequestration leads to disease is poorly understood. 
However, the finding of differential var gene expression in the microvasculature of 
different organs has led to the suggestion of organ-specific sequestration 
(Montgomery et al., 2007, Tembo et al., 2014). Our attempts to sequence the full 
length genes of the short 28B1-1 and 62B1-1 sequences, identified specifically in 
the brains of fatal CM (Tembo et al., 2014), were unsuccessful due to a lack of 
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parasite material for experimentation. However, the Pf3k database hits to these 
sequences have properties of virulent var genes. Both hit sequences are long var 
genes that are predicted to bind EPCR. In addition, the 62B1-1 returned sequence 
has the domain structure associated with IgM-mediated rosetting. Future studies 
should test for the presence of these sequences to assess their prevalence within 
the population and their association with CM. In addition, the acquisition of 
parasites harbouring these genes could provide valuable information on host cell 
binding and allow the study of mechanisms of disease pathogenesis.  
Our SPR results of recombinant DBLβ∷ICAM-1 interactions suggest an overall 
shared binding site between the DBLβ domains tested with minor differences in 
contact residues. This is in agreement with  previous studies of IE binding, although 
some key differences between assays were observed (Tse et al., 2004, Madkhali et 
al., 2014, Madkhali, 2015) (see Discussion 5.4). A comparison of our DBLβ 
sequences to key peptides in the interaction of a group A DC4 DBLβ3 domain with 
ICAM-1 showed that they are distinct (see section 4.3.6), suggesting differential 
binding peptides between group A and group B and C proteins. A co-crystal of DC4 
DBLβ3 bound to ICAM-1 has been solved and confirms involvement of the D2 
domain (Frank Lennartz, unpublished data). Current efforts are focussed on 
obtaining the crystal structures of the group B BC12aDBLβ and the group C J1aDBLβ 
bound to ICAM-1 for comparison (Frank Lennartz, current work). Crystal structures 
will provide insight into important binding residues on both ICAM-1 and the DBLβ 
domains and will reveal any epitopes shared between the different PfEMP1 groups. 
This information will inform on the design of therapeutic interventions such as 
drugs and vaccines and will reveal whether multiple targets will be required to 
prevent broad PfEMP1 binding to a single host cell receptor. The evidence to date 
suggests that key epitopes will vary between the PfEMP1 groups. The merits of such 
therapeutics against PfEMP1 are discussed below.  
Potential therapeutic strategies can be broadly placed into three categories: 
vaccine development against PfEMP1, blocking and/or reversing PfEMP1 adhesion 
as an adjunct to current drugs, and blocking the pathology induced by IE binding. 
The development of such therapies requires considerable time and money and 
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must be justified. The main justification is that even with hospitalisation and drug 
treatment the mortality rate of SM is at least 8-11% (Dondorp et al., 2010) and has 
been reported as high as 50% in patients with multiple SM disease phenotypes 
(Hora et al., 2016). In such a complex disease, alleviation of one facet, such as 
parasitaemia with drug treatment, may not be enough to reverse disease 
progression, suggesting that multi-faceted treatment is required. Reducing the 
sequestered IE burden is one such strategy that could improve patient outcomes.  
The first strategy of the development of vaccines against PfEMP1 is supported by 
findings that antibodies against PfEMP1 comprise the majority of anti-IE antibodies 
and are protective against disease (Chan et al., 2012). However, the high level of 
sequence variation both within and between parasite PfEMP1 repertoires presents 
a formidable challenge in finding disease-protective targets. Antibodies protective 
against SM are developed in early life, in regions of high transmission, and have 
identified group A PfEMP1 proteins as important in anti-disease immunity (Jensen 
et al., 2004). This knowledge, combined with an increase in understanding of 
particular group A interactions with host receptors (Bengtsson et al., 2013b, Berger 
et al., 2013, Turner et al., 2013, Lau et al., 2015), provides a starting point for 
vaccine design, although further studies will be required to determine the level of 
cross-reactivity that may be achieved. VAR2CSA is the most extensively studied 
PfEMP1 in relation to vaccine development targeting PAM. Great optimism 
surrounded this protein due to the specific receptor-ligand interaction involved and 
the relative conservation of the var2csa gene between isolates (Hviid, 2011). 
However, identification of vital epitopes has proven more difficult than anticipated, 
partly due to the compact quaternary structure of the protein (Khunrae et al., 
2010), and higher than expected sequence variation between isolates (Fried and 
Duffy, 2015). A modular protein structure is anticipated to be the norm among 
other PfEMP1 proteins (Brown et al., 2013), suggesting that single domains mediate 
binding. In this case, sequence variation is the main challenge to vaccine design, 
although conservation of structure has been shown in spite of sequence variation 
(Lau et al., 2015). An additional challenge lies in identifying which receptor-ligand 
interaction to target. EPCR is perhaps the most obvious due to a clear mechanism 
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for disease progression. In addition, the CIDRα binding site is simple and sequence 
analysis accurately predicts binding of recombinant CIDRα proteins (Lau et al., 
2015). However, the study of this receptor in relation to PfEMP1 binding is in its 
infancy and greater understanding of EPCR binding and its occurrence in clinical 
settings is required. An ideal vaccine would encompass multiple epitopes involved 
in several interactions with, for example, EPCR, ICAM-1 and PECAM-1, to provide 
the best chance of preventing IE binding. Alternatively, the confirmation of the 
importance of a single host receptor in pathogenesis would support the inclusion of 
the epitopes involved in a vaccine targeting multiple parasite life cycle stages. 
The second strategy of blocking and/or reversing PfEMP1 adhesion could be 
achieved by drug or monoclonal antibody treatment. The high variability among 
PfEMP1 proteins is, again, the main challenge to interventions. However, rational 
drug design has been demonstrated against ICAM-1-binding PfEMP1 by mimicking 
the ICAM-1 binding site (Dormeyer et al., 2006). The compound in question, (+)-
epigalloyl-catechin-gallate, was shown to be effective at micromolar concentrations 
against two parasite strains of IT lineage and inhibition of binding ranged from 37-
80% in a panel of culture-adapted patient isolates, providing proof of concept for 
rational drug design (Dormeyer et al., 2006, Patil et al., 2011). The structure was 
based on the ICAM-1 DE loop (Dormeyer et al., 2006), which includes residue L44, 
suggesting that this drug would also inhibit BC12aDBLβ, J1aDBLβ and IT4var13DBLβ 
binding. The recent development of a high-throughput screening platform to 
identify drug candidates against IE-binding is hoped to identify more molecules 
which can be further developed into anti-adhesion drugs (Gullingsrud et al., 2015). 
This is a useful initial screen but levels of cross-blocking ability between parasite 
strains will need to be tested to evaluate the effectiveness of such a drug. The use 
of a heparin with reduced anticoagulant activity, Sevuparin, has been shown to 
disrupt rosettes (Leitgeb et al., 2011) and is currently in Phase II clinical trials. The 
results are highly anticipated and will provide insight into the effectiveness of 
targeting IE adhesion and the merits of pursuing additional anti-adhesion drugs. A 
monoclonal antibody raised against the ICAM-1 binding domain of the 3D7 DC4-
containing PfEMP1 was shown to be cross-reactive with other DC4 PfEMP1 proteins 
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(Lennartz et al., 2015), providing proof of principle for antibody therapy. However, 
such a treatment is likely to be too expensive for use in such a widespread disease 
affecting some of the world’s poorest countries. Cross-reactive monoclonal 
antibodies instead provide valuable information on important epitopes that will be 
useful in drug and vaccine design.  
The third strategy is to block the pathology induced by IE binding. This has the 
advantage of targeting host factors rather than the highly variable PfEMP1 proteins 
themselves and overcomes the existence of binding redundancy (e.g. the 
contribution of other VSAs to receptor binding, such as RIFINs and STEVORs in 
rosetting). However, extensive knowledge of the pathways involved is required to 
ensure the safety of such interventions. One such therapy currently under 
investigation is treatment with L-arginine (Brussee et al., 2015). L-arginine is the 
substrate for nitric oxide (NO) synthase found in endothelial cells. Plasma levels of 
L-arginine are low in SM resulting in reduced NO availability which is linked to 
endothelial dysfunction. Testing of the efficacy of L-arginine treatment is on-going 
but early results show no improvement on lactate clearance or endothelial NO 
bioavailability (Yeo et al., 2013, Brussee et al., 2015). Identification of EPCR as a 
PfEMP1 receptor (Turner et al., 2013) and the reported loss of EPCR in CM (Moxon 
et al., 2013), has led to optimism for pathology blocking interventions. The 
involvement of EPCR in anti-coagulant and cytoprotective pathways provides 
mechanisms for disease progression which are currently under investigation as 
therapeutic targets.  
All the therapeutic strategies described above require extensive understanding of 
PfEMP1-receptor interactions and their role in pathogenesis. Of particular interest 
is the extent of PfEMP1 sequence diversity which can maintain receptor binding, 
and the relationship between binding to a particular host receptor and disease 
progression. However, the expected outcome of interventions targeting PfEMP1 
warrants consideration. Specifically, what is the target product profile (TPP) of 
therapeutics against SM? What are the desired features and characteristics of such 
interventions? How can the efficacy of therapeutics be demonstrated? Targeting IE 
sequestration aims to prevent the development of associated pathology and allow 
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parasite clearance by the spleen and the immune response. How would efficacy be 
measured and what level of efficacy would be deemed sufficient for widespread 
use? These are all challenging questions and highlight the difficulty of designing 
anti-disease therapies. Greater understanding of the complex interplay between P. 
falciparum IE and their human host is required for progression towards answering 
these key questions.  
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Appendix A 
PCR primer sequences 
DBLα tag, UPS and Exon 2 previously published primers 
Target TA (°C) Primer name Sequence 5’-3’ 
DBLα tag † 47 DBLαAF’ GCACG(A/C)AGTTT(C*/T)GC 
DBLα tag † 47 DBLαBR GCCCATTC(G/C)TCGAACCA 
UPS A ‡ 52 upsA-5’ ATTAYATTTGTTGTAGGTGA 
UPS B ‡ 52 17DBLa-5’ ATGTAATTGTTGTTTTTTTTTTTGTTAGAATATTTAAA 
UPS C ‡ 52 5B1-5’ CACATATARTACGACTAAGAAACA 
Exon 2 ᶳ 48 Ex2-reg TCTTCATAYTCRCTTTC 
† (Bull et al., 2005), ‡ (Mugasa et al., 2012), ᶳ (Lavstsen et al., 2012) 
  
ICAM-1 binding isolate RT-qPCR primers 
Target TA (°C) Primer name Sequence 5’-3’ 
DBLα tag BC12a 60 E-195F AAGCGGAAAAACACTACGAAGAT 
DBLα tag BC12a 60 E-196R TAGCCATAGATGGACTTTCACTA 
DBLα tag BC12b 60 E-197F AAGCGCAACACAAAAGCATTATGCA 
DBLα tag BC12b 60 E-198R TTTGTTATATGTTATATTTCCTCCATTACA 
DBLα tag BC12d 60 E-201F GACGAGAGGGAGGACGAA 
DBLα tag BC12d 60 E-202R ATTATCACCACCACATGTTTTTCGA 
DBLα tag BC12e 60 E-203F AGATCTCGCTACAAAAAAGACGGT 
DBLα tag BC12e 60 E-204R TAGCAGTCGTACCGTATGTGAT 
DBLα tag BC12f 60 E-205F ACGGATCCCAAAGCGAAAGA 
DBLα tag BC12f 60 E-206R TTGGGCTCCACTTTGTCCAT 
DBLα tag J1a 60 E-183F TCGTACTACAAAAATGATAATGACCG 
DBLα tag J1a 60 E-184R ATGCCCACCCTTAATGGAAGA 
DBLα tag J1b 60 E-185F AGACGAATGGGAAGGTACCAGA 
DBLα tag J1b 60 E-186R AGCCGAACTTCCTCCTTCAGA 
DBLα tag J1c 60 E-211F AGGCAGCRAAAGACCACTAC 
DBLα tag J1c 60 E-212R TTCTCCTGAACCACATGTATTTCTA 
DBLα tag J1d 60 E-213F AAGAAGAACAATAAGAATCCGGCAA 
DBLα tag J1d 60 E-214R TCTAAAATATTCAGCATTATCTGTTACA 
DBLα tag J1e 60 E-215F AGACGAATGTGAAGACGAATGT 
DBLα tag J1e 60 E-216R TGCACACGCTCTTTGTCGAA 
DBLα tag J1f 60 E-217F AGAGGGAAGAAAGGCGCAA 
DBLα tag J1f 60 E-218R AGAGTCATACCATCATCTGCGAT 
DBLα tag PCM7a 60 αE-3F TGGATTGATGAACGGCGCACA 
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DBLα tag PCM7a 60 αE-4R TACCACTCTTAACGTCACACG 
DBLα tag PCM7b 60 αE-1F AGATCGCTACCAAGATACTGA 
DBLα tag PCM7b 60 αE-2R CATTCCAAAGAGTCATACCAT 
DBLα tag PCM7c 60 E-269F AAGATGAACAAATTAGGGAATACTGGT 
DBLα tag PCM7c 60 E-270R TGGCATTTATCCAGACTCCAAGT 
DBLα tag PCM7d 60 E-271F ACAATGATGATACTGACAAAAACTATTACA 
DBLα tag PCM7d 60 E-272R AGGCTCTCCATTGACACATCTA 
DBLα tag PCM7e 60 E-273F TACAAACTCGCTACGGAAGTGAT 
DBLα tag PCM7e 60 E-274R AGTTCCATCGATACACTGGCA 
DBLα tag PO69a 60 E-189F GAAGAATGTGGCGCTAAGAGAT 
DBLα tag PO69a 60 E-190R TCATTTTGCTCCGCCTTACATGTAAT 
DBLα tag PO69b 60 E-191F ACAAGCAGCAGGAATGGGAAGA 
DBLα tag PO69b 60 E-192R TCGCCTGTAGGTTTTTCTCCGT 
DBLα tag PO69c 60 E-193F TCGCTACAATGGTGATAAAGATCCAA 
DBLα tag PO69c 60 E-194R TCCTTTGGCGCTTCGCATGTTA 
DBLα tag PO69d 60 E-221F AATATATGAAAAATTGAATGGCGCAGAA 
DBLα tag PO69d 60 E-222R TCGTTCTCCTCTATTGCACGT 
DBLα tag PO69e 60 E-223F TGACAAATTGAAGGATAAGGAGGAA 
DBLα tag PO69e 60 E-224R ATGGATTTAGTGCATCACCACAT 
DBLα tag 8206a 60 E-207F TGGCGCTAAGAGATCGCTA 
DBLα tag 8206a 60 E-208R TTGTTAGAACATCTCCAGTAGCA 
DBLα tag 8206b 60 E-209F AAGCAGCAGGAATGGGAAGA 
DBLα tag 8206b 60 E-210R CTGTAGGTTTTTCTCCGTTAGA 
  
Genotyping primers published in Recommended Genotyping Procedures (Medicines for Malaria Venture, 
Amsterdam May 2007) 
Target TA (°C) Primer name Sequence 5’-3’ 
MSP primary (p) 54 M1-OF CTAGAAGCTTTAGAAGATGCAGTATTG 
MSP p 54 M1-OR CTTAAATAGTATTCTAATTCAAGTGGATCA 
MSP p 54 M2-OF ATGAAGGTAATTAAAACATTGTCTATTATA 
MSP p 54 M2-OR CTTTGTTACCATCGGTACATTCTT 
MSP secondary (s) 50 S1TAILFW GCTTATAATATGAGTATAAGGAGAA 
MSP s 50 N5-3D7-RVVIC CTGAAGAGGTACTGGTAGA 
GLURP p 54 G-F3 ACATGCAAGTGTTGATCCTGAAG 
GLURP p + s 54 G-F4 TGTAGGTACCACGGGTTCTTGTGG 
GLURP s 54 G-NF TGTTCACACTGAACAATTAGATTTAGATCA 
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Primers designed against var database hits to ICAM-1 binding isolates 
Target TA (°C) Primer name Sequence 5’-3’ 
XX0156-C.g40 (BC12a) 52 E-227F TAGTGAAAGTCCATCTATGGCTA 
XX0156-C.g40 (BC12a) 52 E-228R TCCATTCATCATACAGTTTCTGACT 
XX0156-C.g40 (BC12a) 52 E-229F TGGTGATGGACAAACAGAAATTGAA 
XX0156-C.g40 (BC12a) 52 E-230R ACGCCTTTCTACCACCAGCA 
XX0156-C.g40 (BC12a) 52 E-231F ACCTATTATGAGATCCAATCCATGT 
XX0156-C.g40 (BC12a) 52 E-232R TTTCTCATATTTATCGCAGGCGTTT 
XX0156-C.g40 (BC12a) 52 E-233F TGCAATCACAGGAGTATGAGACA 
XX0156-C.g40 (BC12a) 52 E-234R TTCTTTAGGTTTTGGGAATATTGTATCT 
XX0156-C.g40 (BC12a) 52 E-235F AGGTCCCTCCAGAATTTTTGC 
XX0156-C.g40 (BC12a) 52 E-236R TGGGTGGCACACAAATACTAC 
XX0156-C.g40 (BC12a) 52 E-237F AGTCTCAATGCCGCCTGCT 
XX0156-C.g40 (BC12a) 52 E-238R TTGACCCCATTCTTCAAGGTAAC 
XX0156-C.g40 (BC12a) 52 E-239F TGTCACACTTAAAGATGAAAGTAGT 
XX0156-C.g40 (BC12a) 52 E-240R ATGGGGATTCTTCACGATTTTTCATA 
XX0156-C.g40 (BC12a) 52 E-241F ATGAGGAAAAAGTCAGTGGGAAA 
XX0156-C.g40 (BC12a) 52 E-242R AGTGAACGCAGCAAAACCGAT 
XX0156-C.g40 (BC12a) 52 E-242F ATCGGTTTTGCTGCGTTCACT 
XX0004-C.g20 (J1a) 52 E-257F TCTTCCATTAAGGGTGGGCAT 
XX0004-C.g20 (J1a) 52 E-258R ACATTTACTAATTTCTTTCCTCCATTCT 
XX0004-C.g20 (J1a) 52 E-259F TGATGAAGATAATGACTGTGAAACGA 
XX0004-C.g20 (J1a) 52 E-260R ACATATGTTCTCTTCTTTGTGGCA 
XX0004-C.g20 (J1a) 52 E-261F TGAAAATCATTCCAATCGTAATCCTAA 
XX0004-C.g20 (J1a) 52 E-262R ACTATTTGGAGGGAGTAATTCTTGTA 
XX0004-C.g20 (J1a) 52 E-263F ATGGGACAAAATGCAACTGAAATACT 
XX0004-C.g20 (J1a) 52 E-264R ATTATCGCCACTAAATGTAACGGTTT 
XX0137-C.g35 (J1a) 52 E-309F AAAGGTGACCAAACAGATGAAAAGAA 
XX0137-C.g35 (J1a) 52 E-310R AGTGATAAATATCTATCTCCATCTGTTGT 
XX0137-C.g42 (J1b) 52 E-243F ATGCCAACTTAATCACTCTCTTCAT 
XX0137-C.g42 (J1b) 52 E-243R ATGAAGAGAGTGATTAAGTTGGCAT 
XX0137-C.g42 (J1b) 52 E-244R TGTTTCAGCACAGAACGCGTT 
XX0137-C.g42 (J1b) 52 E-245F AGTGGTACTAATGATAAAGAAAAAGGAA 
XX0137-C.g42 (J1b) 52 E-246R TGTGGGTCTGGGCACTTGT 
XX0137-C.g42 (J1b) 52 E-247F AAGAAACAAAACGCATTAAGGACAT 
XX0137-C.g42 (J1b) 52 E-248R TGTGGGAGGAGGTTTGGAA 
XX0137-C.g42 (J1b) 52 E-249F ATATAGTAGTACGTGGTGTTGCT 
XX0137-C.g42 (J1b) 52 E-250R AGTTTTGCAGTCCTTTTCTTTACCAT 
XX0137-C.g42 (J1b) 52 E-251F AGGTAGTGAGATAACTTTTGATGATA 
XX0137-C.g42 (J1b) 52 E-252R TTCATCACTATTATCTGCTGGTTCA 
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XX0137-C.g42 (J1b) 52 E-253F TGAACCAGCAGATAATAGTGATGAA 
XX0382-C.g38 (J1d) 52 E-254R TGTAACCTCATAATAAGAACATTGCCA 
XX0382-C.g38 (J1d) 52 E-255F AGTAATAAAGAGCGTGAGAATAATCCT 
XX0382-C.g38 (J1d) 52 E-256R ACCTCACTTGACGGCCATCT 
XX0352-C.g23 (J1d) 52 E-275F ACAGAAAAGGGGGTAAAGCAGAT 
XX0352-C.g23 (J1d) 52 E-276R TCAATCGCATGCTTGTCTTTATCTTT 
XX0352-C.g23 (J1d) 52 E-277F AAAATCAATGGAAACAAATGGACGAA 
XX0352-C.g23 (J1d) 52 E-278R TGTGATAGACCACATAACATTCCT 
XX0352-C.g23 (J1d) 52 E-279F AGGTAGTGATGTGAGTGATGTAGA 
XX0352-C.g23 (J1d) 52 E-280R ACCTGTTTTCAAACGATTCATACCT 
XX0352-C.g23 (J1d) 52 E-281F AAGCATACATGAAGGATCAGAAGATT 
XX0352-C.g23 (J1d) 52 E-282R CTGTCGCGGCCTTGCATTTA 
XX0352-C.g23 (J1d) 52 E-283F TAAAGAATACAGCATACTTGTTAGTAA 
XX0352-C.g23 (J1d) 52 E-284R TCTGTAAAGTGTTTCTCACCCATA 
VAR0141-C.g21 (PCM7a) 55 E-15F TGTGGTGGAGGAAATCTAAC 
VAR0141-C.g21 (PCM7a) 55 E-16R CTTCTCCGCAGGTTTCGTGACC 
VAR0141-C.g21 (PCM7a) 55 E-17F CATATTGCGAAGCATGTCCGTG 
VAR0141-C.g21 (PCM7a) 55 E-18R GCATCCACATGTGTATCTTC 
VAR0141-C.g21 (PCM7a) 55 E-19F GGCAACACATGTATAACAGG 
VAR0141-C.g21 (PCM7a) 55 E-20R GGTGGCATGTAGATATCTTCGGC 
VAR0141-C.g21 (PCM7a) 55 E-21F GCAAGATTGACACAACGTATTCC 
VAR0141-C.g21 (PCM7a) 55 E-22R CTTACACGTACCACTAACACCCG 
VAR0141-C.g21 (PCM7a) 55 E-23F GTCCTGGTATGCCAGTTGACG 
VAR0141-C.g21 (PCM7a) 55 E-24R GCCATATTTGAGGTTGCATGC 
VAR0141-C.g21 (PCM7a) 55 E-25F GAGGAGGAAGTCACTGACGAC 
VAR0141-C.g21 (PCM7a) 55 E-26R CACCAGTCAACACGCTTGTCAC 
VAR0141-C.g21 (PCM7a) 55 E-27F GATTAAGGCGTTAGAAGCTAGTGG 
VAR0141-C.g21 (PCM7a) 55 E-28R GCAGCGTCAGTGCACGTATCTAG 
VAR0141-C.g21 (PCM7a) 55 E-29F GTGCCATTTCTTGTAGATC 
VAR0141-C.g21 (PCM7a) 55 E-30R CAGTTCTCTGTTCGAATTGCTC 
VAR0141-C.g21 (PCM7a) 55 E-31F GGCCATGTATAGAAAATGG 
VAR0141-C.g21 (PCM7a) 55 E-32R GGAAGCGGACATAACATCGC 
XX0488-C.g40 (PCM7d) 52 E-289F AACCCCTTTCAGAACTTTGTCAT 
XX0488-C.g40 (PCM7d) 52 E-289R ATGACAAAGTTCTGAAAGGGGTT 
XX0488-C.g40 (PCM7d) 52 E-290R TACACGCTTCATTTCCGTCATCT 
XX0488-C.g40 (PCM7d) 52 E-291F TCAAGTGGTGAAGAACATGAAGATA 
XX0488-C.g40 (PCM7d) 52 E-292R TTGACGTCGGGGAGGTAAATA 
XX0488-C.g40 (PCM7d) 52 E-293F ATGAGCGTAATACAGGTGAACCA 
XX0488-C.g40 (PCM7d) 52 E-294R TGCGGTACTATAAACGGTGTTACT 
XX0488-C.g40 (PCM7d) 52 E-295F ACCTGTGGTTAACTTCTTGTTCGA 
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XX0488-C.g40 (PCM7d) 52 E-296R ACGCAAACTCCTCGAGATATTCT 
XX0488-C.g40 (PCM7d) 52 E-297F TATGGCAAGGAATGTTATGTGCTTT 
XX0488-C.g40 (PCM7d) 52 E-298R ACTTTTGGGTATTTGCAGTATTTGGAA 
XX0488-C.g40 (PCM7d) 52 E-299F TTATGTTCGATAGCTTTTCTGTTCATGA 
XX0488-C.g40 (PCM7d) 52 E-300R TTGTCCAGATCCTCCAAGATAGT 
XX0488-C.g40 (PCM7d) 52 E-300F ACTATCTTGGAGGATCTGGACAA 
    
Primers designed against PF0311-C.g26 hit to clinical sequence 62B1-1 
Target TA (°C) Primer name Sequence 5’-3’ 
PF0311-C.g26 (62B1-1) 57 E-51F CATGTGATGCTCCAAGGGATG 
PF0311-C.g26 (62B1-1) 57 E-52R GATCGGCACTATAGAGGACAG 
PF0311-C.g26 (62B1-1) 57 E-53F GACATGTGACACAGTGGAC 
PF0311-C.g26 (62B1-1) 57 E-54R GCATCTTGTAAATCTTTGGTACCTG 
PF0311-C.g26 (62B1-1) 57 E-55F CCGCGGATTGTATTGATG 
PF0311-C.g26 (62B1-1) 57 E-56R GGCTGCGAGAAGCACATGAACC 
PF0311-C.g26 (62B1-1) 57 E-57F CTAATCGTGATACTAGGCGTTC 
PF0311-C.g26 (62B1-1) 57 E-58R CATGCTGGTTTGCACTTTTCAC 
PF0311-C.g26 (62B1-1) 57 E-59F GCGGATATAGTGATCATACCC 
PF0311-C.g26 (62B1-1) 57 E-60R CTTCTAGGAGGCATACATGG 
PF0311-C.g26 (62B1-1) 57 E-61F GAATGAACGACCAGTGCCAG 
PF0311-C.g26 (62B1-1) 57 E-62R CCATCACACTCTGTCACC 
PF0311-C.g26 (62B1-1) 57 E-63F GATGTGCGCGCGAAACTTATG 
PF0311-C.g26 (62B1-1) 57 E-64R CACTATCCTCACAGGTACAC 
PF0311-C.g26 (62B1-1) 57 E-65F GCTAACACGTATGATAGCGC 
PF0311-C.g26 (62B1-1) 57 E-66R GATTCTCGTATGAGTAGTC 
PF0311-C.g26 (62B1-1) 57 E-67F GACTGGTGGAAAGAACATGGTC 
PF0311-C.g26 (62B1-1) 57 E-68R CGTTTCCACAGCAGCGCATTG 
PF0311-C.g26 (62B1-1) 57 E-69F CCTGATGCGTGCAAAATAGTGG 
PF0311-C.g26 (62B1-1) 57 E-70R GCAAATTCCTCCAAGGTGG 
PF0311-C.g26 (62B1-1) 57 E-71F GGTAGTGATGTGAGTGAAGTAG 
PF0311-C.g26 (62B1-1) 57 E-72R GAGGTCTCGCTGGTTGAGGTG 
PF0311-C.g26 (62B1-1) 55 E419-79F AAGTGTAATGTTGCTGATGGA 
PF0311-C.g26 (62B1-1) 55 E419-80R ATGAACCCCGATTATAACAAC 
PF0311-C.g26 (62B1-1) 55 E419-81F TGCGCCGTAACAAATAGC 
PF0311-C.g26 (62B1-1) 55 E419-82R ACAGATGTAATAGAAGAGTGC 
PF0311-C.g26 (62B1-1) 55 E419-83R ACCTACTCCCGTGTCACC 
PF0311-C.g26 (62B1-1) 55 E419-84R CTTACCGGCCTCAACAGCAAA 
PF0311-C.g26 (62B1-1) 52 E-91F TTAGATTACGTCCCTCAATATTTA 
PF0311-C.g26 (62B1-1) 52 E-93F ATTACCTTTACTAACCCTGATGAA 
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PF0311-C.g26 (62B1-1) 52 E-93R TTCATCAGGGTTAGTAAAGGTAAT 
PF0311-C.g26 (62B1-1) 52 E-94F AAGCCTGATGGTAATTGTGGA 
PF0311-C.g26 (62B1-1) 52 E-94R TCCACAATTACCATCAGGCTT 
PF0311-C.g26 (62B1-1) 52 E-95R ATCTTTCCACGTTATAGTTTCCGT 
PF0311-C.g26 (62B1-1) 52 E-97F AAACGGAAGGCATACGAGGAA 
PF0311-C.g26 (62B1-1) 52 E-97R TTCCTCGTATGCCTTCCGTTT 
PF0311-C.g26 (62B1-1) 52 E-98F TTGCCTCCAAGAAGACAACAT 
PF0311-C.g26 (62B1-1) 52 E-99F TGTCGTGCTATCCGTTACAGT 
PF0311-C.g26 (62B1-1) 52 E-100F TAATGATACATCGGTCACCACA 
PF0311-C.g26 (62B1-1) 52 E-101F TACGAACATGCACGAGTCGAT 
PF0311-C.g26 (62B1-1) 52 E-101R ATCGACTCGTGCATGTTCGTA 
PF0311-C.g26 (62B1-1) 52 E-105F AACACCTACCCCAATGTCAAA 
PF0311-C.g26 (62B1-1) 52 E-105R TTTGACATTGGGGTAGGTGTT 
PF0311-C.g26 (62B1-1) 52 E-110F AATGGAGAGGAAAGTCAGAAAACA 
PF0311-C.g26 (62B1-1) 52 E-110R TGTTTTCTGACTTTCCTCTCCATT 
PF0311-C.g26 (62B1-1) 52 E-115F AGACCTCAATGGACACAACAA 
PF0311-C.g26 (62B1-1) 52 E-115R TTGTTGTGTCCATTGAGGTCT 
PF0311-C.g26 (62B1-1) 52 E-120F ATCTGGTCATGTGGAAAGAATATA 
PF0311-C.g26 (62B1-1) 52 E-120R TATATTCTTTCCACATGACCAGAT 
PF0311-C.g26 (62B1-1) 52 E-124F AAGGAACAACCAGAAGGATATGAA 
PF0311-C.g26 (62B1-1) 52 E-124R TTCATATCCTTCTGGTTGTTCCTT 
PF0311-C.g26 (62B1-1) 52 E-128F GCATTGGCCTTGACTTCGATT 
PF0311-C.g26 (62B1-1) 52 E-128R AATCGAAGTCAAGGCCAATGC 
    
Gene-specific forward primers used in combination with Ex-reg for Exon 2 PCR 
Target TA (°C) Primer name Sequence 5’-3’ 
BC12a 48 241F ATGAGGAAAAAGTCAGTGGGAAA 
J1a 48 310F ACAACAGATGGAGATAGATATTTATCACT 
J1b 48 253F TGAACCAGCAGATAATAGTGATGAA 
J1d 48 285F TGGTTAGTTGAATGGGGTAAAGAA 
PCM7a 48 73F ATGAAAGAAATATCAGATAAAATAG 
PCM7d 48 297F TATGGCAAGGAATGTTATGTGCTTT 
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DBLβ expression construct primers (contain BamHI (F) and XhoI (R) digestion sites) 
Target TA (°C) Primer name Sequence 5’-3’ 
BC12a_DBLβ 52 E-301F ggtggaggatccCCATGTGCTAAACCCAGTGGT 
BC12a_DBLβ 52 E-302R tccaccctcgagttaACAATTACATGGTGTATCGTGATCAT 
J1a_DBLβ 52 E-303F ggtggaggatccGCTTGTAGTGGAGACCCCA 
J1a_DBLβ 52 E-304R tccaccctcgagttaACACTTACATACATCACCATACCCA 
J1d_DBLβ 52 E-305F ggtggaggatccCCGTGTGCTACTCCTAGTG 
J1d_DBLβ 52 E-306R tccaccctcgagttaACACTCACAAGCATTAGCATACT 
PCM7a_DBLβ * 50 E-179F ggtggagctagcCCATGTACAGGCAAAGATAACG 
PCM7a_DBLβ * 50 E-182R tccaccggtaccttaACATTTACACGCTTTATCGTACC 
PCM7d_DBLβ 52 E-307F ggtggaggatccCCGTGTGGCAAAACAGATGGT 
PCM7d_DBLβ 52 E-308R tccaccctcgagttaACAAGCACAAGCTTTTTTATGGTCAT 
*contain digestion sites NheI (E-179F) and KpnI (E-182R) 
    
IT4 RT-qPCR primers (Viebig et al., 2007) 
        Target TA (°C) Primer name Sequence 5’-3’ 
IT4var01 60 IT4var01F GATCCGCCAGCAAAAGAAG 
IT4var01 60 IT4var01R CCCCCTTTATATTTTTGTCTGC 
IT4var13 60 IT4var13F GTAAACATCAGGCGTGTAAGG 
IT4var13 60 IT4var13R TGTTCCTCTCCGCTGAAGA 
IT4var14 60 IT4var14F CAAGATGGAAGCGGTAAAG 
IT4var14 60 IT4var14R CATGCATTATCCCAAAGAT 
IT4var16 60 IT4var16F ATGGTAGACAAGCTGTTCGTTT 
IT4var16 60 IT4var16R AGCACAGGCTCCTACTGAATT 
IT4var27 60 IT4var27F CAATAACGACAACCCTGGCA 
IT4var27 60 IT4var27R TGGTGTCTTCGTCGGTTTTT 
IT4var31 60 IT4var31F ACTGGTCGTAAAGGTGCACA 
IT4var31 60 IT4var31R CTCCCTTCAAATCACTTCCC 
IT4var41 60 IT4var41F AACATATGTTTGATAGAATTG 
IT4var41 60 IT4var41R TGGCATCTGTAGGCACGAA 
 
